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ABSTRACT 
Cervical cancer is the second most frequent cancer among women 
in the world. It develops by a multistage pathogenesis. However, the 
molecular mechanism of cervical carcinogenesis remains unclear. 
Apoptosis, or programmed cell death, has received widespread attention 
during the past decade due to its essential role as an effective defense 
against the emergence of cancer. Anticancer agents are effective through 
the induction of apoptosis specifically in cancer cells. 5-Fiuorouracil {5-
FU) is a commonly used, effective anticancer drug. In addition, our 
laboratory has developed a model system for multistage cervical 
carcinogenesis. To obtain a better understanding of how the progression 
of cervical cancer may occur in women, we studied whether and how 5-FU 
may differentially induce apoptosis in the multiple cellular stages. 
To determine whether 5-FU induces apoptosis in our multistage 
model system composed of primary human ectocervical cells (HEC), HPV 
18-immortalized HEC (HEC-18), and CSC-transformed HEC-18 cells 
(HEC-18T), we treated these cells with 5-FU. 5-FU induced apoptosis in 
HEC, HEC-18, and HEC-18T, as evidenced by morphologic changes, DNA 
ladder formation, and flow cytometry analysis. Growth inhibition assay 
results further indicated that 5-FU-induced apoptosis occurred in a dose-
and time-dependent manner. In addition, comparison of HEC with HEC-
18 and HEC-18T revealed that both of the latter cell lines were less 
sensitive to 5-FU-induced apoptosis than HEC when cultured in serum-
free medium KGM. However, a higher level apoptosis induced by 5-FU 
was observed when HEC-18 and HEC-18T were grown in serum-
containing medium DMEM compared with KGM. 
The expression level of apoptosis-regulating proteins without 
treatment with apoptotic stimuli is known to correlate with the sensitivity of 
cells to apoptosis. To examine whether such a correlation exists in our 
model system for multistage cervical carcinogenesis, a panel of apoptosis-
regulating proteins was analyzed by Western blot analysis without 5-FU 
treatment. The results revealed that the levels of pro-apoptotic p53, Bak, 
and Bax proteins were lower in HEC-18 and HEC-18T compared to those 
in HEC, whereas anti-apoptotic Bcl-2 and BAG-1 p33 isoform, but not Bci-
XL and BAG-1 p50, p46 and p29, were found in enhanced levels. These 
findings suggest that immortalization by HPV 18 results in decreased 
sensitivity to 5-FU-induced apoptosis, possibly due to underexpression of 
pro-apoptotic proteins and overexpression of specific anti-apoptotic 
proteins. On the other hand, pro-apoptotic p53 and Bax, but not Bak, 
showed higher expression levels in HEC-18 and HEC-18T in DMEM than 
KGM, whereas anti-apoptotic Bcl-2, but not Bcl-xL and BAG-1 isoforms, 
was lower in expression. These findings suggest that the two media 
differentially affect the sensitivity of cells to 5-FU-induced apoptosis, 
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possibly involving the overexpression of p53 and Bax pro-apoptotic 
proteins and underexpression of anti-apoptotic Bcl-2. 
Apoptosis is of special interest for chemotherapy for human 
cancers. Extensive studies have been performed towards the 
understanding of the mechanism for the initiation of apoptosis. Various 
apoptosis-regulating proteins have been identified and studied. To 
investigate whether the expression of apoptosis-regulating proteins is 
involved in the initiation of apoptosis induced by 5-FU treatment, a panel 
of such proteins was assayed by Western blot analysis in 5-FU-treated 
HEC-18 and HEC-18T grown in DMEM. Of the apoptosis-regulating and 
related proteins, p53, p53 target proteins p21 and PCNA but not MDM-2, 
and Bak but not Bax displayed enhanced expression, whereas anti-
apoptotic Bcl-2 and BAG-1, but not Bcl-xL. exhibited decreased 
expression. These results suggest that the dysregulated expression of 
certain apoptosis-regulating proteins is involved in the initiation of 5-FU-
induced apoptosis. 
Resistance to anticancer agents is the major limitation to 
chemotherapy for cancers. It has become clear that the sensitivity of cells 
to apoptosis reflects the sensitivity to being killed by anticancer drugs. 
Therefore, any method that can increase the sensitivity of cells to 
apoptosis may be effective in chemotherapeutic strategies. As described 
above, higher susceptibility of HEC-18 and HEC-18T to 5-FU-induced 
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apoptosis was observed when the medium used was DMEM instead of 
KGM. To study in more detail methods to increase susceptibility to 
apoptosis, low-density lipoproteins (LDL) or elevated Ca2• concentration 
was employed to study the factors involved in the difference between 
susceptibility to apoptosis in KGM versus DMEM. Both HEC-18 and HEC-
18T exhibited more apoptosis induction by 5-FU treatment when they were 
cultured in KGM plus LDL than in only KGM or KGM plus Ca2•. This 
suggests that elevated delivery of 5-FU may play an important role in the 
differential sensitivity to apoptosis in the two media. Furthermore, both 
Western blot analysis and flow cytometry results showed that differential 
expression of LDL receptor on cell surfaces was not involved in the 
differential apoptotic response. 
In summary, this study showed that 5-FU induces apoptosis in our 
model system for multistage cervical carcinogenesis, discovered that 
expression level changes of apoptosis-regulating proteins correlate with 
sensitivity changes of cells to 5-FU-induced apoptosis, implied how 5-FU-
induced apoptosis might be initiated and regulated in human ectocervical 
cells, and also provided information suggesting a feasible approach for 
clinical application of 5-FU in cervical cancer chemotherapy. 
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CHAPTER 1 INTRODUCTION 
1.1 Carcinogenesis 
1.1.1. Introduction 
Tumor cells show a number of features differentiating them from 
normal cells. They have lost the finely controlled balance. which is found 
in normal cells, between growth promoting and growth restraining so that 
proliferation normally occurs only when required. Consequently. in tumor 
cells. continued cell proliferation occurs. loss of differentiation may be 
found, and the normal process of programmed cell death (apoptosis) may 
not operate. Specifically: (1) Tumor cells are no longer as dependent on 
growth factors as normal cells and therefore their proliferation is 
continuously stimulated. (2) Normal cells require extracellular contact for 
growth. whereas tumor cells do not. (3) Normal cells respond to the 
presence of other cells and form a monolayer in culture due to contact 
inhibition, whereas tumor cells often grow over or under each other. (4) 
Tumor cells are less adhesive than normal cells. (5) Normal cells stop 
proliferating once they reach a certain density. but tumor cells continue to 
proliferate (MacDonald et a/ .• 1997). 
It has been recognized for many years that cancer is a genetic 
disease. Cancers arise from a single cell as a result of genetic mutation. 
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The initial mutation will cause cells to produce a genetically homogeneous 
population of cells. Additional mutations will in turn occur. giving rise to 
subclones with different properties within the tumor. Therefore, most 
tumors are heterogeneous. 
Cancer development exhibits a multistage nature. Berenblum and 
Shubik (1949) concluded that carcinogenesis was at least a two-stage 
process. Armitage and Doll (1954) took this observation a step further 
and suggested that carcinogenesis is a six or seven stage process. 
Additionally, Foulds (1957) showed that tumor progression occurred in a 
stepwise fashion. Although each of these steps is not always found in 
specific tumors, it is clear that malignancy occurs via multistage 
progression (Figure 1.1 ). The initial step is believed to be caused by 
some form of genotoxic agents such as radiation. chemical carcinogens or 
viruses. The cells at this stage are phenotypically normal although they 
have altered DNA levels. Further mutation events lead to the emergence 
of clones with additional properties associated with tumor cell 
progression. Finally, additional changes allow the outgrowth of clones 
with metastatic potential. Animal model studies enabled these steps to be 
classified as initiation. promotion, malignant progression and metastasis 
(Nowell, 1976). 
Various factors are associated with the development of human 
cancers. They fall into two types: biophysical and biochemical factors. 
2 
Figure 1.1 Multistage progression to malignancy (adapted from 
Nowell, 1976). 
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Biophysical factors consist of physical factors such as ultraviolet 
(UV) light and radiation and chemical factors such as chemical 
carcinogens. Biochemical factors include oncogenes, tumor suppressor 
genes and cell cycle control genes. The biochemical factors are of 
special interest for oncologists, since they provide much valuable 
information about the pathogenesis of human cancers. 
1.1.2. Oncogenes 
The origin for what we know today about oncogenes comes from 
studies with viruses. Many DNA viruses, such as SV40, and RNA viruses, 
such as the retrovirus, Rous sarcoma virus are associated with animal 
cancers, and some are implicated in human diseases (Table 1.1 ). These 
viruses have also been used to reveal the molecular basis for human 
carcinogenesis (Cheng. 1992). Another useful method, DNA transfection 
assay, was used to identify oncogenes in the human genome that are specific to 
tumor cells and responsible for uncontrolled cell proliferation (Shih eta/., 1981}. 
However, only about 20°k of tumors contained oncogenes that could be identified 
this way. Alternative strategies were required for identifying additional 
oncogenes. It has long been clear that some tumors carry a consistent 
chromosome translocation. In some examples the chromosome breakpoints 
were shown to coincide with the location of oncogenes already identified by 
retroviral studies. making chromosomal translocation analysis another usefut 
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Table 1.1 Viruses associated with human cancers and their oncogenes 
(adapted from MacDonald and Ford, 1997) 
Virus Associated tumors 
DNA viruses 
Epstein-Barr 
Hepatitis B 
Papilloma virus 
RNA viruses 
Burkitt's lymphoma 
Nasopharyngeal cancer 
Liver cancer 
Benign warts 
Cervical cancer 
Human immunodeficiency virus(HIV-1) Kaposi's sarcoma 
Human T -cell leukemia virus Type 1 (HTLV-1) Adult T -cell leukemia 
HTLV-2 Hairy cell leukemia 
HTLV-5 Cutaneous T -cell leukemia 
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method for identifying oncogenes (Heim et al., 1987). Two other chromosome 
abnormalities observed in tumors, homogeneous-staining regions (HSRs) and 
double-minute chromosomes (OMs), have been used to locate cellular 
oncogenes (Schwab et a/., 1990). Currently, 60-100 different cellular proto-
oncogenes have been identified, and they exhibit their oncogenic activities when 
activated. In normal cells, the expression of these proto-oncogenes is tightly 
controlled and they are transcribed at the appropriate stages of growth and 
development of cells. However, alterations in these genes or their control 
sequences lead to inappropriate expression, contributing to malignant 
progression. 
Proto-oncogenes have been predicted to be involved in the basic 
essential functions of the cell related to control proliferation and 
differentiation. Cells are stimulated by external signals, such as growth 
factors and hormones, which bind to cell surface receptors, thereby 
activating their function as signal transducers. In turn, this stimulates 
intracellular signaling pathways, eventually leading to alternations in gene 
expression. The proto-oncogenes function at each of these steps; 
therefore, mutations in any of the genes can result in their abnormal 
activation, cell growth promotion in the absence of external stimuli and 
malignant transformation. Growth factors act at the first step of the 
pathway and exist as polypeptides, oligopeptides or steroid hormones 
(Aaronson, 1991 ). They bind to specific receptors to stimulate or inhibit 
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cell growth acting via alterations in gene expression. Two models, 
autocrine model and paracrine model, have been established to suggest 
auto-stimulation and reciprocal stimulation of growth factor production, 
respectively {Sporn et a/., 1980). A second group of proto-oncogenes 
encode either growth factor receptors themselves or their functional 
homologs. The growth factor receptors link the information from the 
extracellular signals to intracellular signaling pathways. With respect to 
cancer development, the transmembrane receptor tyrosine kinases play 
the most important role (Aaronson, 1991 ). The third group of proto-
oncogenes produce proteins which are capable of interacting with 
activated tyrosine kinases and are involved in cell signaling {Schlessinger, 
1994 ). The final group of proto-oncogenes are those involved in the 
control of gene expression by their function as transcription factors. This 
is the last step of signal transduction and is the level at which control of 
growth and proliferation ultimately operates. Several proto-oncogene 
proteins, such as MYC (Amati et a/., 1994; Harrington et a/., 1994 ), JUN 
and FOS (Angel et a/., 1991 ), have been shown to bind to DNA and 
presumably control the transcription of genes. Since the various groups 
of proto-oncogenes perform major functions in the cell, any disruption in 
their expression would therefore be expected to result in disruption in the 
control of that cell, leading to its death or transformation. 
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Certain mechanisms have been reported by which proto-oncogenes 
are activated. The first mechanism is the production of an abnormal 
product which can occur by point mutations (McCormick, 1995; Rodrigues 
et al., 1994 ). chromosomal translocation (Rabbitts, 1994 ), or deletion of 
part of the protein (Seidel-Dugan et a/., 1992). The second mechanism is 
the over-production of the normal protein by amplification of the proto-
oncogene (Schwab et al., 1990). The third mechanism of activation is 
described as loss of control mechanisms (Spencer et al., 1991 ). There is 
no single consistent mechanism of activation of these genes, but the final 
result is to give a protein that can cause abnormal growth. 
Oncogenes have been found in most groups of cancers so far 
examined. A few of the most common cancers and associated oncogenes 
are listed in Table 1.2 (Cooper, 1990; MacDonald et at., 1997). Mutations 
in proto-oncogenes are very rarely the cause of familial cancers, since 
they are likely to be lethal. In many tumors such as Burkitt's lymphoma, 
the presence of the oncogene is likely to have an important, but not 
necessarily primary, role in the cancer development. In the majority of 
other cancers it is not clear exactly what role the oncogene has to play in 
the carcinogenesis. It was also reported that one gene might be able to 
destablize the cell sufficiently to provide an environment in which further 
changes in other oncogenes are likely (Wyllie et a/., 1987). A single 
mutational event usually is not enough for a tumor to develop, and much 
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evidence indicates that there is collaboration between different oncogenes 
necessary to produce the fully transformed phenotype. In model systems 
it was initially demonstrated that whereas a single oncogene was 
insufficient for transformation, collaboration between genes could result in 
full transformation. More direct observations have been made in 
transgenic mice (Sinn et a/., 1987). Since carcinogenesis is a multistage 
process, model systems with components representing different stages 
involved in malignant developments are usually crucial for more detailed 
investigation on mechanistic studies. 
1.2. Human papillomavirus (HPV) 
Cervical cancer is a major health issue for women, because it is the 
third most common and fourth most deadly malignancy among women in 
the world (Parkin et al., 1999; Pisani et a/., 1999). The global estimates 
are for 452,000 new cases and more than 234,000 deaths from cervical 
cancer each year around 2000(Miller et al., 2000). Screening for cervical 
cancer has undoubtedly led to an overall decline in incidence and 
mortality in many countries. However, mortality rates are leveling off or 
increasing in women under 40 years of age in most countries (Beral eta/., 
1994 ). Consequently, developing therapeutic strategies for treating 
cervical cancer continues to be an important objective. 
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Table 1.2 Oncogenes in human tumors (adapted from MacDonald and 
Ford, 1997) 
Tumor Associated oncogenes 
Bladder HRAS, KRAS, /NT-2 
Brain ERBB 1, SIS 
Breast ERBB2, HRAS, MYC, INT-2 
Cervical MYC, HRAS, ERBB2 
Colo rectal 
Gastric 
Lung 
Melanoma 
Neuroblastoma 
Ovarian 
Pancreas 
Prostate 
Testicular 
Leukemia 
HRAS,KRAS,MYB,MYC 
ERBB1, HST, MYB, MYC, NRAS, YES 
ERBB1, HRAS, KRAS, MYC, LMYC, NMYC 
HRAS 
NMYC 
ERBB2,KRAS 
KRAS, MYC 
MYC 
MYC 
ABL, MYC, BCR, BCL 1, BCL2 
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1.2.1. Introduction 
Sexual activity has been recognized as one of the most important 
risk factors involved in the development of cervical carcinoma, and 
numerous infectious agents have been suggested to play a causative role 
(Davies et a/., 1993; Vousden, 1989). Currently, the most likely 
candidates among those are human papillomaviruses (HPVs). The 
hypothetical link between HPVs and cervical carcinoma was first 
suggested in the 1970s (zur Hausen, 1975; zur Hausen, 1976). Less than 
1 0 years after the hypothesis, the DNAs of HPV types were cloned and 
characterized (zur Hausen, 1989). Moreover, these DNAs are regularly 
and frequently found in biopsies obtained from cervical cancer patients 
throughout the world (Durst eta/., 1983; Boshart eta/., 1984). 
There is a large virus family known as papovaviradae consisting of 
polymaviruses, simian virus 40 (SV 40), and human papiflomaviruses 
(HPVs) (Salsman, 1986). HPVs are small DNA viruses known to be 
capable of inducing papillomas or warts in a number of higher vertebrates 
including human beings (Table 1.3 ). Infection by HPVs is restricted to 
epithelial cells of the epidermis or squamous epithelial cells of the oral or 
genital mucosa. Infection is believed to occur by the entry of the virus into 
basal epithelial cells exposed by microlesions or local abrasions of the 
skin, or into proliferating cells that are exposed at the squamocolumnar 
border of the cervix uteri (Subramanian, 1993). 
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Table 1.3 Naturally occurring cancers associated with papillomaviruses (adapted from Shah eta/., 
1990) 
Species Cancer Predominant viral types Co factors 
Humans Skin carcinomas in EV patients HPV-5, -8 Sunlight, genetic defect 
lower-genital-tract cancers HPV-16, -18, -31, -33 Not known 
Malignant progression of HPV-6, -11 X-irradiation 
respiratory papillomas 
Cattle Alimentary-tract carcinoma BPV-4 Bracken fern 
Eye and skin carcinoma Not characterized Sunlight 
Sheep Skin carcinoma Not characterized Sunlight 
Cottontail rabbit Skin carcinoma Cottontail rabbit Not known 
papillomavirus(CRPV) 
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1.2.2. Classification 
More than 70 HPV types have been isolated and characterized so 
far, among which 30 types are associated with anogenital tract lesions 
including cervical carcinomas (DeVilliers, 1989). According to infection 
region, HPVs can be divided into two groups: those that cause cutaneous 
lesions and those that cause lesions of the oral or genital mucosa (Orth, 
1986). According to malignant potential of lesions they induce, HPVs are 
classified into two other groups. The low-risk group is associated with 
benign lesions, whereas the high-risk group is associated with malignant 
lesions (zur Hausen et a/., 1994 ). A majority of HPVs causing mucosal 
lesions have been found to be associated with lesions of the genital tract. 
Following the initial evidence implicating HPVs related to cervical 
carcinogenesis, further investigations identified the first high-risk type 
HPV16 DNA and the second high-risk type HPV18 DNA in 70-80o/o of 
cervical tumors and tumor cell lines (Pater et a/., 1985). Approximately 
85% of all cervical carcinomas are conservatively estimated to be high-
risk HPV positive. Epidemiological studies have shown that infection with 
a high-risk HPV is a significant risk factor for developing cervical cancer 
(Munger, 1995). 
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1.2.3. Genome organization 
Papillomaviruses are small, nonenveloped, icosahedral DNA viruses 
that replicate in the nucleus of squamous epithelial cells. The 
papillomavirus particles are 52-55 nm in diameter and consist of an 
icosahedral outer shell or capsid made up of viral structural proteins 
enclosing a core that contains the viral DNA complexed with host histones 
forming a nucleosome structure similar to that of the host cellular DNA. 
Two viral proteins constitute the capsid. The major protein has a 
molecular weight of approximately 55 kDa and represents approximately 
80% of the total structural protein. The minor protein has a molecular 
weight of approximately 70 kDa (Howley, 1991 ). 
Full HPV particles contain the viral genome in a double-stranded 
circular DNA form. All HPVs have a genome with a size of approximately 
8,000 base pairs (bp) and a molecular weight of 5.2x 106 Daltons. The 
guanosine (G) : cytosine (C) content is approximately 42°k. The DNA 
constitutes approximately 12°/o of the virion by weight, accounting for the 
density in cesium chloride of approximately 1.34 g/ml (Cranford et a/., 
1963). 
Despite the significant differences in target cell specificity of HPVs. 
the structural genome organization (Figure 1.2) and functions of each 
genomic region (Table 1.4) of all of the known HPVs are similar. The viral 
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Table 1.4 Functions of HPV encoded proteins (adapted from Davies et 
a/., 1993) 
Early proteins 
E1 
E2 
E5 
E6 
E7 
Late proteins 
L1 
L2 
E4 
Non-coding region 
URR 
Control of replication 
Control of transcription 
Transformation (not expressed in cancers) 
I mmortalisation/transcriptional control 
I mmortalisation/transcriptional control 
Structural protein 
Structural protein 
Disruption of cell keratin cytoskeleton 
Cis acting transcription and replication control 
16 
Figure 1.2 Genomic organization of HPVs (adapted from Park et 
a/., 1995). 
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genome is generally organized into three major regions: early region (E), 
late region (L), and upstream regulatory region (URR). 
1.2.3.1. Upstream regulatory region 
Upstream regulatory region (URR), also called long control region 
(LCR) or non-coding region (NCR), is a 400 bp DNA segment adjacent to 
the origin of viral replication. URR does not encode protein, but instead, 
contains a complex array of overlapping binding sites for many different 
transcriptional repressors and transcriptional activators (Turek, 1994 ). 
These include activator protein 1 (AP1 ), keratinocytic-specific transcription 
factor 1 (KRF1 ), and nuclear factor (NF-1/CTF) as well as virally derived 
transcriptional factors encoded by the early region. Functioning as 
enhancer elements, URR regulates transcription from the early and late 
regions and controls the production of viral proteins and infectious 
particles. It is generally believed that URR plays a critical role in 
determining the host range of specific types of HPV because of its 
potential for binding a wide array of specific transcriptional factors 
(Hoppe-Seyler et a/., 1994 ). 
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1.2.3.2. Early region 
The early region is downstream of the URR and consists of six open 
reading frames (ORFs), designated E1. E2. E4, E5, E6, and E7. Open 
reading frames are DNA segments that are transcriptional units and are 
capable of encoding proteins. Two of the early region ORFs, E6 and E7, 
encode oncoproteins critical for viral replication as well as host cell 
immortalization and transformation. In several malignant lesions and in 
cell lines derived from cervical cancer (SiHa. CaSki and Hela). HPV DNA 
is integrated in the cellular genome in single or multiple copies. This viral 
DNA integration results in the disruption of several viral genes with 
preservation of only E6 and E7 genes (Baker et at., 1987a; Matsukura et 
at., 1986; Munger et al .• 1992; Schwarz et a/ .• 1985). Both E6 and E7 
proteins are reported to have an immortalizing and transforming activity in 
vitro (Tommasino eta/., 1995). The E1-encoded protein of HPV 11 has 
ATPase activity (Bream et al .• 1993). The full-length E2-encoded protein 
acts as a transcriptional activator that binds to specific DNA sequences in 
URR to increase transcription of the early region. whereas a smaller E2-
encoded protein inhibits transcription of the early region (Ward et al .• 
1989). On the other hand. the E4 protein appears to be important for the 
maturation and replication of the virus and, like the L 1 and L2 capsid 
proteins, is expressed in later stages of infection when complete virions 
are being assembled (Brown et at .• 1994 ). However, less is known about 
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the function of E5 in the viral life cycle. The E5 protein interacts with cell 
membrane receptors, and this may stimulate cell proliferation in HPV-
infected cells (Conrad eta/., 1994 ). 
1.2.3.3. Late region 
The late gene region contains two separate ORFs, termed L 1 and 
L2, which encode the viral capsid proteins. The L 1 encodes the major 
viral capsid protein, which is highly conserved among different HPVs. 
Antibodies made against bovine papillomavirus l1 capsid proteins cross-
react with HPVs and have been used to identify HPV capsid proteins in 
human tissues. In vitro vaccinia virus and baculovirus expression systems 
have been used to produce HPV L 1 capsid protein that self-assemble to 
form empty viral-like particles and results showed that HPV type-specific 
antibodies occur in HPV-infected women (Galloway, 1994; Kinnbauer et 
a/., 1994 ). The l2 encodes the minor capsid protein, which has 
considerably more sequence variation between HPV types than does the 
l1 protein and has been used as a source of antigen for type-specific 
HPV antibodies. Transcription from the L1 and l2 ORFs occurs when 
complete virions are being assembled. Transcription appears to be 
regulated by cell-derived transcriptional regulators that are only produced 
by the more differentiated epithelial cells in the upper layers of infected 
epithelium (Baker et al., 1987b). 
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1.3. Apoptosis 
Apoptosis or programmed cell death (PCD) is a genetically 
controlled response for cells to commit suicide (Kerr et al .• 1972; Wyllie et 
a/., 1980; White, 1996). It is recognized to play critical roles in a wide 
variety of normal physiologic processes. including fetal development, 
immune cell education, and tissue homeostasis (Reed, 1994; 1998). 
Moreover, dysregulation of apoptosis contributes significantly to the 
pathogenesis of many human diseases, including those such as cancer, 
autoimmunity, and restenosis characterized by insufficient cell death, as 
well as those involving excessive cell death, such as acquired 
immunodeficiency syndrome (AIDS), stroke, myocardial infarction, and 
some neurodegenerative diseases (Thompso, 1995). 
Apoptosis differs from necrosis or accidental cell death in a number 
of important ways. Firstly, it is an active process as opposed to an 
unplanned process induced by cell injury. Secondly. apoptotic cells are 
recognized by phagocytes and removed before they disintegrate. As a 
consequence. there is no surrounding tissue damage or induction of 
inflammatory responses. In contrast, in necrosis, cells become leaky, 
release macromolecules and rapidly disintegrate, thereby inducing 
inflammation (Darzynkiewicz et a/., 1998 ). 
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Table 1.5 Changes in cell morphology and gene expression during 
apoptosis (adapted from Darzynkiewicz eta/., 1998) 
Morphological Changes 
• Cell shrinkage 
• Cell shape change 
- Nuclear chromatin condensation 
- Loss of visually recognizable nuclear structure (framework) 
• DNA hyperchromicity 
• Dissolution of nuclear envelope 
• Nuclear fragmentation 
• Condensation of cytoplasm 
• Loss of cell surface structures (pseudopodia, microvilli) 
• Formation of apoptotic bodies ("budding", "blebbing") 
• Detachment of cells in cultures 
• Phagocytosis of the apoptotic cell remains 
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Biochemical and Molecular Events of Apoptosis 
• Increased ratio of apoptosis promoters vs inhibitors of Bcl-2 family 
• Mitochondrial changes 
- Decrease in the transmembrane potential 
- Leakage of cytochrome C 
- Oxidative stress (formation of ROI) 
• Intracellular Ca2 + rise 
• Cell dehydration 
• Loss of asymmetry in plasma membrane phospholipids 
• Activation of serine protease(s) 
• Cascade-activation of caspases 
- Proteolysis of the "death substrates" 
• Degradation ofF actin and proteins other than .. death substrate" 
• Loss of DNA stability to denaturation 
• Presence of ss DNA sections 
• Endonucleolytic DNA degradation 
- 50-300 Kb fragments 
- Cleavage in internucleosomal DNA 
• Activation of transglutaminase 
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1.3.1. Characteristics 
Table 1.5 lists the morphological and molecular characteristics that 
appear during apoptosis. Many of these features serve as markers to 
identify and quantify apoptotic cells. 
1.3.1.1. Morphological 
One of the early events of apoptosis is cell dehydration. Loss of 
intracellular water leads to condensation of the cytoplasm followed by cell 
shape and size changes. As a consequence. the cells become elongated 
or acquire irregular shape and become smaller. Another change is 
condensation of nuclear chromatin, which is one of the most characteristic 
features of apoptosis. The condensation starts at the periphery of the 
nucleus with the areas of condensed chromatin often acquiring a concave 
shape resembling a half-moon or horseshoe. The condensed chromatin 
has a very uniform. smooth appearance, with no evidence of any texture 
normally seen in the interphase nucleus (Darzynkiewicz et a/., 1997; 
Szabo eta/., 1987). 
During further progression of apoptosis the nuclear envelope 
disintegrates, lamin is proteolytically degraded. and the nucleus 
undergoes fragmentation. Nuclear fragments are then scattered 
throughout the cytoplasm. Together with constituents of the cytoplasm, 
the nuclear fragments are packaged and enveloped by fragments of the 
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plasma membrane. These structures, called apoptotic bodies 
subsequently detach from the surface of the cell by the process often 
defined as "blebbing", which rather resembles the mechanism of "budding" 
in yeast (Majno et al., 1995). Loss of cell surface structures is also a 
characteristic feature of apoptosis (Endersen et a/., 1995). Cells detach 
during apoptosis and float in the medium when they grow in tissue culture. 
When apoptosis occurs, in vivo apoptotic bodies are phagocytized by 
neighboring cells, including those of epithelial or fibroblast origin, without 
triggering an inflammatory reaction or scar formation in the tissue (Arends 
et al., 1995; Wyllie, 1992). 
1.3.1.2. Molecular 
Changes in the expression level ratio of apoptosis promoters of the 
Bcl-2 protein family, such as Bax, Bik, and Bad, over apoptosis inhibitors 
such as Bcl-2, Bcl-xL. and Bcl-w, appear to be among the earliest 
molecular events of apoptosis (Golstein, 1997; Kumar, 1997; Nagata, 
1997). These proteins dimerize with one another, which is modulated by 
their phosphorylation (Gajewski et al., 1996). However, little is known 
about the mechanism by which the Bcl-2 proteins execute their function in 
promoting or inhibiting apoptosis. The structure of Bcl-xL suggests that it 
may form pores in biological membranes and interactions between the 
antagonistic members of the Bct-2 family may regulate the pore's 
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permeability (Muchmore et a/.. 1996). The loss of mitochondrial trans· 
membrane potential (Petit et al., 1995), the appearance of reactive 
oxidative intermediates (ROis) within the cell (Hedley et al., 1996), and 
the release of cytochrome C (Kluck et al., 1997) and Ca2• from 
mitochondria (McConkey et al., 1989) are all presumed as consequences 
of the opening of pores in the mitochondrial membrane. These events can 
activate downstream caspases, and appear to be the earliest events, 
triggering the cascade of the apoptotic process (Krippner et a/ .• 1996; Wu 
et a/., 1997). 
The most characteristic change in the plasma membrane is the loss 
of asymmetry of the phospholipids on the plasma membrane leading to 
exposure of phosphatidylserine on the surface (Fadok et al., 1992). 
Exposure of phosphatidylserine on the out leaflet of the plasma membrane 
preconditions remnants of the apoptotic cells to become a target for 
phagocytizing cells. Loss of pseudopodia or microvilli is paralleled by 
degradation of F actin (Endersen et al., 1995). In addition, activation of 
transglutaminase results in a change in the physical properties of the cell, 
making them stiffer and resistant to deformation under pressure 
(Piacentini eta/ .• 1995). 
Emerging evidence demonstrates the important role of a family of 
aspartate specific cysteine proteases recently termed caspases in 
apoptosis (Ainemri et a/., 1996). The cascade-like activation leads to 
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proteolytic degradation of selected proteins. These substrate proteins 
include poly(ADP)ribose polymerase(RARP), lamin, actin, U1 small 
nuclear ribonucleo protein (snrp), rho-DGI. and DNA-dependent protein 
kinase (Lazebnik et al .• 1994; Nicholson et al .• 1995). Some specificity in 
degradation of the proliferation-associated nuclear proteins Ki-67, p120, 
and proliferating cell nuclear antigen (PCNA) has also been observed 
(Gorczyca et a/., 1993 ). 
The activation of an endonuclease(s) is another very characteristic 
event of apoptosis (Compton. 1992). Initially, DNA is cleaved at the sites 
of attachment of chromatin loops to the nuclear matrix {Oberhammer et 
a/., 1993). Subsequently, DNA is preferentially cleaved between 
nucleosomes. The products are discontinuous DNA fragments 
representing nucleosomal- and oligonucleosomal- sized DNA sections. 
They form a characteristic "ladder" pattern during agarose gel 
electrophoresis (Gong et a/., 1994). However. in many cell types, DNA 
cleavage during apoptosis does not proceed to inter nucleosomal-sized 
sections but rather proceeds only to 300-350 Kb size DNA fragments 
(Ormerod et al .• 1994; Zakeri et al., 1993; Zamai et al .• 1996). 
1.3.2. Inducers 
Apoptosis is imperative for host survival since it discards unwanted, 
damaged. and atypical cells. This process is implicated jn the continuous 
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regulation of development, differentiation, and homeostasis. Furthermore, 
apoptosis is a response to physiological and pathological factors that 
disrupt the balance rates of cell proliferation and death (Dixon et al., 
1997). Both the activation and inhibition of apoptosis are genetically 
controlled. Additionally, they are influenced by physiological and 
nonphysiological stimuli (Fesus eta/., 1991 }. 
Loss of protective signals, such as hormones and cytokines, is an 
important physiological trigger of apoptosis. Several growth factors and 
hormones have been shown to promote cell survival. Apoptosis occurs in 
normal tissues when there is a loss of these hormonal signals. Loss of 
androgen stimulated by castration of male nude mice or rats leads to 
prostate atrophy (Kyprianou et al., 1988; 1991 }. Glucocorticoids are 
steroid hormones that are involved in the induction of apoptosis in 
immature T -cells in the thymus. The cell death induced in this case 
requires protein synthesis (Cohen et at., 1984}. Adhesion molecules 
(intergins) have also been shown to promote cell viability upon binding to 
specific cell surface receptors (Ruoslahti eta/., 1994 }. 
Cytokines are low molecular weight signaling molecules that bind to 
high affinity receptors on target cells. They may provide signals for cell 
survival, proliferation, differentiation or death. Death inducing cytokines, 
such as FasL and tumor necrosis factors (TNF), can act as membrane 
bound ligands or soluble secreted factors. Fas and TNF receptor ligation 
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induces apoptosis in the absence of RNA or protein synthesis (ltoh et a/., 
1991; Yonehara et al., 1989). TNF mediates a subset of mature T cells to 
undergo apoptosis through the p75 TNF receptor (Zheng et al., 1995). 
lnterleukin (IL)-4 was shown to trigger apoptosis in immature B cells 
(Mana be et a/., 1994 ). On the other hand, IL-6 inhibited the apoptotic 
response of myeloid cells induced by transfected wild type p53 and in 
malignant plasma cells (Lichtenstein et a/., 1995; Yonish-Rouach et a/., 
1991 ). 
One of the most important initial observations with respect to drug-
induced apoptosis was that etoposide caused rapid internucleosomal 
fragmentation (Kaufmann, 1989). This chemotherapeutic agent was thus 
recognized as a potent inducer of apoptosis. The spectrum of diverse 
acting cytotoxic agents known to trigger an apoptotic response includes 
inhibitors of protein and RNA synthesis, dihydrofolate reductase inhibitors, 
topoisomerase I and II targeting drugs, nucleoside analogues, microtubule 
poisons, alkylating agents, cisplatin, ionizing radiation, and hydrogen 
peroxide (Fisher, 1994; Hannun, 1997). Many of these agents have been 
shown to provoke consistently an apoptotic response in a variety of cell 
types. Another nonphysiological factor is Ca2• concentration elevation 
(McConkey et a/., 1990). Ca2• concentration control is critical to cell 
viability and function. However, uncontrolled Ca2• increase can mediate 
cell killing (Orrenius et a/., 1989). Current studies demonstrate that it is 
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possible that both physiological and nonphysiological inducers utilize 
common molecular mediators in the induction of apoptotic cell death. 
1.3.3. Regulation 
A large number of apoptosis regulators have been identified, and 
several gene families largely comprised of cell death mediators have 
emerged. In addition, a variety of previously identified oncogenes or 
tumor suppressor genes have been shown to modulate pathways for 
apoptosis. Functional and comparative studies with some cell death 
regulators have enabled a limited amount of molecular ordering in the 
apoptotic pathway as shown in Figure 1.3 (McKenna eta/., 1998). 
1.3.3.1. Bcl-2 protein family 
Bcl-2 pr'ltein family includes both pro-apoptotic proteins, such as 
Bax, Bak, Bad, and Bik, and anti-apoptotic proteins, such as Bcl-2 and 
Bcl-xL. Family members interact to form homodimers and heterodimers 
with other related or non-related proteins. Bci-2/Bcl-2 homodimerization 
involves a head-to-tail association in which sequences located in the first 
approximately 80 amino acids of the protein where the BH4 domain 
resides form an interaction with sequences located in the more remote 
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Figure 1.3 Gene regulation of apoptosis (adapted from McKenna 
eta/., 1998) 
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portions of the protein where BH1, BH2, and BH3 domain are located 
(Sa to et a/., 1994 ). Therefore, it is not a surprise that Bcl·2 mutants with 
the deletion of BH4, BH1, or BH2 do not form homodimers with 
themselves but still bind the wild·type Bcl·2 protein affording mutant/wild· 
type heterodimers (Hanada et al., 1995). These mutants are deficient in 
anti·apoptotic function in mammalian cells, suggesting that Bci·2/Bcl·2 
homodimerization is important for function (Borner et a/., 1994 ). Recent 
data suggest that deletion of BH4 domain of Bcl·2 converts the protein to 
a dominant inhibitor of the wild·type Bcl·2 protein, suggesting that 
mutant/wild·type heterodimers may be dysfunctional dimmers. 
In contrast to Bci·2/Bcl·2 homodimerization, the BH4 domain of Bel· 
2 is completely expendable for dimerization with Bax. Actually, the first 
approximately 80 amino acids of Bcl·2 can be removed without impairing 
heterodimerization with Bax. Although BH4 is not required for 
heterodimerization with Bax, the BH 1 and BH2 domains are necessary 
(Hanada et al., 1995). BH4 domain of Bcl·2 is postulated to sterically 
interfere with the binding of Bax to some other death effector protein or to 
modulate somehow post·translational modifications of the Bax protein. 
However, it is also possible that this domain is required for Bci·2/Bcl·2 
homodimerization or for interactions of Bcl·2 with other proteins that 
require the BH4 domain for their association with Bci-2/Bax complexes 
(Wang et a/., 1994 ). 
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Further studies show that the BH1 and BH2 domains of Bax are 
expendable for both homodimerization with Bax and heterodimerization 
with Bcl-2. In contrast, the BH3 domain of Bax is absolutely required for 
binding to both wild-type Bax and Bcl-2 (Zha et a/., 1996). Bax/Bcl-2 
heterodimerization appears to occur through a tail-to-tail interaction. N-
terminal truncation mutants of Bax can also homodimerize with 
themselves, indicating that Bax/Bax homodimerization also occurs via tail-
to-tail interaction (Zha eta/., 1996). 
Data show that many other Bcl·2 family members can form 
homodimers with themselves and heterodimers with other proteins. Cell 
susceptibility to apoptosis is generally thought to be largely influenced by 
the relative ratios of pro·apoptotic and anti·apoptotic Bcl-2 family proteins. 
1.3.3.2. Caspase family 
Subsequent to the description of the pro .. apoptotic function of CED-
3, interleukin-1 J3-converting enzyme (ICE), and murine Nedd2, a family of 
homologues have been identified, all of which are cysteine proteases that 
share the requirement for cleavage at aspartate residues. These 
proteases have been termed caspases (Yuan et a/., 1993 ). There are 11 
caspases being identified and described so far. 
Caspases are produced as inactive pro-enzymes, and they are 
activated by proteolytic cleavage. which generates two subunits that form 
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a tetramer. Emerging evidence suggests the caspases containing a long 
pro-domain are the first to be activated in response to apoptotic stimuli, 
while those with short or absent pro-domains are activated subsequently 
and are the effector proteases responsible for cleaving the cellular 
substrates that mediate apoptotic cell death (Harvey et a/., 1998). 
The genetic evidence from C. elegans implying a central effector 
role for proteases was supported by the fact that over-expression of 
caspases induces apoptosis in a variety of cell types (Ellis et a/., 1986). 
Moreover, specific inhibitors of caspases block apoptosis induced by a 
wide range of stimuli. Caspase inhibitors include viral gene products and 
short synthetic polypeptides. Viral gene products, ermA and p35, can 
inhibit apoptosis induced by both Fas and TNF, suggesting that caspases 
are downstream mediators of their cytotoxicity (Tewari et al., 1995). It is 
also shown that inhibition of apoptosis by over-expression of Bcl-2 or Bci-
XL also inhibits activation of caspases. Bcl-2 is unable to prevent 
substrate cleavage by active caspases (Kumar, 1997). 
1.3.3.3. Tumor suppressor genes 
The p53 tumor suppressor gene encodes a protein that is critical for 
maintaining the integrity of the genome. It is the most frequently mutated 
gene in human tumors (Vogelstein, 1990; Hollstein. 1991 ). Reintroduction 
of p53 into transformed cells can induce apoptosis {Yonish-Rouach et at., 
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1991 ). p53 accumulates and directs apoptosis in response to DNA 
damage in skin, thymocytes, and intestinal epithelium (Clarke et al., 1993; 
1994; Merritt et at., 1994; Ziegler et a/., 1994). Endogenous p53 
expression was shown to significantly accelerate apoptosis in myeloid 
32D cells upon withdrawal of IL-3 (Blandino et al., 1995). Additionally, 
anti-sense p53 oligonucleotides reduced the level of apoptosis in growth 
factor-dependent leukaemia cells after withdrawal of growth factor (Zhu et 
a/., 1994 ). The mechanism whereby p53 leads to G 1 arrest following DNA 
damage can be attributed to its role as a transcription factor. It is 
reasonable to suspect that a similar transcription·dependent mechanism 
might exist for apoptosis. In that case, p53 might activate the 
transcription of death genes (Bax) or repress the transcription of survival 
genes (Bcl-2) (Miyashita et a/., 1994 ). Furthermore, p53 has been 
reported to stimulate Bax expression in promoter-reporter assays in 
cultured cells (Miyashita et at., 1995). These results indicate that up-
regulation of Bax transcription is a means by which p53 induces 
apoptosis. 
Rb is another tumor suppressor gene, which is inactivated by 
deletion or mutation in many different cell types (lee, 1991 ). The 
connection between Rb and apoptosis came from several directions. 
Induction of apoptosis by E1A was genetically inseparable from the ability 
of E1A to stimulate DNA synthesis and bind p300 and Rb, suggesting that 
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some aspect of deregulation of cell growth control by E 1 A is responsible 
for apoptosis (White et al.. 1987; 1991 ). A loss of Rb function during 
development apparently produces inappropriate DNA synthesis and 
apoptosis, suggesting that Rb function is required in development to 
inhibit cell cycle progression, thereby avoiding the apoptotic response 
(Morgenbesser et al., 1994; Pan et at., 1994 ). Overriding Rb by enforced 
E2F expression induces both DNA synthesis and apoptosis (Qin et at .• 
1994; Kowalik et al., 1995). 
1.3.3.4. Fas and TNF receptor family 
Many cellular responses such as proliferation, differentiation and 
survival are initiated by extra-cellular signals such as cytokines acting 
through specific cell surface receptors. It is not surprising that specific 
receptor-ligand binding can also mediate apoptosis. Since these external 
stimuli are only part of the information influencing the decision between 
self-destruction and survival, intracellular signaling pathways, such as the 
Fas-mediated pathway, are of particular importance in controlling 
apoptosis. Cell-surface receptor-mediated mechanisms involve the 
stimulation of the receptor, the activation of protein kinase/phosphatase 
cascades, and the release of second messengers to upregulate or 
suppress the transcription of specific genes. 
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Fas and TNF receptors belong to the expanding tumor necrosis 
factor receptor (TNFR) family of cell-surface receptors (Nagata et a/., 
1995). Induction of apoptosis through aggregation of cell surface Fas, eg. 
by binding to Fas-ligand, is particularly important in regulation of the 
immune system. It appears that apoptosis induced by engaging the T -cell 
receptor on T -lymphocyte cell lines is mediated through interaction 
between Fas-ligand and Fas. Both Fas and TNF receptors are 
functionally dependent on a specific sequence of 60-70 amino acids in 
their carboxyl terminus termed the "death domain" (Golstein et al., 1995). 
It is noted that this region is homologous to the protein reaper (White et 
al., 1994), which is essential for most programmed cell death in 
Drosophila. This suggests that Fas and TNFR were produced in evolution 
after gene fusion of exons encoding an inducer of apoptosis related to 
reaper with those encoding a surface receptor. 
Several proteins that may form part of the intracellular pathway 
induced by Fas have been identified recently, including MORT1/FADD 
(Chinnaiyan et al., 1995), TRADD (Hsu et al., 1995), and RIP (Stanger et 
a/., 1995). Over-expression of any of these three genes in transient 
expression systems induces apoptosis. 
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1.3.3.5. Oncogenes 
The Myc family of proto-oncogenes encodes DNA binding proteins 
that can heterodimerize with other factors to form transcriptional 
activators or suppressors. They have been implicated in the regulation of 
genes involved in proliferation, differentiation, and apoptosis (Amati eta/., 
1994 ). Normal proliferating fibroblasts maintain c-Myc expression through 
the cell cycle. Constitutive high-level expression of c-Myc abolishes cell 
cycle arrest in fibroblasts following serum deprivation, and results in 
concomitant proliferation and apoptosis (Evan et a/., 1992). It is shown 
that the insulin-like growth factors and platelet-drived growth factor 
(PDGF) could inhibit Myc induced apoptosis in low serum (Harrington et 
a/., 1994). Moreover, anti-apoptotic proteins such as Bcl-2 and mutant 
p53 can inhibit Myc induced cell death, enabling proliferation (Lotem et 
a/., 1995). However, mice with Myc alone did not show hyperplasia, 
whereas Myc/Bcl-2 double transgenic mice rapidly developed malignant 
lymphomas (Cory eta/., 1994 ). 
Ras genes encode a family of small GTP-binding signal transducing 
proteins associated with apoptosis (Izquierdo Pastor et al., 1995). Ras 
genes become oncogenic when activated by mutation, and can cooperate 
with other genes such as p53, Myc, EIA, and SV40 in cellular 
transformation (Barbacid, 1987). In the presence of interferon regulatory 
factor 1 (IRF-1) eDNA, cells with activated ras undergo apoptosis, 
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suggesting that IRF-1 may act like a tumor suppressor gene as it can 
mediate the death of an oncogenic activated cell (Tanaka et al., 1994). 
Other studies suggested that the consequence of ras activation is 
dependent on the activity of protein kinase C (PKC). Activated ras 
induced apoptosis in a T-lymphoblastoid cell line, when PKC activity was 
suppressed. Apoptosis induced by ras in this system could be blocked by 
Bxl-2 (Chen et al., 1995). In contrast, other groups have reported that 
activation or over-expression of H-ras could have a protective effect on 
apoptosis (Lin eta/., 1995). 
1.4. Multistage cervical carcinogenesis 
Like all the other human cancers, the development of cervical 
cancer is a multistage process. The current concept of squamous 
carcinoma of the cervix is that it is a multistage disease developing over a 
period of 10 to 15 years and arising as a result of mutational event in the 
metaplastic epithelium of the transformation zone in early adult life. Three 
stages are recognized as preinvasive, microinvasive and invasive stage, 
respectively. The characteristic histological feature of the preinvasive 
lesions is that the malignant cells are confined to the epithelium. The 
terminology "cervical intraepithelial neoplasia" {CIN) is used to describe 
this initial stage. The second stage, microinvasive cancer, is believed to 
represent the earliest stage of invasion. Invasive cancer. which is the 
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final stage, occurs once vascular and lymphatic channels have been 
breached by tumor cells (Coleman et al., 1986). 
Evidence to support this sequence of events has been obtained 
from studies of the natural history of CIN and invasive cancer. 
Epidemiological studies have shown that the risk factors for both 
preinvasive and invasive lesions are identical. Multiplicity of sexual 
partners, early age at first coitus, venereal disease and smoking are 
important determinants of risk for squamous cervical cancer (Greenberg 
eta/., 1985; Vessey eta/., 1983). 
The more important evidence linking preinvasive and invasive 
cancer comes from retrospective studies of untreated patients with 
precancerous lesions of the cervix. It was found that 57o/o of the women 
with untreated precancerous lesions of the cervix developed invasive 
cancer within 10 years. Furthermore, 19% of women with preinvasive 
lesions may develop invasive cancer if they remain untreated for two 
years or more (Kinlen et al., 1978; Peterson, 1956). 
However, the evidence linking these two forms of disease is largely 
circumstantial, and objective evidence of a biological connection between 
the different stages of the disease is obviously needed. For this sake, 
studies of the role of HPVs in cervical carcinogenesis may reveal this link 
efficiently. 
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1.4.1. HPV 
Normal cells in vitro replicate only a limited number of times before 
they stop dividing and undergo senescence. Immortalized cells have 
overcome this limitation of life span and can be propagated indefinitely in 
tissue culture. Normal cells suspended in fluid or in a semisolid agar gel 
stop proliferating and eventually undergo senescence. In contrast, tumor-
derived cells demonstrate anchorage independency of cell growth and 
continue to grow and form colonies when suspended. The ability to grow 
in the absence of attachment is a characteristic feature of fully 
transformed cells that is clearly different from immortalization (Park et a/., 
1995). 
Introduction of HPV 16 or 18 DNA into rodent cell lines that are 
already immortalized causes the recipient cells to develop the capacity for 
anchorage independency of growth and the capacity to form tumors when 
injected into mice (Bedell et a/., 1987; Crook et a/., 1988). However, 
when HPV 16 or 18 DNA is introduced into early passage, 
nonimmortalized cells, a different result is observed. The recipient cells 
become immortalized but are not transformed and cannot form tumors in 
experimental animal systems (McCance et a/., 1988; Woodworth et a/., 
1988). 
HPV positive cervical cancers and cervical cancer-derived cell lines 
contain mRNA transcripts of the E6 and E7 ORFs, suggesting that the 
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viral genes are required for maintenance of the transformed phenotype. 
The hypothesis that E6 and E7 are the major transforming proteins gained 
further evidence with the demonstration that both proteins have 
transforming and immortalizing activities in vitro (Vousden, 1990). The 
amino terminal of E7 protein has been shown to play a role in the ability to 
form a complex with the cell encoded retinoblastoma (Rb) gene product 
and also provide the recognition signals for phosphorylation by casein 
kinase II (CK II). In turn Rb is associated with transcription factors, such 
as E2F, transactivation factors (TF) and c-Myc during certain stages of the 
cell cycle, thereby disrupting cell cycle control (Chellappan et al., 1992). 
Unlike E7, E6 exerts its oncogenic activity through interaction with the 
cellular protein. p53, which appears to possess both positive and negative 
functions in regulating cell growth (levine et a/., 1990). The mechanism 
by which HPV E6 proteins contribute to abnormal cell growth appears to 
be by binding and rapidly targeting the p53 protein for degradation via the 
ubiquitin pathway (Schaffner eta/., 1990). 
In summary, HPVs possess immortalizing and transforming 
functions by defeating intracellular defense mechanisms against 
neoplastic proliferation (Mansur eta/., 1993). As shown in Figure 1.4, the 
most critical is the double inactivation of the two anti-oncogene products 
pRb and p53, thus initiating cascades of events along two oncogenic 
pathways. 
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Figure 1.4 Summary of the cascades of oncogenic pathways of 
high-risk HPVs (adapted from Kao et a/., 1994 ). 
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1.4.2. HPV cofactors 
Association of HPVs with cervical infections and malignancies has 
been indicated by epidemiological, pathological clinical and in vitro data. 
However, the long latency period between the initial HPV infection and 
cancer development indicates that HPV infection alone is insufficient for 
cervical cacinogenesis. In addition, HPV-associated carcinogenesis is an 
inefficient process, because only a small fraction of women who are 
infected with high-risk HPVs will ever develop invasive cervical cancer. 
This suggests that additional factors might also be required for cervical 
carcinogenesis. Indeed, a number of endogenous and exogenous factors 
were reported to contribute directly or indirectly to the development of CIN 
and malignancy in HPV-infected individuals (Herrington, 1995). 
Exogenous cofactors with HPVs are more applicable for therapy than the 
endogenous factors and are proposed to play important roles in the 
process of initiation and progression, including cell DNA mutations, 
transregulation of HPV and cell transcription, regulation of cell growth, 
differentiation and death, virus neutralization and cell killing. Exogenous 
agents can be classified into physical-chemical cofactors, hormones, 
microbiological cofactors, and immune response cofactors {Khare et at., 
1995). 
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As one of physical-chemical cofactors. cigarette smoke and tobacco 
have been evidenced to be associated with cervical cancer (Brisson et a/., 
1994; Daling et al .• 1992). Also, clinical studies of the cervix found 
tobacco components in the endocervical mucus and DNA adducts from 
cigarette smoke constituents in the cells, implicating the chemical 
carcinogens in smoke as a cofactor in cervical cancer development 
(Sasson eta/., 1985: Simons eta/., 1995). 
Many exogenous hormones bind to a growing family of nuclear 
protein receptors and regulate viral and cellular transcription in epithelial 
cells. Progesterone and glucocorticoid endocrine steroid hormones have 
a profound influence on the differentiation of the cervical epithelium (Mittal 
eta/., 1993; Reagon eta/., 1983). 
Microbiological cofactors can be grouped as viruses and bacteria. 
The transforming region of herpes simplex virus-2 was associated 
epidemiologically with high grade CIN and cervical cancer and all the 
lesions containing this region were also positive for HPV (Yamakawa et 
al .• 1994 ). Although the association and mechanism are uncertain, the 
bacteria may promote progression to cancer by lowering the pH of the 
cervix or by inducing an inflammatory immune response (Guijon et a/., 
1992). 
The relatively immune system-inaccessible epithelial target of HPVs 
and the external release of virions reduce the effectiveness of the immune 
48 
response. The cell-mediated response is apparently compromised for 
CINs containing oncogenic HPVs, as evidenced by the decrease in the 
number of Langerhans' cells (Hawthorne et a/., 1988 ). Additionally, 
natural killer cell activity was increased significantly in CINs during 
regression of the lesions and loss of the HPV infection (Garzetti et a/., 
1995). 
1.4.3. Model systems 
As described previously. cancer development is a multistage 
process, and cervical carcinogenesis, with no exception, also exhibits this 
multistage feature. It is generally postulated that the infection with high-
risk HPVs, such as HPV 16 and HPV 18, can initiate CIN lesions and, in 
the presence of some cofactors, then result in the progression of CIN to 
invasive cervical cancer. Therefore, hypothetical model systems are 
mandatory components for in vitro studies of multistage cervical 
carcinogenesis. 
A number of groups have reported the immortalization of human 
cervical epithelial cells by transfection with HPV 16 and HPV 18 DNA 
(Pecoraro et a/., 1989; Woodworth et a/., 1988). Our laboratory 
discovered that both endocervical and ectocervical cells are targets for 
immortalization by either HPV 16 or HPV 18 (Sun et a/., 1992; Yokoyama 
et a/., 1994 ). Moreover, the metaplastic cells were immortalized by HPV 
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16 and featured CIN Ill in nude mice xenotransplants (Tsutsumi et a/., 
1993). The cell lines were named as HEC-18, HEC-16, and HEN-16, after 
immortalization by HPV 18 or HPV 16 (Pater et al., 1994; Sun et al., 1993; 
Tsutsumi et al., 1992; 1994; Yokoyama et al., 1995). They were 
subsequently transformed by cigarette smoke condensate (CSC) 
treatment to afford cell lines HEN-16T, HEN-16-2T, and HEC-18T (Nakao 
eta/., 1996; Yang et al., 1996; Yoshifumi et al., 1996). All of the cell lines 
provide effective model systems representing the final 2 stages of 
malignant progression of cervical cells for investigations on multistage 
carcinogenesis (Yang eta/., 1997). 
1.5. Cancer chemotherapy 
1.5.1. Introduction 
Regulation of apoptosis is essential for normal development and is 
an important defense against the emergence of cancer. Too much cell 
death can lead to impaired development and degenerative diseases, 
whereas too little cell death can result in cancer (White, 1996). In human 
cancers, there is disequilibrium between the rates of cell division and cell 
death, which is reflected by genetic alterations in apoptosis regulators 
stated previously. 
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Bcl-2 is the acronym for the B-cell lymphomalleukemia-2 gene. As 
implied by its name, Bcl-2 was first discovered because of its involvement 
in chromosomal translocations in B-cell lymphomas (Tsujimoto et a/., 
1985). Bcl-2 expression at abnormally high levels or in aberrant patterns 
is found in approximately 50% of human cancers, suggesting that 
deregulation of this proto-oncogene represents one of the most common 
events associated with human malignancy (Reed, 1995a). Bcl-2 is 
reported to be capable of blocking apoptosis induced by all types of anti-
cancer drugs by preventing drug-induced damage from being efficiently 
translated into cell death. Thus, tumor cells that contain high levels of 
Bcl-2 still experience the cell cycle inhibitory effects of drugs, but they 
remain viable for protracted periods of time, resulting in enhanced 
clonigenic survival in many cases (Delia et a/., 1995; Miyashita et a/., 
1994b). Furthermore, overexpression of Bcl-2 has been associated with 
poor responses to chemotherapy and shorter survival for patients with 
some types of lymphomas, acute myelogenous leukemias, and prostate 
cancer (Reed, 1995b). 
As stated before, both oncogene Myc and tumor suppressor gene 
p53 are involved in the control of apoptosis. Overexpression or 
deregulation of Myc in tumors has important implications for the control of 
apoptosis. The importance of p53 has been demonstrated in "knockout" 
mice in which both copies of p53 are absent. A high rate of tumors is 
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observed in these animals and in addition they are highly resistant to the 
induction of apoptosis (Angel eta/., 1991 ). 
1.5.2. Apoptosis 
Inhibition of apoptosis, either by suppression of genes that induce 
cell death or by activation of genes that cause cell survival, contributes to 
the development of cancer. There is considerable interest in this area not 
only to better understand the mechanism of carcinogenesis but also to 
reveal novel targets for the therapy of cancers. Chemotherapy 
significantly improves survival rates in certain tumors, such as testicular 
cancer and acute lymphocytic leukemia (All). Cancer cells are relatively 
resistant to apoptosis (Carson et a/., 1993; Stellar, 1995). The key to 
effective therapy strategies using programmed cell death is that there is a 
highly regulated pathway with a myriad of points where intervention could 
occur. Tumor cells can undergo apoptosis under nonphysiological 
conditions, such as chemotherapy, leading to the suppression of tumor 
growth and micrometastases (Thompson, 1995). Pharmacologic agents 
capable of inducing apoptosis, therefore, may be worth investigating. 
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1.5.3. Fluoropyrlmldinea 
Fluoropyrimidines are a rationally developed group of anticancer 
drugs, and are of special interest since they are transformed into oral 
formulations, which improve their anticancer activity and minimizes their 
toxicity (lamont et a/.. 1999). Fluoropyrimidines exert their antitumor 
effects through several mechanisms including inhibition of RNA synthesis 
and function, inhibition of thymidylate synthase activity, and incorporation 
into RNA, leading to DNA strand breaks (Grem, 1996). The pattern and 
extent of cell damage induced by fluoropyrimidines in human cancer cells 
have been suggested to depend on pathways downstream from drug-
target interactions that, once triggered, will initiate apoptosis (Canman et 
a/., 1992; Lowe et at., 1993). Indeed, fluoropyrimidines have been 
demonstrated to be capable of inducing programmed cell death in human 
cancer cell lines, such as human colon cancer cell lines, human colorectal 
tumor cell lines and Hela cells (Dusenbury eta/., 1990; Elliott et at., 1998; 
Nita et a/., 1998 ). 
1.6. Purposes of this study 
Cervical cancer is the second most common cancer among women 
worldwide. Cervical cancer, like all the other human cancers, possesses 
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a multistage nature during its development. HPV and many cofactors are 
closely associated with the multistage carcinogenesis of cervical cells. 
However, the mechanism of this multistage, multifactor carcinogenesis 
towards full malignant conversion of human cervical cells still remains 
unclear. To better understand this process, several model systems for 
multistage cervical carcinogenesis have been established in our 
laboratory. One of them, which consists of primary human ectocervical 
cells (HEC), HPV-18-immortalized HEC (HEC-18), and a cell line 
subsequently transformed with CSC from HEC-18 (HEC-18T), is chosen 
for my study. 
Apoptosis is genetically controlled events to remove unwanted cells 
without disrupting normal cells, and therefore, usually serves as a potent 
defense against the emergence of human cancers. As a consequence, 
apoptosis has been widely investigated to gain better understanding of the 
mechanisms involved in multistage development of human cancers. 
Additionally. apoptosis has also been used as an ideal target for 
chemotherapy of cancer. Among a variety of anticancer drugs, 
fluoropyrimidines appear to be very promising. The most common 
fluoropyrimidine, 5-fluorouracil (5-FU), was the first synthesized in an 
attempt to exploit the increased avidity of tumor cells for uracil 
(Heidelberger et a/.. 1957). Although 5-FU has been reported to induce 
apoptosis in many tumor cell types. to the best of our knowledge. it was 
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only once investigated for apoptosis in cervical carcinoma cells (Ueda et 
a/., 1997). Even less is known about its molecular basis, such as its 
effects on expressions of apoptosis-related proteins. Experimental data 
suggested the involvement of p53, Bcl-2 family, and BAG-1 in 
chemotherapy-induced apoptosis (Harris, 1996; Jaattela, 1999). The first 
purpose of my study is to investigate the apoptosis induced by 5-FU in our 
model system for multistage cervical carcinogenesis. In addition to the 
morphological changes, molecular changes including modulations of p53, 
p53-related proteins, some Bcl-2 family members, and BAG-1 have been 
examined to afford implications for involved mechanisms in apoptosis and 
multistage cervical carcinogenesis. 
During the past 10 years, interest of basic scientists and clinicians 
in the influence of apoptosis on the sensitivity of tumors to anticancer 
treatment has risen and continues to rise dramatically (Brown et al., 
1999). The present view is that the level of apoptosis and/or genes 
controlling apoptosis affects the sensitivity of cancer cells to being killed 
by genotoxic agents (McGill et al., 1997; Weinberg, 1996). Tumor cells 
are relatively resistant to apoptosis. Therefore, the best expectation of 
chemotherapies based on apoptosis is increasing the sensitivity of tumor 
cells to anticancer drug-induced apoptosis because this means that cells 
are sensitive to anticancer agents as well. As expected, we have 
primarily found that immortalized cell line HEC-18 and transformed cell 
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line HEC-18T were less sensitive to 5-FU-induced apoptosis than primary 
HEC cell line. We have also found that the cell lines in our model system 
for multistage cervical carcinogenesis, which were insensitive to 5-FU-
induced apoptosis, became sensitive upon the medium change from KGM 
to DMEM. As implied by these findings, another purpose of my study is to 
investigate the role of HPV-18 immortalization and medium change in the 
sensitivity change of cell lines in our model system to 5-FU-induced 
apoptosis. This would be expected to reveal more details in mechanisms 
of sensitivity change, and, if possible, to provide some predictive value for 
clinical application of 5-FU. 
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CHAPTER2 MATERIALS AND METHODS 
2.1. Materials 
Keratinocyte growth medium (KGM) and Dulbecco's modified Eagle 
medium (DMEM) were purchased from GIBCO-BRL and ICN, respectively. 
GIBCO-BRL was the supplier for the fetal calf serum (FCS) and trypsin-
ethylenediamine tetraacetic acid (EDTA). Penicillin-streptomycin was 
obtained from ICN. HEC-18 and HEC-18T cells were established as 
described previously (Yokoyama et a/., 1994; Nakao et a/., 1996, 
respectively). HeLa cell was purchased from ATCC. 
Taq DNA polymerase, 0.1 M OTT, restriction endonucleases and 
and superscript reverse transcriptase with their respective 1 Ox reaction 
buffers were obtained from GIBCO-BRL. 
GIBCO-BRL supplied the 1 Kb and 100 bp DNA ladder markers. 
Low melting point agarose, agarose, acrylamide, N,N'-
methylenebisacrylamide, urea and 10 mM dNTPs were purchased from 
GIBCO-BRL. Baker Inc., Bio-Rad, and Carnation were the suppliers of 2-
mercaptoethanol, N,N,N',N'-tetramethylethylenediamine (TEMED) and 
skim milk powder, respectively. 
5-Fiuorouracil (5-FU), and 5'-deoxy-5-fluorouridine (5-FUdR) were 
purchased from Sigma Chemical Co.. RNase cocktail and proteinase K 
were obtained from Ambion Co .. 
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Mouse anti-BAG-1 monoclonal antibody (mAb) was generated and 
prepared in our laboratory (Yang et a/., 1998). Rabbit polyclonal 
antibodies for Bak and mouse mAbs for Bcl-xL and p21 were obtained 
from Santa Cruz Biotechnology. Mouse mAbs for Bax, PCNA, MDM-2, 
and LDLR were purchased from Oncogene Co.. DAKO Co. supplied p53 
and Bcl-2 mouse mAbs. Other mouse mAbs used were: anti-P-actin 
(Sigma Chemical Co.) and secondary antibodies (Amersham Co.). 
Rainbow protein markers and biotinylated protein marker were purchased 
from Amersham Co. and New England Biolabs Inc., respectively. 
The MTT assay kit was purchased from Promega. Annexin V-FITC 
apoptosis assay kit was obtained from PharMingen Co.. The DC protein 
assay kit was purchased from Bio-Rad Co.. ECL system and Hybond 
nitrocellulose membrane was obtained from Amersham Co.. Kodak was 
the supplier of X-ray film. 
Four-well and eight-well tissue chamber slides; 35-mm, 60-mm and 
1 00-mm tissue culture plates; 6-well plates; 96-well microplates and 
culture tubes were obtained from NUNC. Eppendorf microcentrifuge test 
tubes for PCR were obtained from Fisher Scientific Co .. 
2.2. Cell culture 
Primary human ectocervical cells (HEC) were obtained after 
dissection of pathologically normat cervical tissues derived from 
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hysterectomies performed for benign conditions and were maintained in 
serum-free medium for keratinocytes. as described previously (Boyce et 
al .• 1985). HEC·18 and HEC·18T were cultured in serum-free KGM 
containing 1 °/o penicillin/streptomycin. Hela was cultured in DMEM 
containing 1 Oo/o FCS and 1 °/o penicillin/streptomycin. 
All cells were maintained at 37 °C in a humidified incubator 
containing So/a C02. After three days or when the cells had reached 
approximately 80°/o confluence. the medium was aspirated from the plates 
and the cells were washed with phosphate·buffered saline (PBS). Then, 2 
ml of trypsin-EDTA was added into each plate, which was placed in the 
incubator for 15 minutes. For cells cultured in KGM, 8 ml of PBS 
containing 10% FCS was added to the trypsinized cells to quench the 
activity of trypsin. The cells were then suspended and centrifuged at 
1 ,000 rpm for 10 minutes. The cell pellets were resuspended with KGM 
and passaged at a dilution of 1:10, 1 :4, or 1 :2 into plates. For cells 
cultured in DMEM containing 10°/o FCS, 8 ml of this medium was added 
directly to the trypsinized cells, which were further passaged at 1:10, 1:4, 
or 1 :3 into fresh plates. The cell numbers were counted with a 
hemocytometer. 
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2.3. Growth rate and saturation density assay 
Exponentially growing primary HEC, HEC-18 and HEC-18T cells 
were trypsinized, centrifuged, and resuspended in 2 ml medium. 
Approximately 2 x 104 cells were dispensed into 60-mm plates for each 
cell line. The cell numbers were counted from each of three plates every 
two days for 8 days. 
The saturation density of each cell line was measured by the same 
procedure 5 days after the cells reached confluence. 
2.4. Soft agar or anchorage-independent growth assays 
The 0. 7o/o agarose underlying gel was prepared by mixing equal 
volumes of 2x DMEM containing 20% FCS and low melting point agarose 
melted in sterilized water, dispensing 2.5 ml into 60-mm plates, and 
leaving the plates at room temperature until the gel solidified. 
Subsequently, the cells were trypsinized, resuspended in 2x DMEM, and 
counted using a hemocytometer. The 0.35o/o agarose overlaying gel was 
prepared by mixing approximately 105 cells in 2.5 ml of 2x DMEM with 2.5 
ml of 0.7% low melting point agarose in sterilized water, pouring the 
mixture into the 60-mm plates containing the 0. 7°/o underlying gel. The 
plates were placed at 4 °C for 5 minutes, and then incubated at 37 °C. 
One week later, 1 ml DMEM was carefully added onto the surface of the 
soft agar to replenish nutrients. The colony formation was monitored 
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every two days for 2-4 weeks. Generally, triplicate assays were 
performed for each cell line. Representative photographs were taken for 
documentation. 
2.5. Morphology analysis 
For light microscopic analysis of morphology, cells in either DMEM 
or KGM were cultured in 4-well tissue culture chamber slides. Medium 
was aspirated from approximately 80% confluent cells and the cells were 
washed with PBS. The chamber frame was released from the slides and 
the cells were examined under light microscopy. Cell morphology was 
documented with Kodak TMX 100 film. 
2.6. Drug treatment 
5-FU and 5-FUdR were prepared as 1 00 mM stocks in DMSO and 
stored at -20°C. Immediately prior to cell treatment, the drug was diluted 
in medium to the concentration as indicated. Log phase cells were 
supplemented with the drug and they continued to be incubated for 
indicated periods. Control cells received equivalent solvent treatment. 
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2. 7. Cytotoxicity assay 
Cell drug sensitivity was determined by the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assay kit (Promega 
Co.) after 72 hr continuous drug incubation. Briefly, 1 04 cell aliquots in 
1 00 IJI of growth medium/well were uniformly seeded into 96-well 
microplates for 24 hr before exposure to drug. Each concentration was 
performed in quadruplicate. · The absorbance of each of four wells was 
measured by a microplate reader at 590 nm. Control cells received 
equivalent solvent treatment. The average growth inhibition rates 
compared with the control were calculated from the results of three or 
more independent experiments. The 5-FU or 5-FUdR concentrations 
causing a 50% growth inhibition compared with the controls (ICso) were 
calculated from a semilogarithmic dose-response curve by linear 
extrapolation. 
2.8. Cell viability assay 
Cell viability was evaluated using try pan blue dye exclusion assay. 
In brief. 105 cells/well were seeded in 6-well plates, incubated for 24 hr, 
and then treated with drugs. Untreated and treated cells were trypsinized, 
and equal volumes of cell suspensions and 4°/o trypan blue were mixed 
gently. Cell viability was examined immediately by microscopy. Viable 
cells were unstained whereas dead cells stained blue. Cell viability was 
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calculated as the percentage of treated cells compared with untreated 
cells that excluded trypan blue dye. 
2.9. Apoptosis assays 
2.9.1. Morphological analysis 
Cells were cultured in triplicate on 4-well tissue culture chamber 
slides for 24 hr, and then incubated with drug for 6 hr. Then, the chamber 
frame was removed from slides, and cells were examined using phase-
contrast microscopy. Apoptotic cells were documented with Kodak TMX 
100 film. 
2.9.2. Flow cytometry apoptosls analysis by annexin V-fluorescein 
isothiocyanate (FITC) assays 
Apoptosis was analyzed using an annexin V-FITC assay kit 
(PharMingen Co.), according to the manufacturer's instructions. Briefly, 
approximately 105 cells/plate in 6-well plates were incubated for 24 hr. 
Cells were treated with drug. and both floating dead cells and attached 
viable cells were harvested. Approximately 105 cells were incubated with 
Annexin V-FITC and 5 JJQ/ml propidium iodide (PI) in binding buffer (1 0 
mM HEPES-NaOH, pH 7.4, 140 mM NaCI, 2.5 mM CaCI2) at room 
temperature in the dark for 15 min. Apoptotic cells were quantified using 
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a FACStar Plus flow cytometer (Becton Dickinson). Data analysis was 
performed with the standard Cell Quest software (Becton Dickinson). 
Combination Annexin V-FITC/PI staining was used for simultaneous 
detection of viable (-/-), apoptotic (+/-)and necrotic cells (+/+). 
2.9.3. DNA fragmentation assays 
Cells were seeded into 6-well plates and incubated with drug for 24 
hr. Aliquots of cells were washed in PBS and lysed in DNA lysis buffer 
(1 0 mM Tris/HCI, pH 7 .4, 400 mM NaCI, 1 °/o sodium dodecyl sulfate 
(SDS), and 0.2 mg/ml proteinase K) at 37 °C for 4 hr. Samples were 
treated further with DNase-free RNase A/T1 (0.2 mg/ml) at 37 °C for 1 hr. 
The resulting extracts were loaded onto 1.5% agarose gels containing 
ethidium bromide (0.5 ~g/ml). Electrophoresis was performed at 60 V at 
room temperature for 3 hr. The gel was viewed and photographed on an 
ultraviolet (UV) transilluminator. 
2.1 0. Western blot 
For protein extraction, cells were washed twice with ice-cold PBS, 
and proteins were extracted from approximately 1 07 cells by lysis in 1 ml 
ice-cold extraction buffer (50 mM Tris/HCI pH 8.0, 150 mM NaCI, 0.02o/o 
sodium azide, 1% NP-40, 0.1 °/o sodium dodecyl sulfate (SDS), 0.5% 
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sodium deoxycholate, 200 g/ml phenylmethylsulfonyl fluoride (PMSF) and 
20 g/ml aprotinin) for 30 min and centrifuged at 4 °C for 10 min, after 
which the supernatant was transferred into another fresh microcentrifuge 
tube and stored at -70 °C. Protein concentration was quantified using a 
DC Lowry protein assay kit (Bio-Rad), as instructed by the manufacturer. 
Protein extracts, usually 10 ~g. were boiled in 2x 50S-
polyacrylamide gel electrophoresis (PAGE) gel loading buffer (200 mM 
Tris/HCI (pH 6.8), 4o/o SDS, 0.2o/o bromophenol blue, 20o/o glycerol) for 3 
min and resolved in an SDS-PAGE gel. The running gel was prepared 
with 8-12o/o acrylamide, 375 mM Tris/HCI (pH 8.8), 0.1 °/o SDS, 0.1% 
ammonium persulphate, and 6 ~I of TEMED. The stacking gel was 
composed of 5°k acrylamide, 125 mM Tris/HCI (pH 6.8), 0.1°k SDS, 0.1% 
ammonium persulphate and 5 ~I of TEMED. Electrophoresis was at 200V 
in SDS-PAGE running buffer (25 mM Tris, 250 mM glycine) using a 
Protein II minigel apparatus (Bio-Rad). 
After electrophoresis, the gel was incubated at room temperature in 
Towbin transfer buffer (25 mM Tris, 192 mM glycine and 20o/o methanol) 
for 10 min. Subsequently, the proteins were transferred to Hybond 
enhanced-chemiluminescence nitrocellulose membranes (Amersham Co.) 
under semidry conditions at 20 V for 50 min using a Trans-Blot SO 
transfer apparatus (Bio-Rad). After transfer, the membranes were air-
dried and probed immediately or wrapped in Saran Wrap and stored at 4 
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°C prior to probing. To eliminate nonspecific binding of antibodies, 
membranes were blocked by gentle shaking in 5o/o skim milk powder in 
TBST (20 mM Tris/HCI {pH 7 .6), 137 mM NaCI, 0.1% Tween-20) for 1 hr 
at room temperature. Subsequently, membranes were incubated with the 
primary antibody diluted in 5% skim milk powder in TBST overnight at 4 °C 
with shaking. After washing thrice with TBST for 10 min, membranes 
were incubated with horseradish peroxidase-conjugated secondary 
antibody diluted in 5% skim milk powder in TBST for 1 hr at room 
temperature, and then washed in TBST for three times. Signals were 
detected using the enhanced chemilumiscence (ECL) system (Amersham 
Co.) and subsequently exposing the membranes to ECL film, as instructed 
by the manufacturer. 
After primary signals were detected with the ECL system, they were 
removed from the membranes by incubation in stripping buffer (1 00 mM 2-
mercaptoethanol, 2°k SDS, 62.5 mM Tris/HCI, pH 6.7) at 50 °C for 30 min 
with occasional agitation. Then, membranes were rinsed with TBST and 
reprobed with anti-13-actin mAb and the signals were detected as for the 
primary signal. 
Signal intensities were quantified by densitometry of bands with an 
Eagle Eye II Still Video system (Stratagene ). 
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2.11. Flow cytometry 
The expression of LDLR on 1 06 cells was quantified by flow 
cytometry. Cells were washed in washing buffer (PBS. 0.2o/o bovine 
serum albumin and 0.02°/o sodium azide) and incubated at room 
temperature in 50 J,JI of washing buffer containing 2.5 IJg/ml normal mouse 
immunoglobulin for 15 min. Next. anti-LDLR antibody (lgG2a) was added 
to the final concentration of 2.5 J,Jg/ml. After being incubated for 30 min, 
cells were washed, resuspended in 50 JJI of washing buffer containing 2.5 
IJQ/ml of FITC-conjugated goat-anti mouse lgG2a. and incubated for 15 min 
at 4 °C. Negative controls, cells that were LDLR-negative cells, were 
treated only with FITC-conjugated goat-anti mouse lgG2a. treated with 
nonspecific normal mouse lgG antibodies. After staining, cells were 
washed once and resuspended in PBS containing 2% formaldehyde. 
Stained cells were analyzed in a FACStar Plus flow cytometer (Becton 
Dickinson). 
2.12. Statistical analysis 
Statistical analysis was conducted using the Student's t-test. 
Differences with a value of p < 0.05 were considered to be significant. 
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CHAPTER3 RESULTS 
3.1. Morphology of HEC, HEC-18, and HEC-18T 
It has been reported that the morphology of cultured cervical 
epithelial cells indicated the differentiation potential and oncogenicity of 
the normal or abnormal tissue from which the cells are derived (Turyk et 
a/., 1989; Vooijs, 1991 ). Compared with normal cells, premalignant and 
tumor cells usually have obvious, progressive morphological abnormalities 
in vitro. In addition, it has been observed that cellular morphology 
depended on the culture medium (Nakao eta/., 1996; Yang eta/., 1996). 
Therefore, the morphology of HEC, HEC-18, and HEC-18T grown in KGM 
or DMEM was compared. 
In monolayer cultures, cells were grown either in KGM, a serum-free 
medium containing 0.15 mM calcium, or in DMEM, a medium containing 
10% fetal calf serum (FCS) and a physiological level of calcium (1.5 mM). 
In KGM, HEC (Figure 3.1 A), HEC-18 (Figure 3.2 A), and HEC-18T (Figure 
3.3 A) formed monolayers consisting of polygonal, keratinocyte-like cells. 
HEC grew faster than HEC-18 and HEC-18T, as suggested by cell 
densities after the same period of culture time. 
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Figure 3.1 Morphology of primary human ectocervical cells 
(HEC) grown in KGM and DMEM. Panel A represents HEC grown in 
KGM. Panel B represents HEC grown in DMEM. {Magnifications: x100) 
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Figure 3.2 Morphology of HPV 18-immortalized human 
ectocervical cells (HEC-18) grown in KGM and DMEM. Panel A 
represents HEC-18 grown in KGM. Panel B represents HEC-18 grown in 
DMEM. (Magnifications: x 1 00) 
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Figure 3.3 Morphology of esc-transformed HPV 18· 
immortalized human ectocervlcal cells (HEC-18T) grown in KGM and 
DMEM. Panel A represents HEC-18T grown in KGM. Panel B represents 
HEC-18T grown in DMEM. (Magnifications: x1QO) 
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However, when cells were adapted to and grown in DMEM, HEC 
(Figure 3.1 B) could do neither, stopped growing and died after 2 weeks. 
The other two cell lines. HEC-18 (Figure 3.2 B) and HEC-18T (Figure 
3.38), were slowly growing. Initially, all the three cell types became 
flattened, dendritic (having branched cytoplasm), uneven-sized cells and 
distributed heterogeneously in the culture plates. Moreover. the cells 
displayed a smaller size. and an increasingly higher nucleus/cytoplasm 
ratio for HEC, HEC-18, and HEC-18T. The morphology of the three cell 
lines is obviously different in DMEM from that in KGM in each case. 
3.2. Growth characteristics of HEC, HEC-18, and HEC·18T 
The growth rate, the saturation density and the potential of 
anchorage-independent growth in soft agar are three important in vitro 
indicators of the stages of multistep carcinogenesis (Li et a/., 1992). To 
characterize the growth potential of HEC, HEC-18, and HEC-18T, their 
proliferation either in both KGM and DMEM was examined. 
In KGM, transformed cell line HEC-18T proliferated slightly faster 
than its parental immortalized counterpart HEC-18 and HEC-18, in turn, 
proliferated faster than HEC (Figure 3.4; Table 3.1 ). The doubling times 
of HEC, HEC-18, and HEC-18T in KGM were 39, 36, and 32 hr, 
respectively. However. HEC did not proliferate in DMEM. The other two 
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Table 3.1 Growth characteristics of ectocervical cells 
Ectocervical cells 
Growth characteristics HEC HEC-18 HEC-18T 
KGM DMEM KGM DMEM KGM DMEM 
Doubling time 1 39±6 NG 36±2 32±2 32±2 25±3 
Saturation density 2 0 0 157±26 92±9 287±35 174±21 
Soft agar growth 3 
- - - -
+ + 
1 The doubling time in hours± standard error is presented. NG, no growth. 2 The number of cells± standard 
error x 10"5 is presented as the average number of duplicate counts of triplicate 100 mm dishes. 3 -, 5 negative 
dishes; +, 5 positive dishes. 
7ci 
Figure 3.4 Proliferation of multistage cervical carcinogenesis 
model cells in serum-free medium and high calcium, serum 
containing medium. Cells were cultured in 100 mm plates in serum-free 
medium (KGM) and high calcium, serum-containing medium (DMEM). 
Values represent the mean +/- the standard deviation from three 
independent experiments. See text for details. 
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6 8 10 
cell lines, HEC-18 and HEC-18T proliferated much slower in DMEM than 
in KGM. Predictably, HEC-18T proliferated faster than HEC-18. The 
doubling times of HEC, HEC-18 and HEC-18T in DMEM were no growth, 
32 hr and 25 hr, respectively. Additionally, transformed cell line HEC-18T 
obtained much higher saturation density than its immortalized counterpart 
HEC-18 in both media. The saturation densities in 100 mm dishes of 
HEC-18 and HEC-18T were 1.57x107 and 2.87x107 cells in KGM, and 
9.2x106 and 1.74x107 cells in DMEM. respectively. 
Oncogenicity is correlated with anchorage-independent growth of 
tumor cells. To characterize the oncogenic phenotype. anchorage-
independent growth in soft agar was assayed, in which HEC-18 and HEC-
18T were growth adapted to either KGM or DMEM before soft agar 
assays. and Hela were first growth adapted to DMEM. Generally, the 
formation of colonies was observable after one week of incubation, and 
the colonies were unequivocally identified after 2-4 weeks. HEC-18 
(Figure 3.5 A and B) remained as single cells after adaptation to both 
media, whereas HEC-18T {Figure 3.6 A and B) formed colonies that were 
smaller than those formed by Hela (Figure 3.5 C and Figure 3.6 C). 
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Figure 3.5 Anchorage-independent growth assays of HPV 18-
immortalized human ectocervical cells (HEC-18). A, HEC-18 initially 
grown in KGM; B, HEC-18 initially grown in DMEM; C, Hela cells used 
as the control. See text for details. 
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Figure 3.6 Anchorage-Independent growth assays of esc-
transformed HPV 18·immortalized human ectocervical cells (HEC-
18T). A, HEC-18T initially grown in KGM; B, HEC-18T initially grown in 
DMEM; C, Hela cells used as the control. See text for details. 
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3.3. Morphological modifications of HEC, HEC-18, and HEC-18T 
treated with 5-FU 
Morphological changes often serve as markers of apoptotic cell 
death. To evaluate whether 5-FU induces apoptosis in HEC, HEC-18, and 
HEC-18T, cells were examined using phase contrast microscopy after 
incubation with 5-FU in the concentration of IC50 for 6 hr. Initially, HEC, 
HEC-18, and HEC-18T cultured in KGM were analyzed after 5-FU 
treatment (Figure 3. 7). Apoptotic characteristics, including cell shrinkage 
due to cell dehydration, irregular shape, smaller size, and apoptotic 
bodies (blebbing of cytoplasmic and nuclear membranes), were observed 
in all cases. 
HEC-18 and HEC-18T were then adapted to DMEM, and 
subsequently treated with 5-FU for 6 hr. Apoptotic characteristics were 
again observed in both (Figure 3.8). 
3.4. Flow cytometry analysis of apoptosis Induced by 5-FU 
By staining cells with a combination of Annexin V-FITC and PI, it is 
possible to detect apoptotic cells by flow cytometry (Koopman et a/., 
1994). To confirm the apoptosis induced by 5-FU in HEC-18 and HEC-
84 
Figure 3. 7 Morphological changes of cells grown in KGM 
undergoing apoptosis induced by 5-FU. A-B, HEC; C-D, HEC-18; E-
F, HEC-18T. Left panel represents controls. Right panel represents cells 
treated with 5-FU for 6 hr. Morphology was examined by phase contrast 
microscopy. 
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Figure 3.8 Morphological changes of cells grown in DMEM 
undergoing apoptosis induced by 5-FU. A-8, HEC; C-D, HEC-18; E-
F, HEC-18T. Left panel represents controls. Right panel represents cells 
treated with 5-FU for 6 hr. Morphology was examined by phase contrast 
microscopy. 
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Figure 3.9 Analysis of apoptosis in HEC-18 and HEC-18T 
treated with 5-FU. Cells were treated with 5-FU for 0, 6, 12, 24, 36, and 
48 hr, respectively, stained with Annexin V-FITC and PI, and analyzed by 
flow cytometry as described in Materials and Methods. Apoptotic cells are 
represented by the numbers indicating Annexin V-FITC positivity (right 
panels). The upper right panel indicates late-apoptotic or necrotic cells 
that have become permeable to Pl. The data are representative of three 
separate experiments. 
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18T, flow cytometric analysis was performed using Annexin V·FITC assay. 
As shown in Figure 3.9, the majority of HEC-18 remained viable. The 
proportion of apoptotic cells was increased along with the increase of 
treatment time with 5~FU. Similarly, Figure 3.9 also shows that the 
apoptotic effect of S~FU on HEC-18T also exhibited time dependence. 
3.5. DNA fragmentation analysis of apoptosls induced by 5-FU 
Activation of endonuclease cleavage of DNA into discrete fragments 
is considered to be a hallmark of apoptosis (Oberhammer et al., 1993 ). 
Therefore, this phenomenon provides a strong indication of apoptotic cell 
death. To further confirm the apoptosis induced by 5-FU, the cellular DNA 
of 5-FU-treated and untreated HEC, HEC-18, and HEC-18T was extracted 
and assayed on 1.5°k agarose gels. At first, experiments were performed 
on cells incubated in KGM for 72 hr (Figure 3.1 0). Obvious ladder-pattern 
DNA fragmentation, a characteristic feature of apoptosis, was observed in 
all 5-FU-treated cells. No ladder formation was detected in cells not 
exposed to 5-FU. Consistent with results from flow cytometry analysis, 5-
FU-induced apoptosis occurred in a time·dependent fashion. More 
importantly, the induction of apoptosis by 5~FU was more pronounced in 
HEC than in HEC-18 and HEC-18T, implying that immortalization may 
decrease the sensitivity of cells to apoptosis, as reported (Yang et al., 
1998b). 
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Subsequently, HEC-18 and HEC-18T cultured in OMEM were also 
analyzed. As shown in Figure 3.11, discrete DNA fragments were 
apparent for both 5-FU-treated cell lines. Again, the extent of apoptosis 
increased with treatment time. It was observed that apoptosis induced for 
cells adapted to and grown in different culture media appeared to affect 
the extent of cleavage, as shown in Figure 3.11 compared with Figure 
3.10. 
These results encouraged us to directly compare the differences in 
the level of apoptosis induced by 5-FU in HEC and HEC-18 and HEC-18T 
cultured in different media for the optimal time. Cells, initially cultured in 
different media, were incubated with 5-FU for 72 hr. and analyzed. 
Indeed, as shown in Figure 3.12, apoptosis was more significant in DMEM 
than in KGM for both HEC-18 and HEC-18T, and almost equivalent to that 
of HEC. This suggested that growth medium affected the sensitivity of 
immortalized cells to 5-FU-induced apoptosis. 
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Figure 3.1 0 Effects of 5-FU-treatment on DNA fragmentation 
in human ectocervical cells. Cells (1 06 ) cultured for 24 hr in KGM were 
treated with 5-FU. Cells without 5-FU treatment were used as controls. 
DNA was extracted and analyzed by 1 .5 °/o agarose gel electrophoresis 
and ethidium bromide staining, as described in Materials and Methods. 
93 
HEC 
(KGM) 
HEC-18 
(KGM) 
94 
HEC-18T 
(KGM) 
Figure 3.11 DNA fragmentation assays of human actocarvical 
calls treated with 5-FU. Each cell line is indicated on the top of the 
figure. Cells (106 ) were cultured for 24 hr in OMEM, then 5-FU was added 
and the incubation period continued for another 24, 48. and 72 hr. 
respectively. Cells without 5-FU treatment are used as controls. DNA 
was extracted and analyzed by agarose gel electrophoresis in the 
presence of ethidium bromide, as described in Materials and Methods. 
95 
HEC-18 
(DMEM) 
96 
HEC-18T 
(DMEM) 
Figure 3.12 DNA fragmentation assays of human ectocervical 
cells treated with 5-FU. Each cell line is indicated on the top of the 
figure. Cells (106 } were cultured for 24 hr in either KGM or DMEM, then 5-
FU was added and the incubation period continued for another 72 hr. DNA 
was extracted and analyzed by agarose gel electrophoresis in the 
presence of ethidium bromide, as described in Materials and Methods. 
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3.6. Effects of 5-FU treatment on apoptosis in HEC, HEC-18, and 
HEC-18T 
As described above, immortalization decreased the sensitivity of the 
ectocervical cells to apoptosis, and growth medium affected apoptosis 
determined by DNA fragmentation assay. To examine a different measure 
of apoptosis for confirmation, a marker of membrane integrity, apoptosis 
was assessed with the trypan blue dye exclusion assay (Figure 3.13). 
Ectocervical cells of the model system cultured in different media were 
treated with 5-FU at different concentrations for constant times (Figure 
3.13 A), or treated with 5-FU at the same concentrations for different 
periods of time (Figure 3.13 B). In both cases, the same trend was 
observed: HEC-18 and HEC-18T culture in KGM were less sensitive than 
HEC to 5-FU-induced apoptosis, arad HEC-18 and HEC-18T were more 
sensitive in DMEM than in KGM to 5-FU-induced apoptosis. Moreover, 
apoptosis induced by 5-FU in all cultures was time-dependent and dose-
dependent. 
Furthermore, drug sensitivity was also determined by MTT 
cytotoxicity assay. The 5-FU concentrations causing a 50% growth 
inhibition (IC50 ) compared with untreated cells were calculated from a 
dose-response curve by linear interpolation, and summarized in Table 3.2. 
A fluoropyrimidine prodrug, 5'-deoxy-5-fluorouridine (FUdR), was tested 
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Table 3.2 Concentrations of 5-FU and FUdR inhibiting proliferation by 
50% (IC50 ) of human ectocervical cells cultured in KGM or 
DMEM 
Cells ICso (~M) 5-FU FUdR 
HEC (KGM) 23.1 ± 1.5 17.7 ± 1.2 
HEC-18 (KGM) 48.7 ± 3.7 30.9 ± 2.1 
HEC-18T (KGM) 72.3 ± 4.3 48.3 ± 2.5 
HEC-18 (DMEM) 19.9±1.8 10.2 ± 0.9 
HEC-18T (DMEM) 20.3 :t 1.1 15.2 :t 1.3 
100 
Figure 3.13 Dose- and time-dependent induction of apoptosis 
in human ectocervical cells induced by 5-FU. The percentage of viable 
cells was determined by trypan blue dye exclusion assays. Results 
represent the mean from three independent experiments. The bars 
indicate standard deviation (SD). Panel A represents cells treated with 5-
FU for 72 hr. Panel 8 represents cells treated with IC50 concentrations of 
5-FU. 
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for comparison. In KGM, ICso values for HEC, HEC-18 and HEC-18T were 
23.1 IJM, 48.7 ~M and 72.3 1JM, respectively. This is consistent with the 
finding that immortalization decreased the sensitivity of cells to 5-FU-
induced apoptosis. For HEC-18, and HEC-18T, IC50 values were 19.9 IJM 
and 20.3 tJM, respectively in DMEM. These overall results showed that the 
sensitivity to 5-FU-induced ectocervical cell death was greater in 
immortalized than transformed cells, greater in immortalized cells in 
DMEM than KGM and equal in transformed cells. For FUdR-induced 
cytotoxicity, the pattern was the same except that it was less in 
transformed cells and it was greater for all values. 
3. 7. Expressions of apoptosis-regulating proteins in HEC, HEC-18, 
and HEC-18T 
It has been hypothesized that defects in apoptosis-regulating genes 
may cause human cancer (Williams, 1991 ). This hypothesis has been 
supported by several reports of inactivation of genes inducing apoptosis, 
such as p53, and activation of genes inhibiting apoptosis, such as Bcl-2, 
in various human cancers (Haldar et a/., 1994; Hirose et a/., 1997; 
Rampino et a/., 1997). To investigate whether there is a correlation of 
expression of apoptosis-regulating proteins with sensitivity changes of 
cells to 5-FU-induced apoptosis, which may in turn closely relate to 
multistage cervical carcinogenesis. the expression of p53 in KGM, some 
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Bcl-2 family members, and BAG-1 proteins were examined by Western 
blot analysis. 
3. 7 .1. Apoptosis-promoting proteins 
The apoptosis-promoting protein, p53, is known to suppress tumor 
growth and progression by induction of apoptosis. The expression of p53 
protein was 6-fold lower in HEC-18 and 33-fold lower in HEC-18T 
compared with that in HEC (Figure 3.14, and Table 3.3). However, when 
cells were in DMEM compared with KGM, the levels of p53 were 
dramatically enhanced in both HEC-18 and HEC-18T. 
In KGM, the expression levels of Bak were lower in HEC-18 than in 
HEC (Figure 3.15). Nevertheless, Bak levels did not show significant 
difference when the immortalized and transformed cells were compared 
and culture medium was KGM or DMEM in both HEC-18 and HEC-18T. 
Similar to p53, Bax was expressed 2-fold lower in HEC-18 and 5-
fold lower in HEC-18T than in HEC when cells were cultured in KGM 
(Figure 3.16, and Table 3.3). The Bax levels increased 2-fold in HEC-18 
and 7-fold in HEC-18T when cultured in DMEM. 
These results suggest that there is a correlation of expression of 
apoptosis-promoting proteins with sensitivity changes of cells to 5-FU-
induced apoptosis and cytotoxicity. The reduced levels of p53, Bak, and 
Bax are correlated with decreased sensitivity of 
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Figure 3.14 Expressions of p53 In human ectocervlcal cells. 
The top panel shows Western blot analysis of cells grown in KGM. The 
bottom panel presents the corresponding densitometry results. Values 
represent the mean ± the standard deviation of three independent 
experiments. *P < 0.05 and **P < 0.005 are the statistical significance of 
the difference in p53 expression between untreated and treated cells. 
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Figure 3.15 Expressions of Bak in human ectocervical cells. 
The top panel shows Western blot analysis of cells grown in KGM . The 
bottom panel presents the corresponding densitometry results. Values 
represent the mean :t the standard deviation of three independent 
experiments. *P < 0.05 and **P < 0.005 are the statistical significance of 
the difference in Bak expression between untreated and treated cells. 
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Figure 3.16 Expressions of Bax in human ectocervical cells. 
The top panel shows Western blot analysis of cells grown in KGM. The 
bottom panel presents the corresponding densitometry results. Values 
represent the mean ± the standard deviation of three independent 
experiments. *P < 0.05 and **P < 0.005 are the statistical significance of 
the difference in Bax expression between untreated and treated cells. 
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HEC-18 and HEC-18T compared with HEC to 5-FU-induced apoptosis and 
cytotoxicity. The enhanced levels of p53 and Bax, but not changed level 
of Bak, are correlated with increased sensitivity of HEC-18 and HEC-18T 
in DMEM compared with in KGM to 5-FU-induced apoptosis. 
3. 7 .2. Apoptosis-inhibiting proteins 
In KGM, the expression of Bcl-2 increased more than 7-fold and 14-
fold in HEC-18 and HEC-18T compared with the cells of the previous 
stage of carcinogenesis (Figure 3.17, and Table 3.3). However, the Bcl-2 
levels decreased progressively in both HEC-18 and HEC-18T when the 
culture medium was changed from KGM to DMEM. 
Since it was increased after immortalization in both cell lines and 
again after transformation in the HEN multistage carcinogenesis model 
(Yang et a/., 1998), it was surprising that there were no significant 
differences for the Bcl-xL expression levels in all three cell lines and both 
media (Figure 3.18). 
In the case of BAG-1, previous results have shown that p50, p46 
and p33 of the four isoforms of BAG-1 were overexpressed in all the 
cervical carcinoma cell lines. They were variably detected in cervical 
carcinomas and p29 was not detected in any samples (Yang et a/., 1999). 
In contrast, BAG-1 p46 and p50 in the current model system cells were 
not detectable in any sample in three experiments. In KGM. BAG-1 p29 
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isoform was clearly expressed and showed reduced expression in HEC-18 
and HEC-18T compared with HEC (Figure 3.19). Its expression was 
higher in HEC-18 and HEC-18T cultured in DMEM compared with in KGM. 
Although not apparent in the autoradiograph for HEC-18, densitometric 
comparison with actin control showed the difference to be significant (P 
<0.05). However, another BAG-1 isoform p33 increased remarkably in 
HEC-18 and HEC-18T compared with HEC (Figure 3.20). In addition, p33 
increased even further in HEC-18 and HEC-18T when the medium was 
DMEM. The overall level of BAG-1, which can be obtained by combining 
the results shown in Figure 3.19 and Figure 3.20, increased in HEC-18 
and HEC-18T compared with HEC, and further increased when HEC-18 
and HEC-18T were adapted to DMEM. 
Therefore, for apoptosis inhibiting proteins, the enhanced levels of 
Bcl-2, total BAG-1 and p33 BAG-1 isoform, as summarized in Table 3.3, 
are correlated with decreased sensitivity of HEC-18 and HEC-18T 
compared with HEC to apoptosis. The reduced level of Bcl-2 and BAG-1 
p29 and increased level of total BAG-1 and BAG-1 p33 are correlated with 
increased sensitivity of HEC-18 and HEC-18T in DMEM compared with in 
KGM, respectively, to apoptosis. 
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Figure 3.17 Expressions of Bcl-2 in human ectocervical cells. 
The top panel shows Western blot analysis of cells grown in KGM. The 
bottom panel presents the corresponding densitometry results. Values 
represent the mean ± the standard deviation of three independent 
experiments. •p < 0.05 and ••p < 0.005 are the statistical significance of 
the difference in Bcl-2 expression between untreated and treated cells. 
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Figure 3.18 Expressions of Bcl-xL in human ectocervical 
cells. The top panel shows Western blot analysis of cells grown in KGM. 
The bottom panel presents the corresponding densitometry results. 
Values represent the mean :t the standard deviation of three independent 
experiments. *P < 0.05 and **P < 0.005 are the statistical significance of 
the difference in Bcl-xL expression between untreated and treated cells. 
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Figure 3.19 Expressions of BAG-1-p29 in human ectocervical 
cells. The top panel shows Western blot analysis of cells grown in KGM. 
The bottom panel presents the corresponding densitometry results. 
Values represent the mean :t the standard deviation of three independent 
experiments. *P < 0.05 and **P < 0.005 are the statistical significance of 
the difference in BAG-1-p29 expression between untreated and treated 
cells. 
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Figure 3.20 Expressions of BAG-1-p33 in human ectocervical 
cells. The top panel shows Western blot analysis of cells grown in KGM. 
The bottom panel presents the corresponding densitometry results. 
Values represent the mean ± the standard deviation of three independent 
experiments. *P < 0.05 and ••p < 0.005 are the statistical significance of 
the difference in BAG·1-p33 expression between untreated and treated 
cells. 
119 
...... 
N 
0 
""C 
A 
0 
0 
Ul 
.. 
.. 
""C 
A 
0 
0 
0 
Ul 0 !.. 
BAG-1-p33 optical density(% of controls) 
...... g 
0 0 
VI 
0 
0 
* 
* 
N 
8 
0 
"0:) 
I 
Q) 
0 
..... 
::J 
I 
OJ 
)> 
G> 
I 
~ 
I 
"'0 
VJ 
VJ 
I 
HEC(KGM) 
HEC-18(KGM) 
HEC-18(DMEM) 
HEC-18T(KGM) 
HEC-18T(DMEM) 
Table 3.3 Relative expressions of apoptosis-regulating proteins in HEC, 
HEC-18, and HEC-18T1 
HEC-18 HEC-18T 
Proteins HEC KGM DMEM KGM DMEM 
p53 100.0±0.0 16.3±1.2 106.4±2.7 3.3±1.2 106.7±0.2 
Bak 100.0±0.0 61.0±1.7 53.5±2.7 61.6±0.9 70.4±2.5 
Bax 1 00.0±0.0 43.7±0.3 86.4±2.8 20.7±2.8 156.9±14.7 
Bcl-2 100.0±0.0 697.0±86.0 129.8±10.6 1459±21.0 1047±63.3 
Bcl-xt. 100.0±0.0 93.7±4.8 98.4±3.4 1 06.8±3.8 106.0±5.4 
BAG-1 100.0±0.0 47.6±3.3 129.0±7.3 62.8±3.5 198.9±1.7 p29 
BAG-1 1 00.0±0.0 454.6%80.9 624.6±142.3 731.9%107.8 1677±1 04.4 p33 
1 The levels of cellular proteins were quantified relative to those of HEC after 
normalization to the actin control. Protein expression was quantified by measuring the 
optical density of bands at medium exposure on X-ray film. The data are shown as the 
mean :t the standard deviation of three experiments. 
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3.8. Effects of 5-FU treatment on expressions of apoptosis-
regulating proteins in HEC, HEC-18, and HEC-18T 
The molecular mechanism implicated in apoptosis has been partially 
elucidated and the induction of apoptosis is partly regulated intracellularly 
by several genes, such as p53 and Bcl-2 (Chiarugi et a/., 1994 ). Results 
of DNA fragmentation analysis {section 3.5.) showed that HEC-18 and 
HEC-18T were somewhat resistant to 5-FU-induced apoptosis compared 
with HEC when cultured in KGM. More notably, HEC-18 and HEC-18T 
were highly sensitive to 5-FU-induced apoptosis when they were cultured 
in DMEM. The mechanism of this enhanced susceptibility of cells to 
anticancer drug-induced apoptosis might offer informative clues for 
apoptosis-based chemotherapy of human cancers. To investigate whether 
5-FU regulates apoptosis-associated genes, thus inducing apoptosis, a 
panel of protein products of apoptosis-associated genes, including p53, 
Bcl-2, and their related genes, were examined after 5-FU treatment, and 
the results were summarized in Table 3.4. 
3.8.1. Apoptosis-promoting proteins 
As shown in Figure 3.21, 5-FU treatment upregulated p53 in both 
cell lines cultured in OMEM. Levels of a p53 target protein, p21, were 
also examined. As shown in Figure 3.22, the expression of p21 tumor 
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promoter protein was upregulated more than 2-fold in HEC-18. The same 
trend was observed in HEC-18T, but the result was not as pronounced as 
that in HEC-18. 
MDM-2 proto-oncoprotein is also a transcriptional target of p53 
(Barak et a/., 1993). p53 increases MDM-2 expression whereas MDM-2 
suppresses p53 activity, creating an autoregulatory feedback loop. Figure 
3.23 shows our studies on MDM-2 protein with 5-FU treatment. It 
remained unchanged in HEC-18, but was remarkably increased in HEC-
18T by 5-FU treatment. 
PCNA transcription is suppressed by p53 (Shivakumar eta/., 1995). 
However, PCNA displayed a pattern (Figure 3.24) that was the same as 
that of p53 (Figure 3.21) in HEC-18 and HEC-18T after 5-FU treatment. 
Bax is also the target of p53 and the protein upregulates apoptosis 
by binding with Bcl-2 (Oitvai eta/., 1993). Our experiments did not show 
any significant changes either in HEC-18 or in HEC-18T after 5-FU 
treatment (Figure 3.25). 
Bak, an apoptosis-promoting protein, was upregulated by 5-FU in 
HEC-18 and more significant in HEC-18T (Figure 3.26). 
3.8.2. Apoptosis-inhibiting proteins 
Among apoptosis inhibiting proteins, are members of the Bcl-2 
family. The prototype, Bcl-2, is transcriptionally downregulated by p53 
{Miyashita et al.. 1994b ). Figure 3. 27 shows that Bct-2 was 
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Figure 3.21 Expressions of p53 in human ectocervical cell 
lines detected by Western blot analysis after treatment with 5-FU. 
Each cell line is indicated on the top of the figure. 10 ~o~g of protein from 
each cell-free extract were separated by SDS-PAGE and transferred to 
Hybond ECL nitrocellulose membrane as described in Materials and 
Methods. Western-blots were probed with the mouse monoclonal lgG 
anti-p53 antibody. The blots were also analyzed for expression of P-actin 
protein as controls for protein loading. The bottom graph represents the 
corresponding densitometry for results from Western blot analysis. 
Columns and bars represent mean values :1: SO, respectively. •p < 0.05 
and up < 0.005 are the statistical significance of the difference in 
expression of p53 between each 5-FU-treated cell line and control 
untreated cells. 
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Figure 3.22 Expressions of p21 in human ectocervical cell 
lines detected by Western blot analysis after treatment with 5-FU. 
Each cell line is indicated on the top of the figure . 10 J,Jg of protein from 
each cell-free extract were separated by SDS-PAGE and transferred to 
Hybond ECL nitrocellulose membrane as described in Materials and 
Methods. Western-blots were probed with the mouse monoclonal lgG 
anti-p21 antibody. The blots were also analyzed for expression of 13-actin 
protein as controls for protein loading. The bottom graph represents the 
corresponding densitometry for results from Western blot analysis. 
Columns and bars represent mean values ± SD, respectively. *P < 0.05 
and **P < 0.005 are the statistical significance of the difference in 
expression of p21 between each 5-FU-treated cell line and control 
untreated cells. 
126 
p21-
{3-actin-
Iii 300 
e 
-c 0 
(,) 
-
0 
~ 200 !!.... 
>-
-·u; 
c 
II) 
"'C 
iii 100 (,) 
:;:: 
Q. 
0 
.... 
N 
Q. 
0 
* P<O.OS 
0 72 
** 
Cell lines 
** P<O.OOS 
127 
0 
r-_ 
~:E 
•UJ 
u:E 
UJO 
I-
72 {h) 
Figure. 3.23 Expressions of MDM-2 in human ectocervical cell 
lines detected by Western blot analysis after treatment with 5-FU. 
Each cell line is indicated on the top of the figure. 10 JJQ of protein from 
each cell-free extract were separated by SDS-PAGE and transferred to 
Hybond ECL nitrocellulose membrane as described in Materials and 
Methods. Western-blots were probed with the mouse monoclonal lgG 
anti-MDM-2 antibody. The blots were also analyzed for expression of 13-
actin protein as controls for protein loading. The bottom graph represents 
the corresponding densitometry for results from Western blot analysis. 
Columns and bars represent mean values :t SO, respectively. **P < 0.005 
is the statistical significance of the difference in expression of MDM-2 
between each 5-FU-treated cell line and control untreated cells. 
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Figure 3.24 Expressions of PCNA in human ectocervical cell 
lines detected by Western blot analysis after treatment with 5-FU. 
Each cell line is indicated on the top of the figure. 10 ~g of protein from 
each cell-free extract were separated by SDS-PAGE and transferred to 
Hybond ECL nitrocellulose membrane as described in Materials and 
Methods. Western-blots were probed with the mouse monoclonal lgG 
anti-PCNA antibody. The blots were also analyzed for expression of 13-
actin protein as controls for protein loading. The bottom graph represents 
the corresponding densitometry for results from Western blot analysis. 
Columns and bars represent mean values :t SO. respectively. *P < 0.05 
and **P < 0.005 are the statistical significance of the difference in 
expression of PCNA between each 5-FU-treated cell line and control 
untreated cells. 
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Figure 3.25 Expressions of Bax in human ectocervical cell 
lines detected by Western blot analysis after treatment with 5-FU. 
Each cell line is indicated on the top of the figure. 10 IJ9 of protein from 
each cell-free extract were separated by SDS-PAGE and transferred to 
Hybond ECL nitrocellulose membrane as described in Materials and 
Methods. Western-blots were probed with the mouse monoclonal lgG 
anti-Bax antibody. The blots were also analyzed for expression of ~-actin 
protein as controls for protein loading. The bottom graph represents the 
corresponding densitometry for results from Western blot analysis. 
Columns and bars represent mean values± SO, respectively. 
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Figure 3.26 Expressions of Bak in human ectocervical cell 
lines detected by Western blot analysis after treatment with 5-FU. 
Each cell line is indicated on the top of the figure. 10 1-Jg of protein from 
each cell-free extract were separated by SDS-PAGE and transferred to 
Hybond ECL nitrocellulose membrane as described in Materials and 
Methods. Western-blots were probed with the rabbit polyclonal lgG anti-
Bak antibody. The blots were also analyzed for expression of ~-actin 
protein as controls for protein loading. The bottom graph represents the 
corresponding densitometry for results from Western blot analysis. 
Columns and bars represent mean values :J: SO, respectively. *P < 0.05 is 
the statistical significance of the difference in expression of Bak between 
each 5-FU-treated cell line and control untreated cells. 
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downregulated by 5-FU in both HEC-18 and HEC-18T. Therefore, Bcl-2 
exhibited an opposite trend to that of p53 (Figure 3.21 ). 
Upon treatment of 5-FU, Bcl-xL appeared to be not significantly 
regulated in both cell lines (Figure 3.28). 
BAG-1. known as an apoptosis-inhibiting gene, was isolated by the 
interaction of its protein with Bcl-2 (Takayama et a/ .• 1995). As shown in 
Figure 3.29, BAG-1 isoform p29 was downregulated by 5-FU treatment in 
both HEC-18 and HEC-18T. Another of the four BAG-1 isoforms, p33, 
was also downregulated in HEC-18T (Figure 3.30). However, p33 
remained the same in HEC-18 after 5-FU treatment. Although not 
expressed in KGM. the use of DMEM as a medium led to induction of 
weak expression of BAG-1 p46 and p50 isoforms in HEC-18 and moderate 
expression in HEC-18T (Figure 3.31 ). They did not change in HEC-18 
with treatment of 5-FU. On the other hand, they were both downregulated 
in HEC-18T by 5-FU. In total, BAG-1 proteins showed a trend of 
downregulation by the treatment with 5-FU. 
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Figure 3.27 Expressions of Bcl-2 in human ectocervical cell 
lines detected by Western blot analysis after treatment with 5-FU. 
Each cell line is indicated on the top of the figure. 10 IJg of protein from 
each cell-free extract were separated by SDS-PAGE and transferred to 
Hybond ECL nitrocellulose membrane as described in Materials and 
Methods. Western-blots were probed with the mouse monoclonal lgG 
anti-Bcl-2 antibody. The blots were also analyzed for expression of ~­
actin protein as controls for protein loading. The bottom graph represents 
the corresponding densitometry for results from Western blot analysis. 
Columns and bars represent mean values ± SO, respectively. **P < 0.005 
is the statistical significance of the difference in expression of Bcl-2 
between each 5-FU-treated cell line and control untreated cells. 
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Figure 3.28 Expressions of Bcl-xL in human ectocervical cell 
lines detected by Western blot analysis after treatment with 5-FU. 
Each cell line is indicated on the top of the figure. 10 IJg of protein from 
each cell-free extract were separated by SDS-PAGE and transferred to 
Hybond ECL nitrocellulose membrane as described in Materials and 
Methods. Western-blots were probed with the mouse monoclonal lgG 
anti-Bcl-xL antibody. The blots were also analyzed for expression of 13-
actin protein as controls for protein loading. The bottom graph represents 
the corresponding densitometry for results from Western blot analysis. 
Columns and bars represent mean values± SO, respectively. 
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Figure 3.29 Expressions of BAG-1-p29 in human ectocervical 
cell lines detected by Western blot analysis after treatment with 5-FU. 
Each cell line is indicated on the top of the figure. 10 ~g of protein from 
each cell-free extract were separated by SDS-PAGE and transferred to 
Hybond ECL nitrocellulose membrane as described in Materials and 
Methods. Western-blots were probed with the mouse monoclonal lgG 
anti-BAG-1 antibody. The blots were also analyzed for expression of J3-
actin protein as controls for protein loading. The bottom graph represents 
the corresponding densitometry for results from Western blot analysis. 
Columns and bars represent mean values ±SO, respectively. **P < 0.005 
is the statistical significance of the difference in expression of BAG-1-p29 
between each 5-FU-treated cell line and control untreated cells. 
141 
-en 
e 
-c 
BAG-1-p29-
J3-actin-
8 100 
0 
c 
50 
** P<0.005 
c:o-
-r-:1: 
•W (.):1: 
wo 
:c ........... 
,--A-~ 
0 72 
Cell lines 
142 
.__ 
~:1: 
•w (.):1: 
wo 
:C-
0 72 {h) 
Figure 3.30 Expressions of BAG·1·p33 in human ectocervical 
cell lines detected by Western blot analysis after treatment with 5-FU. 
Each cell line is indicated on the top of the figure. 10 1.19 of protein from 
each cell-free extract were separated by SDS-PAGE and transferred to 
Hybond ECL nitrocellulose membrane as described in Materials and 
Methods. Western-blots were probed with the mouse monoclonal lgG 
anti-BAG-1 antibody. The blots were also analyzed for expression of 13-
actin protein as controls for protein loading. The bottom graph represents 
the corresponding densitometry for results from Western blot analysis. 
Columns and bars represent mean values± SO, respectively. **P < 0.005 
is the statistical significance of the difference in expression of BAG-1-p33 
between each 5-FU-treated cell line and control untreated cells. 
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Figure 3.31 Expressions of BAG·1·p46 and pSO in human 
ectocervical cell lines detected by Western blot analysis after 
treatment with 5-FU. Each cell line is indicated on the top of the figure. 
10 1-Jg of protein from each cell-free extract were separated by SDS-PAGE 
and transferred to Hybond ECL nitrocellulose membrane as described in 
Materials and Methods. Western-blots were probed with the mouse 
monoclonal lgG anti-BAG-1 antibody. The blots were also analyzed for 
expression of 13-actin protein as controls for protein loading. The bottom 
graph represents the corresponding densitometry for results from Western 
blot analysis. Columns and bars represent mean values :.t: SO, 
respectively. •p < 0.05 and up < 0.005 are the statistical significance of 
the difference in expression of BAG-1-p46 and p50 between each 5-FU-
treated cell line and control untreated cells. 
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Table 3.4 Expressions of apoptosis-regulating proteins in HEC-18 and 
HEC-18T after treatment of 5-FU1 
Proteins 
p53 
p21 
MDM-2 
PCNA 
Bax 
Bak 
Bcl-2 
BAG-1 p29 
BAG-1 p33 
BAG-1 p46 
BAG-1- p50 
HEC-18 
0 hr 72 hr 
1 00.0±0.0 128.2±4.5 
100.0±0.0 275.8±9.1 
100.0±0.0 96.5:1:3.0 
100.0±0.0 121.2±4.8 
100.0±0.0 101.8±3.8 
100.0±0.0 117 .5±1.3 
100.0±0.0 66.9±2.0 
100.0±0.0 105.1 ±2.0 
100.0±0.0 49.5±2.5 
100.0±0.0 97 .8:t6.1 
100.0±0.0 108.2±9.0 
100.0±0.0 1 08.0:t8.0 
HEC-18T 
0 hr 72 hr 
100.0±0.0 171. 7:t2.1 
100.0±0.0 156.2±6.8 
100.0±0.0 802.9±21.0 
100.0±0.0 219.4±2.8 
1 OO.O:tO.O 99.0±1.0 
1 00.0±0.0 181.5±9.4 
1 OO.O:tO.O 28.5±0.9 
100.0±0.0 120.3±6.0 
100.0±0.0 24.0±3.0 
100.0±0.0 81.8±0.5 
100.0±0.0 64.9:1:3.4 
100.0±0.0 65.5±2.5 
1 The levels of cellular proteins were quantified relative to those of the corresponding 
cell lines without 5-FU treatment after normalization to the actin control. Protein 
expression was quantified by measuring the optical density of bands at medium 
exposure on X-ray film. The data are shown as the mean :t the standard deviation of 
three experiments. 
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3.9. Effects of low-density lipoprotein (LDL) on 5-FU-induced 
apoptosis 
It is well known that both high calcium concentration (McConkey et a/., 
1990) and serum deprivation (Bryckaert eta/., 1999; Trimble eta/., 1999) are two 
nonphysiological conditions that induce apoptosis. Serum contains LDL, which 
delivers cholesterol to cells, especially to rapidly growing cancer cells. In 
studies reported in this thesis, the experimental data show that ectocervical cells 
were more sensitive to 5-FU-induced apoptosis in DMEM than in KGM. The 
major differences between these two media are calcium concentration and 
serum. DMEM contains a 1 0-fold higher calcium concentration than that in KGM. 
DMEM contains 1 Oo/o fetal calf serum, and KGM is a serum-free medium. LDls 
are a serum component and are of interest for carcinogenesis, because they 
provide the cancer cells with cholesterol, which is required for cell membranes 
during their faster growth compared with normal cells. For example, cervical 
cancer cells metabolize 50-fold more LDL than normal gynecological 
tissue (Gal et a/.. 1981 ). The same requirement applies to faster 
proliferating cells in multistage carcinogenesis. 
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Figure 3.32 Agarose gel electrophoresis of DNA extracted 
from HEC-18 and HEC-18T treated with 5-FU for 72 hr. Each culture 
medium is indicated underneath the cell line. Cells (106 ) were cultured for 
24 hr in indicated medium, then 5-FU was added and the incubation 
period continued for another 72 hr. Cells without 5-FU treatment are used 
as controls. DNA was extracted and analyzed by agarose gel 
electrophoresis in the presence of ethidium bromide, as described in 
Materials and Methods. 
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To investigate whether calcium or the LDL pathway are involved in 
the differential susceptibility of ectocervical cells to 5-FU-induced 
apoptosis in the two media, apoptosis was examined in HEC-18 and HEC· 
18T cultured for 72 hr in KGM, KGM with added LDL, and KGM with the 
physiological level of calcium. Then, DNA fragmentation was analyzed 
(Figure 3.32). There was little difference in apoptotic DNA fragmentation 
in either HEC-18 or HEC-18T in KGM with or without added calcium, 
implying that calcium concentration does not play an important role in 
ectocervical cellular sensitivity to 5-FU-induced apoptosis. On the other 
hand, when cells were cultured in KGM containing LDL, the apoptotic 
effect of 5-FU was dramatically higher than those in KGM not containing 
LDL. 
To examine whether the LDLR plays a role in multistage cervical 
carcinogenesis or the differential sensitivity in KGM and DMEM of the 
cells to apoptosis induced by 5-FU, the expression of LDLR on HEC, 
HEC-18, and HEC-18T was analyzed by Western blot (Figure 3.33 ). No 
differences were observed between either different cells or same cell line 
cultured in different media. Analysis by flow cytometry showed a same 
trend (Figure 3.34). These results suggest that the presence of LDL in 
serum is an important factor involved in the differential susceptibility in the 
two media of HEC-18 and HEC-18T to 5-FU-induced apoptosis. 
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Figure 3.33 Expressions of LDLR in human ectocervical cells. 
Western-blots were probed with the mouse monoclonal lgG2a anti-LDLR 
antibody. The blots were also analyzed for expression of 13-actin protein 
as controls for protein loading. The bottom graph represents the 
corresponding densitometry for results from Western blot analysis. 
Values represent the mean ~ the standard deviation from three 
independent experiments. 
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Figure 3.34 LDLR expressions in human ectocervical cells. 
Each cell line is indicated to the right of the figure. Flow cytometry 
analysis of cells stained with anti-LDLR antibody (black peaks) or negative 
control anti- lgG2a (open peaks) followed by staining with a secondary 
FITC-conjugated antibody. 
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CHAPTER4 DISCUSSION AND FUTURE DIRECTIONS 
4.1. Multistage cervical carcinogenesis and effects on growth in 
vitro and in vivo 
Cervical carcinogenesis is considered to be a multistage process. 
To perform in vitro studies, a model system that mimics the in vivo system 
was required. In this study, a model system was chosen for the malignant 
progression of cervical cells consisting of HEC, HEC-18, and HEC-18T. 
HEC-18 was derived from HEC by transfection and immortalization by 
HPV 18 DNA (Yokoyama et al., 1994). Northern blot analysis using HEC-
18 DNA showed the expression of E6-E7 mRNA, which is known to be a 
template for E6 and E7 oncoprotein synthesis. HEC-18 exhibited a 
squamous phenotype. They formed monolayers of typical keratinocyte-
like polygonal cells, which were similar to HEC in KGM (Figure 3.2 A). 
Some growth characteristics of HEC-18 were also tested, and the results 
indicated that there were no significant differences from those of HEC 
(Figure 3.4 and Table 3.1 ). HEC-18 can be readily subcultured, indicating 
that they are immortalized. However, HEC-18 did not display anchorage-
independent growth assayed by soft agar. indicating an absence of full 
transformation (Table 3.1 and Figure 3.5). Furthermore, tumorigenicity of 
HEC-18 had been tested on nude mice. After 7-14 days, small nodules 
appeared at the site of injection, but they subsequently regressed 
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(Yokoyama et al .• 1994). Therefore, HEC-18 was nontumorigenic in nude 
mice. Because cervical carcinogenesis is a multistep process. HPV 18 
may not be sufficient for the full neoplastic transformation of primary 
human ectocervical cells, although the immortalization by HPV 18 DNA 
remains a prerequisite to the development of tumorigenicity. The 
enhanced life span of HEC-18 would be expected to lead to a greater 
accumulation of genetic changes, and HPV E6 and E7 proteins are known 
to induce chromosomal instability. Consequently, HEC-18 is useful for the 
investigation of factors involved in early multistep progression of cervical 
cancer and of oncogenic events that follow HPV 18-immortalization. 
Since HEC-18 was not tumorigenic in nude mice (Yokoyama et al., 1994), 
to employ a full model system mimicking every major stage in multistep 
progression of cervical cancer, experiments herein used HEC-18T. It was 
established by our laboratory using CSC treatment on HEC-18 (Nakao et al., 
1996). The CSC treatment, representing cigarette smoking as a late-acting 
cofactor for cervical cancer, has been frequently employed in our laboratory 
group to develop malignantly transformed human cervical cell lines from cells 
immortalized by HPV 16 or HPV 18 {Yang et al., 1996; Nakao et a/., 1996). 
Morphological studies of HEC-18T did not evidence significant differences from 
those for HEC and HEC-18 {Figure 3.1. Figure 3.2. and Figure3.3); neither did 
growth potential analysis {Figure 3.4 ). Northam blot analysis, Southern blot 
analysis and RT-PCR all indicated that malignant transformation in HEC-18T had 
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no effect on the physical state of HPV 18 and little effect on the gene expression 
of HEC-18T compared to HEC-18. However. HEC-18T reconstructed severe 
dysplasia I carcinoma in situ (CIS) in the organotypic (raft) culture system and 
produced invasive squamous cell carcinomas on nude mice (Nakao et al .• 1996). 
Furthermore, anchorage independence was observed in soft agar growth of 
HEC-18T (Table 3.1 and Figure 3.6). Therefore, an in vitro model system of HPV 
18-related squamous cell carcinomas derived directly from the uterine ectocervix. 
consisting of normal (HEC), immortalized (HEC-18) and transformed (HEC-18T) 
cell lines. has been established and chosen to mimic multistep cervical 
carcinogenesis for further elaboration in this study. 
4.2. Apoptosis in the cervical oncogenesis model system 
Apoptosis became a central focal point of my experiments. It is a 
highly organized physiologic mechanism that kills abnormal ceUs, such as 
cancerous cells. Regulation of apoptosis is, therefore, an important 
defense against the emergence of cancer. In early carcinogenesis, target 
cell populations become predisposed to genetic lesions leading toward 
malignancy. Apoptotic destruction of predisposed cells may limit the 
number of cells available for malignant progression. This hypothesis may 
be applied to neoplasms known to be indolent. such as follicular 
lymphoma. The cancer typically acquires genetic defects that allow it to 
become more aggressive in later stage (Wynie, 1992). Many changes 
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associated with malignant transformation, such as mutations. occur at 
important checkpoint controls or activate cell survival genes. such as Bcl-
2. This allows cells to proliferate and survive when normal mechanisms 
would trigger the initiation of apoptosis (Dixon et al., 1997). 
An important part of these studies of cervical oncogenesis was to 
further examine the specific roles in apoptosis of cellular genes. Despite 
the myriad of apoptosis-inducing agents. the apoptotic pattern is 
conserved in diverse organisms. This conservation suggests that there 
may be a limited number of shared genes regulating apoptosis (Dixon et 
a/ .• 1997). Since the known genes all participate in regulating apoptosis, 
their expression and interactions have far reaching implications in the 
control and possible treatment of human cancers. However they are 
influenced by a multitude of cellular and environmental factors. 
4.3. Effects of 5-FU on growth In the multistage cervical 
oncogenesis model 
5-FU is an effective anticancer drug that is also used for cervical 
oncogenesis. To better understand the mechanism of 5-FU induced apoptosis 
and its role in multistage cervical carcinogenesis, in this study. the effects of 5-
FU on growth have been investigated in our model system, HEC, HEC-18, and 
HEC-18T, for multistage cervical carcinogenesis. 
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In initial studies, HPV 18 DNA in both immortalized cell line HEC-18 
and transformed cell line HEC-18T had dramatically decreased the 
response to apoptotic stimuli 5-FU (Figure 3.10 and Figure 3.12). 
Similarly, HPV 16 DNA in both immortalized cell line HEN-16 and 
transformed cell line HEN-16T has also been reported to reduce the 
response to various apoptotic stimuli (Yang eta/., 1998b ). 
Cell morphology can change by growing in a different medium 
(Nakao et al., 1996; Yang eta/., 1996). This is also true in our cases 
when HEC, HEC-18, and HEC-18T (Figure 3.1, Figure 3.2, and Figure 3.3, 
respectively) were cultured in KGM or in DMEM. Additionally, transformed 
oral keratinocytes demonstrated enhanced growth potential when the 
medium was shifted from KGM to DMEM (Li et a/., 1992). Growth potential 
(Figure 3.4) and growth characteristics (Table 3.1) of HEC, HEC-18, and HEC-
18T were different when the cells were grown in different media, either KGM or 
DMEM. These results encouraged experiments investigating the apoptotic 
effects of 5-FU on cell lines cultured in KGM, as well as in DMEM. 
Cell morphology is one of the most common and reliable criteria for 
characterizing apoptotic cell death (Huschtscha et al .• 1996). Initially, cell 
morphological changes were compared before and after treatment with 5-FU. In 
KGM, apoptotic characteristics, such as cell shrinkage and surface blabbing, 
were observed after 5-FU treatment in all of three cell types (Figure 3. 7). In 
DMEM, similar phenomena were observed in cell lines HEC-18 and HEC-18T 
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(Figure 3.8). Subsequently, flow cytometry analysis (Figure 3.9) confirmed the 
apoptotic effects of 5-FU. HEC was not tested when grown in DMEM, since they 
did not proliferate in this medium. 
The strongest evidence, indicating the cell death caused by 5-FU 
treatment was apoptotic came from ladder-pattern DNA fragmentation. Since 
DNA fragmentation analysis can function as qualitative evaluation for apoptosis 
levels, cell lines cultured either in KGM (Figure 3.1 0) or in DMEM (Figure 3.11) 
were investigated after treatment with 5-FU for different times. In KGM, HEC 
showed significant apoptosis in a time-dependent manner, whereas HEC-18 and 
HEC-18T did not exhibit apparent DNA fragmentation until the longest 5-FU 
treatment period. This indicated that immortalized HEC-18 and transformed 
HEC-18T were at least resistant to 5-FU-induced apoptosis to some extent 
(Figure 3.1 0). However, surprisingly, the two cell lines were contrarily 
susceptible to 5-FU-induced apoptosis when they were cultured in DMEM (Figure 
3.11 ). After comparing apoptosis levels in different cells grown in different 
media, susceptibility of HEC-18 and HEC-18T to 5-FU-induced apoptosis was 
caused by medium change from KGM to DMEM (Figure 3.12). Furthermore, the 
results from trypan blue exclusion (Figure 3.13) and MTT cytotoxicity assays 
(Table 3.2) were consistent with those from DNA fragmentation analysis 
regarding the sensitivity evaluation of cell lines to 5-FU-induced apoptosis. 
Taken together, the data led to: (1) 5-FU induced apoptotic cell death in 
HEC, HEC-18, and HEC-18T. (2) HPV 18 immortalization and cigarette smoke 
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condensate transformation decreased the sensitivity of cell lines to 5-FU-
induced apoptosis. (3) Medium change from KGM to DMEM increased the 
sensitivity of HEC-18 and HEC-18T to 5-FU-induced apoptosis. 
4.4. Effects on apoptosis-regulating proteins by 5-FU in cervical 
oncogenesis model 
Cellular events can be often rationally explained by molecular 
events. ~-FU is an anticancer drug that functions effectively in cancer 
prevention and treatment. 5-FU usually specifically affects the genetic 
and biochemical signals of apoptosis. However, the molecular basis 
involved in 5-FU-induced apoptosis on human cervical cancer cell lines 
had not been investigated. Therefore, examining the induction of 
apoptosis in multistage carcinogenesis was considered to be important for 
studying the mechanism in the current investigations and gene 
modulations were consequently examined before and after treatment with 
5-FU. 
To measure the correlation between the apoptosis sensitivity and 
medium change, a panel of apoptosis-regulating proteins was tested in 
HEC-18 and HEC-18T, first, without treatment with 5-FU. The relationship 
between 5-FU treatment and apoptosis-regulating proteins in ectocervical 
cells was examined and compared by Western blot analysis in HEC, HEC-
18, and HEC-18T without treatment with 5-FU. 
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p53 is a phosphoprotein composed of 393 amino acids, and it 
resides in the nucleus of the cell. p53 is one of the tumor suppressors 
and it appears to occupy a pivotal role in deciding the fate of cells that 
have been stressed. Activation of p53 drives a series of events that 
culminate in either cell cycle arrest or apoptosis (Steele et at., 1998). p53 
protein level decreased in HPV 16-immortalized HEN and esc-
transformed HEN, which correlated with resistance of celt lines to 
apoptosis induced by DNA-damaging agents, staurosporine and cisplatin 
(Yang et al., 1998b). It was reported that transfection of wild-type p53 
gene enhanced the cytotoxicity of cisplatin and cisplatin-induced 
apoptosis in Hela cells (Miragawa et at., 1999). In this study, p53 level 
decreased remarkably in HEC-18 and HEC-18T, resulting in decreased 
sensitivity to 5-FU-induced apoptosis. It also increased remarkably in 
HEC-18 and HEC-18T when the medium was switched to DMEM, 
accounting for increased sensitivity to 5-FU-induced apoptosis (Figure 
3.14 ). 
Bcl-2 family consists of pro-apoptotic and anti-apoptotic genes and 
it is the balance in expression between these gene lineages that may 
determine the death or survival of a cell. Bak was isolated based on its 
sequence homology to Bcl-2 within the BH1 and BH2 regions and its 
ability to interact with the E1 B 19K protein (Kiefer et at., 1995). Bak is 
expressed widely, and in most cases, accelerates cell death. Therefore, it 
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is one of the pro-apoptotic genes in Bcl-2 family. A downregulation of Bak 
was reported to facilitate the accumulation of neoplastic cells in the early 
stages of colo rectal tumorigenesis (Krajewski et a/., 1996). Our data 
showed that Bak level decreased greatly after immortalization and 
transformation by HPV 18, which correlated with the reduced sensitivity of 
HEC-18 and HEC-18T to 5-FU-induced apoptosis (Figure 3.15). However, 
Bak level did not change significantly when HEC-18 and HEC-18T were 
adapted to DMEM, implying that a Bak-independent mechanism might be 
involved in sensitivity to 5-FU-induced apoptosis change upon medium 
switch. The role of Bak in this process remains elusive. 
.. Bax was the first Bcl-2-associated protein to be identified. It is 
homologous to Bcl-2 in sequence and coimmunoprecipitates with Bcl-2 in 
cell extracts and in vitro (Oitvai et a/., 1993). In functional assays, Bax 
suppresses the ability of Bcl-2 to block apoptosis. Bax knockout mice 
develop normally but display lymphoid hyperplasia consistent with a role 
for Bax in the promotion of apoptosis (Knudson et a/., 1995). It was 
shown that overexpression of Bax gene by transfection of Bax vector 
sensitized erythroleukemia cells to chemotherapeutic agent-induced 
apoptosis (Kobayashi et a/., 1998). Another study reported that Bax 
enhanced apoptosis in ovarian cancer cell lines that were transfected with 
Bax (Strobel et al., 1996 ). Enhanced Bax expression was demonstrated 
to sensitize human breast cancer cells to radiation-induced apoptosis 
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(Wagener et al., 1996). Consistently, our studies also showed the 
correlation between sensitivity to apoptosis and expression level of Bax. 
As shown in Figure 3.16, the down-regulation of Bax is associated with 
decreased sensitivity to 5-FU-induced apoptosis in HPV 18-immortalized 
and -transformed cell lines, while up-regulation is associated with 
increased sensitivity to apoptosis due to medium change. 
The Bcl-2 gene was first discovered as part of the most common 
translocation in human B cell follicular lymphoma (Bakhshi et a/., 1985). 
Bcl·2 has been shown to enhance cell survival by inhibiting apoptosis 
induced under a wide variety of circumstances, suggesting that it is a 
ubiquitous inhibitor of cell death triggered by multiple routes (White, 
1996 ). It was reported that dephosphorylation played an important role in 
anti-apoptosis potential of Bcl-2 (Haldar et al., 1994 ). Overexpression of 
Bcl-2 delayed apoptosis induced by various treatments in a Hela cell line 
in which the expression of Bcl-2 was controlled by the concentration of 
tetracycline (Yin et al., 1995; 1996). In addition , transfection-enforced 
overexpression of Bcl-2 was demonstrated to inhibit chemotherapeutic 
agent-induced apoptosis and enhance clonogenic survival (Elliott et al., 
1998; Kobayashi et al., 1998). More recently, another study showed that 
renal epithelial cells with overexpression of Bcl-2 were significantly less 
sensitive to cisplatin and 5-(1 ,2-dichlorovinyi)-L-cysteine-induced 
apoptosis (Zhan et a/., 1999). Similarly. greatly enhanced expression of 
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Bcl-2 in HEC-18 and HEC-18T was associated with their resistance to 5-
FU-induced apoptosis. On the other hand, reduced expression of Bcl-2 in 
HEC-18 and HEC-18T when_ grown in DMEM resulted in increased 
sensitivity to 5-FU-induced apoptosis (Figure 3.17). 
Bcl-x gene has high homology to Bcl-2 and also functions to 
regulate apoptosis (Boise et a/., 1993 ). Bcl-x transcripts are alternatively 
spliced into long (L) and short (S) forms. The protein product of the long 
form, Bcl-xL. resembles Bcl-2 and is also a potent inhibitor of apoptosis. 
The protein product of the short form, Bcl-xs, antagonizes apoptosis 
inhibition by the Bcl-xL and Bcl-2 (Boise et a/., 1993 ). Bcl-xL was reported 
to block apoptosis induced by immunosuppressants in a B lymphoid cell 
line (Gottschalk eta/., 1994). Furthermore, it was suggested that IL-6 can 
upregulate expression of Bcl-xL, and this may correlate with protection 
against apoptosis in murine myeloma cells (Schwarze eta/., 1995). Bcl-xL 
expression in malignant plasma cells strongly correlated with decreased 
response rates in patient groups treated with melphalan and prednisone 
or vincristine, adriamycin, and dexamethasone. In addition, myeloma 
cells with overexpression of Bcl-xL demonstrated a generalized resistance 
to apoptosis that was induced by several different agents (Tu eta/., 1998). 
However, the present study did not show any significant changes in the 
model system (Figure 3.18). Bcl-xL does not seem to be involved in 
mechanisms regarding sensitivity changes to 5-FU-induced apoptosis 
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caused by HPV 18 immortalization, transformation or medium change. 
Nevertheless, it is generally accepted that the relative ratios of anti-
apoptotic and pro-apoptotic members of the Bcl-2 protein family determine 
the ultimate sensitivity or resistance of cells to various stimuli or 
circumstances that trigger apoptosis. It was reported that Bcl-xL to Bax 
ratio significantly correlated with chemosensitivity to 5-FU (Nita et al., 
1998). Combined with results shown in Figure 3.16, Bci-XL to Bax ratio 
displayed an increasing trend in HEC-18 and HEC-18T, correlating with 
decreased sensitivity to 5-FU-induced apoptosis, and a decreasing trend 
upon medium change, correlating with increased sensitivity to 5-FU-
induced apoptosis. 
BAG-1 is a novel anti-apoptotic protein identified as a Bcl-2-binding 
protein (Takayama et a/., 1995). It is a multi-isoform protein with four 
isoforms, which have molecular masses of 29, 33, 46, and 50 kDa, 
respectively. Although most Bcl-2-binding proteins contain BH domains, 
BAG-1 has no homology with Bcl-2 in its structure. Analysis of 
transfectants overexpressing BAG-1 has revealed that BAG-1 cooperates 
with Bcl-2 to prolong cellular survival against various apoptotic 
stimulations (Takayama et al., 1995). In contrast to Bcl-2, only limited 
data are available so far as to the function of BAG-1. BAG-1 has been 
found to bind the receptors for steroid hormones and prevent their 
apoptosis-inducing function. Therefore, one mechanism through which 
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BAG-1 inhibits apoptosis might be regulation of hormone pathways 
(Kullmann et al., 1998). As expected, the overall level of BAG-1 exhibited 
an increasing tendency in HEC-18 and HEC-18T compared to that in HEC, 
possibly accounting for their decreased sensitivity to 5-FU-induced 
apoptosis (Figure 3.19 and Figure 3.20). However, to our surprise, BAG-1 
expression once again increased in HEC-18 and HEC-18T when cultured 
in DMEM. These results suggest that something more complicated 
occurred and may be due to BAG-1 functions other than anti-apoptosis. 
4.5. Modulation of apoptosis-regulating proteins by 5-FU treatment 
An important focus of this study on the effect of 5-FU was 
programmed cell death, commonly termed apoptosis. Apoptosis is 
regulated by a finely controlled equilibrium between anti-apoptotic genes 
(involved in inhibiting apoptosis) and pro-apoptotic genes (involved in 
triggering apoptosis). A wide variety of studies demonstrate that the 
sensitivity of cells to apoptosis usually can reflect by expression levels of 
anti-apoptotic genes, pro-apoptotic genes or ratio of anti- to pro·apoptotic 
genes. Our studies, as discussed above, also provide supporting 
evidence for these correlations. This is of special interest, since it is 
generally accepted that the sensitivity of cancer cells to apoptosis affects 
the sensitivity to killing by anticancer agents, i.e., the more sensitive the 
cancer cells are to apoptosis, the more sensitive they are likely to be to 
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anticancer agents. Because resistance to apoptosis is now thought to be 
a major problem limiting the utility of anticancer therapy, factors that can 
sensitize cancer cells to apoptosis would be expected to facilitate the 
development of effective anticancer therapy (St. Croix et a/., 1997). 
However, high level endogenous expression of pro-apoptotic genes and/or 
low level endogenous expression of anti-apoptotic genes are by 
themselves insufficient to initiate apoptosis, even though they exhibit 
correlations with cell sensitivity to apoptosis. Additional physiological or 
nonphysiological triggers are required to initiate programmed cell death. 
Anticancer drugs are common exogenous stimuli to induce apoptosis. It 
was, therefore, very important to understand whether anticancer drugs 
modulate apoptosis-associated genes and how these genetic modulations 
finally lead to apoptosis. 
Induction of tumor suppress Jr gene p53 and inhibitor of cyclin-
dependent kinases p21 played an important role. p21 is associated with 
phosphorylation of Bcl-2. Phosphorylation of Bcl-2 and the elevations of 
p21 lead to apoptosis (Wang et a/., 1999). It has become evident that 
apoptosis can be regulated through either p53-dependent or p53-
independent pathways (Liebermann et a/., 1995). The tumor suppressor 
gene p53 has become a major player in the context of studying the 
molecular mechanisms of apoptosis was observed to suppress cell growth 
and induce apoptosis in several cell types (Shaw et a/., 1992). 
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Experimental evidence showed that MDM-2 and p21 were direct target 
genes of p53. 
p21 was found in a quaternary complex that included not only cyclin 
and CDK, but also PCNA, to inhibit the kinase activity and result in 
apoptosis (Henderson et al., 1994). The spectrum of known p53 target 
genes has then broadened to include Bcl-2 and Sax (Miyashita et al., 
1994 ). It was shown that Bcl-2 protein family interacts to form various 
homo- and hetero-dimers to either accelerate or inhibit apoptosis (Boise et 
al., 1993}. On the other hand, treatment of M1 cells with transforming 
growth factor 131 (TGFJ31} induced rapid growth arrest and apoptosis 
through a p53-independent pathway (Selvakumaran et a/., 1994 ). The 
comparison of the kinetics indicated that apoptosis through the p53-
dependent pathway was more rapid than through p53-independent 
pathways. Ectopic expression of Bcl-2 at levels that block TGFJ31-induced 
apoptosis of M1 cells delayed, but did not block, p53-induced apoptosis. 
Moreover, both p53 and TGFJ31 down-regulated endogenous Bcl-2 
expression, but only p53 up-regulated Bax expression. Thus, the p53-
mediated up-regulation of Bax provides at least a partial explanation for 
the more rapid apoptosis induced by p53 compared to TGFJ31, as well as 
for the ineffectiveness of ectopic Bcl-2 to abrogate p53-mediated 
apoptosis (Selvakumaran et a/., 1994). Apoptosis through the p53-
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dependent pathway has been receiving extensively increased interest 
(Meikrantz et al., 1995). 
As discussed before. our studies on expression of apoptosis-
regulating proteins without 5-FU treatment suggested that the sensitivity 
of cells to apoptosis correlated with expression level of p53 (Figure 3.14). 
giving a strong implication that 5-FU-induced apoptosis in HEC, HEC-18, 
and HEC-18T is p53-dependent. To test this hypothesis, a range of 
apoptosis-regulating proteins. including p53 and some p53 target gene 
products, were examined after 5-FU treatment. Since immortalization by 
HPV 18 and transformation decreased the sensitivity of cells to 5-FU-
induced apoptosis while medium change to DMEM increased the 
sensitivity, HEC-18 and HEC-18T grown in DMEM were a better system 
for studies on genetic modulation by 5-FU treatment. 
Anticancer agents, such as 5-FU, etoposide, and adriamycin. have 
been reported to be capable of inducing p53-dependent apoptosis (Lowe 
et a/.. 1993 ). Radiation was also demonstrated to induce p53 
upregulation and result in apoptosis in testicular germ cancer cells 
(Burger et al., 1998). Additionally. 5-FU increased p53 protein levels and 
cause programmed cell death in colonic adenoma cell lines (Piazza et a/., 
1997). It was reported that 5-FU triggered p53-dependent apoptosis in 
oncogenically transformed mouse embryonic fibroblasts (lowe et a/., 
1993). Similarly, in the present study, p53 was upregulated significantly 
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by 5-FU treatment in HEC-18 and HEC-18T that were cultured in DMEM 
(Figure 3.21 ), supporting the idea that 5-FU induced apoptosis in cervical 
cells through a p53-dependent pathway. 
The activated p53 protein shows sequence-specific DNA-binding 
activity. By binding to its target DNA sequence in upstream promoter 
regions, p53 transcriptionally activates a range of genes, including the 
p21 gene (Cox, 1997). p21 is thought to exert its effect by inhibiting 
CDKs that are required to drive the cell division cycle (Henderson et a/., 
1994 ). Overexpression of p21 leads to apoptosis and has been shown to 
effectively suppress tumor growth in vitro and in vivo (Gartel eta/., 1996). 
Radiation has been reported to cause a p53-dependent upregulation of 
the p21 gene in testicular germ cell tumor lines with wild type p53, but not 
in those with mutant p53, and result in apoptosis (Burger eta/., 1998). In 
breast cancer cells, apoptosis was found induced by 12-0-tetradecanoyl-
phorbol-13-acetate (TPA). Also, upregulation of p21 was observed in 
TPA-treated cells, implying the involvement of p21 in TPA-induced 
apoptosis (Li et a/., 1998). A prodrug of 5-FU, FUdR, was demonstrated 
to inhibit cell growth, which was associated with increased expression of 
p21 protein in human colon carcinoma cells (Huang et a/., 1998). 
Moreover. 5-FU treatment induced apoptosis in both intestinal and 
midcolonic crypts. and this has been shown to correlate with a prolonged, 
p53-dependent expression of p21 (Pritchard et at., 1998). More recently, 
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a strict p53-dependence of mRNA up-regulation for p21 was reported 
following ionizing irradiation in mice (Bouvard eta/., 2000). Similarly, p21 
up-regulation was observed in both HEC-18 and HEC-18T following 5-FU 
treatment (Figure 3.22). Therefore, our study showed that 5-FU treatment 
had a similar effect on p21 to that on p53 (Figure 3.21 ), implying an 
association of p53-dependent up-regulation of p21 with 5-FU-induced 
apoptosis. 
p53 could function as a transcription factor, and MDM-2 gene is one 
of its targets (Barak et a/., 1993). On the other hand, the MDM-2 gene 
encodes a protein whose binding to p53 inhibits its transactivation 
function and negatively regulates its stability in cells (Kubbutat et a/., 
1999). As a result, p53 increases MDM-2 expression whereas MDM-2 
suppres~as p53 activity, creating an autoregulatory feedback loop. 
Interestingly, MDM-2 has also been found to bind to Rb (Xiao et a/., 
1995). It was reported that MDM-2-Rb interaction played an important 
role in regulating the stability and apoptotic function of p53, which could 
be achieved by Rb-MDM-2-p53 trimeric complex (Yap et a/., 1999). 
Upregulation of MDM-2 was found to be p53·dependent in irradiated mice 
(Bouvard et a/., 2000). The loss of MDM-2 allowed the unregulated p53 
protein to continuously exert its growth-suppressing activity, which either 
led to a complete G1 arrest or induced p53-dependent apoptosis (de 
Rozieres eta/., 2000). In the present study, the expression level of MOM-
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2 remained the same in HEC-18, and increased remarkably in the case of 
HEC-18T after 5-FU-treatment (Figure 3.23). This could be explained by 
the special relationship between MDM-2 and p53 based on an 
autoregulatory feedback loop. A distinct difference of MDM-2 level 
between HEC-18 and HEC-18T was observed by comparing them by 
Western blot analysis before 5-FU treatment (Figure 3.23). The MDM-2 
level in HEC-18 was much higher than that in HEC-18T before 5-FU 
treatment. The level of MDM-2 did not change at all in HEC-18 after 5-FU 
treatment, probably because the endogenous MDM-2 in HEC-18 was 
sufficient to inhibit upregulated p53 by 5-FU treatment. On the other 
hand, MDM-2 was upregulated along with the regulation of p53 by 5-FU 
until its level was high enough to keep the equilibrium in the 
autoregulatory feedback loop. 
Another p53 target gene, PCNA, plays an essential role in nucleic 
acid metabolism as a component of the replication and repair machinery 
(Kelman, 1997). PCNA is believed to interact with p21 in a quaternary 
complex with CDKs and cyclins, suppressing CDK functions (Henderson 
et al., 1994). An elevation in PCNA expression was mediated by p53 
protein, which was shown to activate transcription from the promoter of 
the PCNA gene (Morris et al., 1996). UV irradiation was able to up-
regulate PCNA expression (Zeng et al., 1994 ). As expected, an up-
regulation of PCNA expression was observed along with the up-regulation 
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of p53 by 5-FU treatment in both HEC-18 and HEC-18T, suggesting the 
possibility of PCNA's involvement in the mechanism of 5-FU-induced 
apoptosis in cervical cells (Figure 3.24 ). 
Bax, another key gene transcriptionally activated by p53, functions 
as an apoptosis promoter (Steele et a/., 1998). Bax expression is induced 
in a variety of biologically and clinically relevant situations associated with 
apoptosis, including treatment with chemotherapeutic drugs or radiation. 
The induction of Bax expression following genotoxic stress has been 
attributed to p53, which binds to typical recognition elements located in 
the Bax gene promoter and directly transactivates this pro-apoptotic gene 
(Reed, 1998). The ability of radiation and chemotherapeutic drugs to 
increase Bax expression may explain why some types of tumors with high 
levels of Bax protein, such as low-grade non-Hodgkin's lymphomas and 
small-cell lung cancers, initially respond well to therapy (Kitada et a/., 
1996). 5-FU and interferon-v were reported to independently or additively 
upregulate Bax expression level and induce apoptosis in colorectal 
carcinoma cells (Koshiji et a/., 1997). The up-regulation of Bax was also 
proposed to be involved in the molecular mechanisms of TPA-induced 
apoptosis in breast cancer cells (Li et al., 1998). Furthermore, a p53-
dependent mRNA upregulation of Bax was detected in ionizing irradiated 
mice, and apoptosis was induced (Bouvard et al., 2000). In the present 
study, there was no significant difference for Bax expression levels before 
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and after treatment with 5-FU in either HEC-18 or HEC-18T (Figure 3.25). 
It is generally accepted that ratios of anti-apoptotic to pro-apoptotic Bcl-2 
family members determine ultimate sensitivity to cell death stimuli. 
Changes in expression of both Bcl-2 and Bax in breast cancer may 
provide an explanation for the seemingly paradoxical observation that 
lower levels of Bcl-2 have been associated with better prognostic features 
in some types of malignancies (Reed, 1998). A lower Bcl-2 to Bax ratio 
can be actually obtained by combining the results for Bcl-2 (Figure 3.27), 
indicating an expected effect from 5-FU-induced apoptosis. 
Similar to Bax, Bak appears to antagonize Bcl-2 function, thus 
abrogating the ability of Bcl-2 to promote cell survival. A high level of Bcl-
2 relative to Bak promotes survival; however, an excess of Bak relative to 
Bcl-2 results in apoptosis (Chittenden et a/., 1995 ). 5-FU was reported to 
remarkably increase Bak expression level in human colon cancer cells 
and induce apoptosis (Nita et al., 1998). According to our data, 5-FU 
significantly upregulated the Bak expression level in HEC-18 and HEC-
18T (Figure 3.26), suggesting that Bak was involved in the signaling 
transduction pathway for 5-FU-induced apoptosis. 
As one of the most important apoptosis regulating genes. Bcl-2 has 
the ability to inhibit apoptosis. Antimicrotubule drugs were reported to 
induce apoptosis, which resulted from the inactivation of Bcl-2 function 
through phosphorylation (Wang et al., 1999a). The induction of Bcl-2 
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phosphorylation is known followed by loss of its ability to form 
heterodimers with Bax. It was reported that there is a significant decrease 
in the formation of Bcl-2 I Bax heterodimers after induction of Bcl-2 
phosphorylation, even though the level of Bax protein is increased in 
MCF-7 cells exposed to vinorelbine {Wang et a/., 1999b ). It was shown 
that 5-FU induced apoptosis in colorectal carcinoma cells in a dose- and 
time-dependent manner, which was correlated with the down·regulation of 
Bcl-2 (Koshiji et a/., 1997). The tumor suppressor p53 is a negative 
regulator of Bcl-2 expression. The Bcl-2 promoter alone coupled to a 
reporter gene does not show regulation by p53, but a 195 bp segment of 
the 5' untranslated region of the Bcl-2 gene confers negative regulation by 
p53 (Miyashita et a/., 1994 ). We also found an inverse correlation 
between the expression of Bcl-2 (Figure 3.27) and p53 (Figure 3.21) upon 
5-FU treatment. This result suggested that p53 down-regulates Bcl-2 
expression. Both effects would be expected consequences from the 
treatment with anticancer agent 5-FU. 
Similar to Bcl-2, Bcl-xL was shown to confer resistance to apoptosis 
induction following exposure to apoptotic stimuli. Bci-XL and Bcl-2 are 
complementary in function as apoptosis inhibitors in mouse development 
(White, 1996). Recent results indicated that ischaemia-induced acute 
renal failure is associated with upregulation of anti-apoptotic Bcl-2 and 
Bcl-xL in the damaged distal tubule (Gobe et a/., 1999). Ionizing radiation 
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has been demonstrated to induce apoptosis, which resulted from the 
downregulation of Bcl-2 and Bcl-xL. in acute lymphoblastic leukemia cells 
(Findley et a/., 1997). Insight into the role of Bcl-xL in regulating apoptosis 
was also obtained from Bcl-x deficient mice (Motoyama et a/., 1995 ). The 
Bcl-x knockout embryos displayed extensive apoptosis involving post-
mitotic neurons of the developing brain, spinal cord, dorsal root ganglia, 
and hematopoietic cells in the liver. My results showed that 5-FU did not 
modulate Bcl-xL expression level in either HEC-18 or HEC-18T (Figure 
3.28). However, the involvement of Bcl-xL in 5-FU-induced apoptosis 
cannot be excluded, since it could be explained by the decreasing trend of 
expression ratio of Bcl-xL to pro-apoptotic Bak {McPake et al., 1998; 
Figure 3.26). Further investigation is needed. 
As an anti-apoptotic gene, BAG-1 was found overexpressed in 
tumor cells, such as breast cancer cells (Takayama et al., 1998). Its anti-
apoptotic function has been extensively studied (Adachi et al., 1998). 
BAG-1 has been reported to have a general regulatory function in signal 
transduction pathways involved in cell survival (Kullmann et a/., 1998). 
The BAG-1 protein was recently identified as a chaperone cofactor of the 
constitutively expressed Hsc70 and the heat-inducible Hsp70 in 
mammalian cytosol and nucleus (Hohfeld eta/., 1997). Furthermore, gene 
transfer .. mediated elevations of the level of BAG-1 isoforms cause a 
variety of cellular phenotypes, possibly through a modulation of 
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Hsc70/Hsp70 activity, including increased resistance to apoptosis, 
enhanced cell proliferation, and altered transcriptional activity of steroid 
hormone receptors (Luders et a/., 2000). However, less is known about 
the status of BAG-1 during apoptosis and the effects of exogenous 
apoptosis inducers on BAG-1 expression. In the present study, it was first 
presented how an anticancer agent, 5-FU, would modulate BAG-1 
expression during apoptosis in cervical cancer cell lines. In agreement 
with the fact that BAG-1 is an apoptosis-inhibiting gene, 5-FU down-
regulated the expression level of BAG-1 in both HEC-18 and HEC-18T, 
favoring 5-FU-induced apoptosis (Figure 3.29. Figure 3.30, and Figure 
3.31 ). However, the p33 isoform, but not other isoforms, was enhanced. 
Various levels of changes were observed in each BAG-1 isoform, 
indicating that they may have different functions in regulating apoptosis. 
4.6. Effects of LDL on S·FU·induced apoptosis 
The observation reported herein that the response to 5-FU of cells 
in the model was medium-dependent may provide informative clues for 
chemotherapies with 5-FU. Two key differences in the media were Ca2• 
level (Kasturi et a/., 1993) and presence of serum. Regarding the LDL in 
the serum, a number of cervical tumor cell lines were found to have higher 
LDL receptor activity than normal cells (Gal et al., 1991 ). The reason for 
these observed differences described herein in different media thus 
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became the next focus. It was shown that reversal of 5-FU susceptibility 
is correlated with the expression level of apoptosis-regulating proteins 
upon medium change. However, the question about more detailed factors 
causing the reversal susceptibility still was required to be addressed by 
continuing study concerning the differences between KGM and DMEM. 
DMEM contains Ca2• with a concentration 10 times higher than that 
in KGM. Being a ubiquitous factor in cell biology, Ca2• has been reported 
to have effects on the complex process of apoptosis (McConkey et al., 
1997). In fact, both increases and decreases in cellular Ca2• levels have 
been shown to promote apoptotic cell death. In general, the prevailing 
view is that elevations in intracellular Ca2• may be one of the key signals 
leading to the promotion of apoptosis (Mason, 1999). To examine 
whether Ca2• plays a role in the reversal susceptibility to 5-FU-induced 
apoptosis, experiments were performed using KGM plus Ca2• with the 
same concentration as in DMEM. When HEC-18 and HEC-18T were 
cultured in above-mentioned medium, there was no significant difference 
in apoptotic response observed after exposure to 5-FU for 72 hr (Figure 
3.32). These results suggested that Ca2• level difference in these two 
media was not involved in the differential susceptibility of cervical cells to 
5-FU-induced apoptosis. 
Another major difference between KGM and DMEM is serum. 
DMEM contains fetal calf serum, while KGM does not. Apparently, serum 
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deprivation is not the reason to change the sensitivity since DMEM 
contains serum and sensitizes cells to 5-FU-induced apoptosis. However, 
one of the principle components in serum, LDL (about 130 mg/dl), may 
have had some effect on 5-FU-induced apoptosis. considering its wide-
accepted role as an effective vehicle for chemotherapeutic drugs (Gal et 
a/., 1981 ). LDLs are particles that enable intracellular uptake of drug, and 
are known to affect chemotherapeutic drug uptake (Wasan et a/., 1996). 
To investigate the rote of LDLs in the reversal susceptibility to 5-FU-
induced apoptosis, KGM plus an appropriate amount of LDLs was 
employed as the culture medium to imitate this difference between KGM 
and DMEM. The apoptotic levels of HEC-18 and HEC-18T greatly 
increased when cells were subject to the KGM plus LDL medium after 5-
FU treatment (Figure 3.32). Therefore, LDLs may play an important role 
in the sensitivity change of HEC-18 and HEC-18T to 5-FU-induced 
apoptosis. Since LDLs usually accelerate the delivery of 
chemotherapeutic drugs through LDLR pathway, the expression level of 
LDLR on the cell surfaces of each cell line was detected by Western blot 
analysis (Figure 3.33) and flow cytometric examination (Figure 3.34). 
Both results showed that LDLRs are comparably expressed on cell 
surfaces of all types of cells, suggesting that LDLR levels are not 
differential as part of the mechanism involved in 5-FU-induced apoptosis. 
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4.7. Future directions 
This study involves investigations on apoptosis, and effects of 
anticancer agent 5-FU, in our model system for multistage cervical 
carcinogenesis and on correlations with molecular basis from mechanistic 
point of view. The results provide valuable information for the 
mechanisms involved in multistage cervical carcinogenesis, 
chemosensitivity of tumor cells, and anticancer agent-induced apoptosis. 
On the other hand, continuing study is always necessary for extensive 
understanding of a molecular biological process. 
The following are additional experiments that could be done in the 
future: 
(1) To further understand the role of apoptosis in cervical 
carcinogenesis, the genetic modulations of E6 and E7 oncogenes 
and their targets in HEC-18 and HEC-18T could be analyzed before 
and after 5-FU treatment. 
(2) To confirm the correlations of apoptosis-regulating protein 
expression with cellular sensitivity to 5-FU-induced apoptosis, 
overexpressions of concluded proteins could be achieved by 
transfecting expression vectors for their genes and examining the 
result and sensitivity to 5-FU-induced apoptosis. 
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(3) To supply more useful clues for chemotherapy of cervical cancer, 
synergistic effects of 5-FU with cytokines, such as TNF-a, IL-1a, and 
INF-v, and growth factors, such as EGF and TGF-a, could be 
measured. 
(4) To investigate the resistance mechanism of cervical cancer cells to 
anticancer drug-induced apoptosis, 5-FU resistant cell lines could be 
established and the effects could be examined on apoptosis-
regulating genes in experiments parallel to those of this thesis. 
(5} To obtain further insight into the role of the LDLR pathway in 5-FU-
induced apoptosis, LDL-5-FU complexes could be prepared and 
employed on our model system for apoptotic studies. 
(6} To link theoretic studies with clinic applications, 5-FU-induced apoptosis 
and expression of apoptosis-regulating proteins could be examined in in 
vivo systems, such as samples from normal and cervical cancer patients or 
mice. 
(7) To study why BAG-1 expression was increased in HEC-18 and HEC-
18T when cultured in DMEM, other BAG-1 functions that irrelated to 
apoptosis could be examined. 
183 
CHAPTER 5 REFERENCES 
Aaronson, S.A. (1991) Growth factors and cancer. Science 254: 1146-
1153. 
Adachi, M.; Torigoe, T.; Takayama, S.; lmai. K. (1998) BAG-1 and Bcl-2 in 
IL-2 signaling. Leukemia and Lymphoma 30: 483-491. 
Alnemri, E.S.; Livingston, D.J.; Nicholson, D.W.; Salvesen, G.; 
Thornberry, N.A.; Wong, W.W.; Yuan, J. (1996) Human ICE/CED-3 
protease nomenclature. Ce//87(2): 171. 
Amati, B.; Land, H. (1994) Myc-Max-Mad: a transcription factor network 
controlling cell cycle progression, differentiation and death. Curr. Opin. 
Genet. Dev. 4(1 ): 102-108. 
Angel, P.; Karin, M. (1991) The role of Jun. Fos and the AP-1 complex in 
cell-proliferation and transformation. Biochim. Biophys. Acta 1072: 129-
157. 
Arends, M.J.; Morris, R.G.; Wyllie, A.H. (1990) Apoptosis. The role of the 
endonuclease. Am. J. Pathol. 136(3): 593-608. 
Armitage, P.; Doll, R.A. (1954) The age distribution of cancer and a 
multistage theory of carcinogenesis. Br. J. CancerS: 1-12. 
Baker, C.C.; Howley, P.W. (1987b) Differential promoter utilization by the 
papillomavirus in transformed cells and productively infected wart tissue. 
EMBO J. 6: 1027·1035. 
Baker, C.C.; Phelps, W.C.; Lindgren, V.; Braun, M.J.; Gonda, M.A.; 
Howley, P.M. ( 1987a) Structural and translational analysis of human 
papillomavirus type 16 sequences in cervical carcinoma cell lines. J. Viral. 
61: 962·971. 
Bakhshi, A.; Jensen, J.P.; Goldman, P.; Wright, J.J.; McBride, O.W.; 
Epstein, A.L.; Korsmeyer, S.J. (1985) Cloning the chromosomal break-
point of the t(14:18) human lymphomas: cloustering around JH on 
chromosome 14 and near a transcriptional unit on 18. Ce//41: 889-906. 
Barak, Y.; Juven, T.; Haffner, R.; Oren, M. (1993) mdm2 expression is 
induced by wild type p53 activity. EMBO J. 12{2): 461-468. 
184 
Barbacid, M. (1987) ras genes. Annu. Rev. Biochem. 56: 779-827. 
Bedell, M.A.; Jones, K.H.; Laimins, L.A. (1987) The E6-E7 region of 
human papillomavirus type 18 is sufficient for transformation of N 1 H 3T3 
and rat-1 cells. J. Viral. 61: 3635-3640. 
Beral, V.; Hermon, C.; Munoz, N.; Devesa, S.S. (1994) Trends in cancer 
incidence and mortality. In cancer surveys, imperial cancer research fund 
(Doll, R.; Fraumeni, J.F .; Muir, C.S. eds.). Cold Spring Harbor Laboratory, 
New York. 
Berenblum, 1.; Shubik, P. (1949) An experimental study of the initiating 
stage of carcinogenesis, and a re-examination of the somatic cell mutation 
theory of cancer. Br. J. Cancer 3: 109-118. 
Blandino, G.; Scardigli, R.; Rizzo, M.G.; Crescenzi, M.; Soddu, S.: Sacchi, 
A. (1995) Wild-type p53 modulates apoptosis of normal, IL-3 deprived, 
hematopoietic cells. Oncogene 10(4): 731-737. 
Boise, L.H.; Gonzalez-garcia, M.; Postema, C.E.; Ding, L.; Lindsten, T.; 
Turka, L.A.; Mao, X.; Nunez, G.; Thompson, C. (1993) bcl-x, a bcl-2-
related gene that functions as a dominant regulator of apoptotic death. 
Ce/174: 597-608. 
Borner, C.; Martinou, 1.; Mattmann, C.; lrmler, M.; Schaerer, E.; Martinou, 
J.C.; Tschopp, J. (1995) The protein bcl-2 alpha does not require 
membrane attachment, but two conserved domains to suppress apoptosis. 
J. Cell Bioi. 126(4 ): 1 059-1 068. 
Boshart, M.; Gissmann, L.; lkenberg, H.; Kleinheinz, A.; Scheurlen, W.; 
zur Hausen, H. (1984) A new type of papillomavirus DNA, its presence in 
genital cancer biopsies and in cell lines derived from cervical cancer. 
EMBOJ. 3:1151-1157. 
Bouvard, V.; Zaitchouk, T.; Vacher, M.; Duthu, A.; Canivet, M.; Choisy-
Rossi, C.; Nieruchalski, M.; May, E. (2000) Tissue and cell-specific 
expression of the p53-target genes: bax, fas, mdm2 and waf1 I p21 , 
before and following ionizing irradiation in mice. Oncogene 19: 649-660. 
Boyce, S.T., Ham, R.G. (1985) Cultivation, frozen storage and clonal 
growth of normal human epidermal keratinocytes in serum-free media. J. 
Tissue Cult. Methods 9: 83-93. 
l85 
Bream. G.L.; Ohmstede, C.A.; Phelps, W.C. (1993) Characterization of 
human papillomavirus type 11 E 1 and E2 proteins expressed in insect 
cells. J. Viral. 67:2655-2663. 
Brisson. J.; Morin, C.; Fortier, M.; Roy, M.; Bouchard, C.; Leclerc. J. 
( 1994) Risk factors for cervical intraepithelial neoplasia: differences 
between low· and high-grade lesions. Am. J. Epidemiol. 140: 700-710. 
Brown, D.R.; Fan, L.; Jones, J.; Bryan, J. (1994) Colocalization of human 
papillomavirus type 11 E 1 AE4 and L 1 proteins in human foreskin implants 
grown in athymic mice. Virology 201: 46-54. 
Brown, J.M.; Wouters, B.G. (1999) Apoptosis, p53, and tumor cell 
sensitivity to anticancer agents. Cancer Res. 59: 1391-1399. 
Brown, M.S.; Goldstein, J.L. (1984) How LDL receptors influence 
cholesterol and atherosderosic. Sci. Am. 251: 58-66. 
Bryckaert, M.; Guillonneau. X.; Hecquet, C.; Courtois, Y.; Mascarelli, F. 
(1999) Both FGF1 and Bcl-x synthesis are necessary for the reduction of 
apoptosis in retinal pigmented epithelial cells by FGF2: role of the 
extracellular signal-regulated kinase 2. Oncogene 18: 7584-7593. 
Burger, H.; Nooter, K.; Boersma, A.W.M.; Kortland, C.J.; van den Berg, 
A.P.; Stater, G. (1998) Expression of p53, p21 I WAF I CIP, BCL-2, BAX, 
BCL-X, and BAK in radiation-induced apotosis in testicular germ cell 
tumor lines. Int. J. Radiation Oncol. Bioi. Phys. 41 (2): 415-424. 
Canman, C.E.; Tang, H.Y.; Normolle, D.P.; Lawrence, T.S.; Maybaum, J. 
(1992) Variations in patterns of DNA damage induced in human colorectal 
tumor cells by 5-fluorodeoxyuridine: implications for mechanisms of 
resistance and cytotoxicity. Proc. Nat/. Acad. Sci. U S A. 89: 10474-
10478. 
Carson, D.A.; Ribeiro, J.M. (1993) Apoptosis and disease. Lancet 341: 
1251-1254. 
Chellappan, S.; Kraus, V.; Kroger, B. (1992) Adenovirus E1A, simian virus 
40 tumor antigen, and human papillomavirus E7 protein share the capacity 
to disrupt the interaction between transcription factor E2F and the 
retinoblastoma gene product. Proc. Nat/. Acad. Sci. USA 89: 4549-4553. 
186 
Chen, C.Y.; Faller, D.V. (1995) Direction of p21ras-generated signals 
towards cell growth or apoptosis is determined by protein kinase C and 
Bcl-2. Oncogene 11(8): 1487-1498. 
Cheng, L. (1992) In RNA oncoviruses, Public Health Press, Beijing. 
Chiarugi, V.; Magnelli, l.; Cinelli, M.; Basi, G. (1994) Apoptosis and the 
cell cycle. Cell. Mol. Bioi. Res. 40(7-8): 603-612. 
Chinnaiyan, A.M.; O'Rourke, K.; Tewari, M.; Dixit, V.M. (1995) FADD, a 
novel death domain-containing proteins, interacts with the death domain 
of Fas and initiates apoptosis. Cell 81: 505-512. 
Chittenden, T.; Harrington, E.A.; Connor, R.; Flemington, C.; Lutz, R.J.: 
Even, G.l.; Guild, B.C. (1995) Induction of apoptosis by the Bcl-2 homologue 
Bak. Nature 374(6524): 733-736. 
Chow, V.T. (1993) Cancer and viruses. Ann. Acad. Med. Singapore 22(2): 
163-169. 
Clarke, A.R.; Gledhill, S.; Hooper, M.l.; Bird, C.C.; Wyllie, A.H. (1994) 
p53 dependence of early apoptotic and proliferative responses within the 
mouse intestinal epithelium following y-irradiation. Oncogene 9: 1767-
1773. 
Clarke, A.R.; Purdie, C.A.; Harrison, D.J.; Morris, R.G.; Bird, C.C.; 
Hooper, M.L.; Wyllie, A.H. (1993) Thymocyte apoptosis induced by p53-
dependent and independent pathways. Nature 362: 849-852. 
Coffin, J.M. (1990) Rettroviridae and their replication. In Virology (Field, 
B.M. eta/., eds), p1437-1490, Raven Press, New York. 
Cohen, J.J.; Duke, R.C. (1984) Glucocorticoid activation of a calcium-
dependent endonuclease in thymocyte nuclei leads to cell death. J. 
lmmunol. 132(1 ): 38-42. 
Coleman, D.V.; Wickenden, C.; Malcolm, A.D.B. (1986) Association of 
human papillomavirus with squamous carcinoma of the uterine cervix. In 
papillomaviruses, Ciba Fundation Symposium. The Bath Press, New York. 
Compton, M.M. (1992) A biochemical hallmark of apoptosis: 
internucleosomal degradation of the genome. Cancer Metastasis Rev. 
11{2): 105-119. 
187 
Conrad, M.; Goldstein, D.; Andresson. T.; Schlegel, R. (1994) The E5 
protein of HPV-6, but not HPV-16, associates efficiently with cellular 
growth factor receptors. Virology 200: 796-800. 
Cooper, G.M. {1990) In Oncogenes. Jones and Bartlett Publishers, Inc., 
Oxford. 
Cory, S.; Harris, A.W.; Strasser, A. (1994) nsights from transgenic mice 
regarding the role of bcl-2 in normal and neoplastic lymphoid cells. Philos. 
Trans. R. Soc. Lond. B. Bioi. Sci. 345{1313): 289-295. 
Cox, L.S. {1997) Multiple pathways control cell growth and transformation: 
overlapping and independent activities of p53 and p21c1P11wAF1' 5di1 • J. 
Pathol. 183: 134-140. 
Crawford, L.V.; Crawford, E.M. {1963) A comparative study of polyma and 
papilloma viruses. Virology 21: 258-263. 
Crook, T.; storey, A.; Almond, N.; Osborn, K.; Crawford, L. (1988) Human 
papillomavirus type 16 cooperates with activated ras and fos oncogenes 
in the hormone-dependent transformation of primary mouse cells. Proc. 
Nat/. Acad. Sci. USA 85: 8820-8824. 
DOrst, M.; Gissmann. L.; lkenberg. H.; zur Hausen, H. (1983) A new 
papillomavirus DNA from cervical carcinoma and its prevalence in cancer 
biopsy samples from different geographic regions. Proc. Nat/. Acad. Sci. 
USA 80: 3812-3815. 
Daling, J.R.; Sherman. K.J.; Hislop, T.G.; Maden, C.; Mandelson, M.T.; 
Beckmann, A.M.; Weiss, N.S. (1992) Cigarette smoking and the risk of 
anogenital cancer. Am. J. Epidemiol. 135: 180-189. 
Darzynkiewicz, Z.; Juan, G.; Li, X.; Gorczyca. W.; Murakami. T.; 
Traganos, F. ( 1997) Cytometry in cell necrobiology: analysis of apoptosis 
and accidental cell death {necrosis). Cytometry 27(1 ): 1-20. 
Darzynkiewicz. Z.; Troganos, F. (1998) Measurement of apoptosis. Adv. 
Biochem. Engineering Biotech. 62: 33-73. 
Davies, R.C.; Vousden, K.H. (1993) Human papillomavirus (HPV) and 
cervical cancer. In molecular biology for oncologists 9Yarnold, J.; 
Stratton, M.; McMillan, T. eds.). Elsevier Science Publishers. 
188 
De Rozieres, S.; Maya, R.; Oren, M.; Lozano, G. (2000) The loss of mdm2 
induces p53 mediated apoptosis. Oncogene 19: 1691-1697. 
Delia, D.; Aiello, A.; Formelli, F. (1995) Regulation of apoptosis induced 
by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated 
bcl-2. Blood 85: 359-367. 
DeVilliers, E.M. (1989) Heterogeneity of the human papillomavirus group. 
J. Viral. 63:4898-4903. 
Dixon, S.C.; Soriano, B.J.; Lush, R.M.; Borner, M.M.; Figg, W.O. (1997) 
Apoptosis: its role in the development of malignancies and its potential as 
a novel therapeutic target. Ann. Pharmacotherapy 31: 76-82. 
Dusenbury, C.E.; Davis, M.A.; Lawrence, T.S.; Maybeaum, J. (1990) 
Induction of megabase DNA fragments by 5-fluorodeoxyuridine in human 
colorectal tumor (HT 29) cells. Molecular Pharmacal. 39: 285-289. 
Elliott, M.J.; Stribinskiene. L.; Lock, R.B. (1998) Expression of Bcl-2 in 
human epithelial tumor (HeLa) cells enhances clonogenic survival 
following exposure to 5-fluoro-2'-deoxyuridine or staurosporine, but not 
following exposure to etoposide or doxorubicin. Cancer Chemother. 
Pharmacal. 41: 457-463. 
Ellis, H.M.; Horvitz, H.R. (1986) Genetic control of programmed cell death 
in the nematode C. elegans. Cell 44(6): 817-829. 
Ellis, R.E.; Jacobson, D.M.; Horvitz, H.R. (1991) Genes required for the 
engulfment of cell corpses during programmed cell death in Caenorhaditis 
elegans. Genetics 129: 79-94. 
Endresen, P.C.; Prytz, P.S.; Aarbakke, J. (1995) A new flow cytometric 
method for discrimination of apoptotic cells and detection of their cell 
cycle specificity through staining of F-actin and DNA. Cytometry 20(2): 
162-171. 
Evan, G.l:; Wyllie, A.H.; Gilbert, C.S.; Littlewood, T.D.; Land, H.; Brooks, 
M.; Waters, C.M.; Penn, L.Z.; Hancock, D.C. {1992) Induction of apoptosis 
in fibroblasts by c-myc protein. Ce/169(1 ): 119-128. 
Fadok, V.A.; Voelker, D.R.; Cammpbell, P.A.; Cohen, J.J.; Bratton, D.L.; 
Henson, P.M. (1992) Exposure of phosphatidylserine on the surface of 
ap~ptotic lymphocytes triggers specific recognition and removal by 
macrophages. J. lmmunol. 148(7); 2207-2216. 
189 
Ferreira, C.G.; Tolis, C.; Giaccone, G. (1999) p53 and chemosensitivity. 
Ann. Onco/.10: 1011-1021. 
Fesus, L.; Davies, P.J.A.; Piacentini, M. (1991) Apoptosis: molecular 
mechanisms in programmed cell death. Eur. J. Cell Bioi. 56: 170-177. 
Findley, H.W.; Gu, L.; Yeager, A.M.; Zhou, M. (1997) Expression and 
regulation of Bcl-2, Bcl-xL, and Bax correlate with p53 status and 
sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 
89: 2986-2993. 
Fisher, D.E. (1994) Apoptosis in cancer therapy: crossing the threshold. 
Ce//78(4 ): 539-542. 
Foulds, L. (1957) Tumor progression. Cancer Res. 17: 355-356. 
Gajewski, T.F .; Thompson, C.B. (1996) Apoptosis meets signal 
transduction: elimination of a BAD influence. Cell 87(4 ): 589-592. 
Gal, D.; Ohashi, M.; McDonald, P.C.; Buchsbaum, H.J.; Simpson, E.R. 
( 1981 ) Low-density lipoprotein as a potential vehicle for chemotherapeutic 
agents and radionucleotides in the management of gynecologic 
neoplasms. Am. J. Obstet. Gynecol. 139: 877-885. 
Galloway, D.A. (1994) Papillomavirus capsids: a new approach to identify 
serological markers of HPV infection. J. Nat/. Cancer lnst. 86: 474-475. 
Gartel, A.L.; Serfas, M.S.; Tyner, A.L. (1996) p21-negative regulator of the 
cell cycle. Proc. Soc. Exp. Bioi. Med. 213(2): 138-149. 
Garzetti, G.G.; Ciavattini, A.; Goteri, G.; Denictolis, M.; Menso, S.: 
Muzzioli, M.; Fabris, N. (1995) HPV DNA positivity and natural-killer-ceH 
activity in the clinical outcome of wild cervical dysplasia: integration 
between virus and immune-system. Gynecol. Obstet. lnv. 39: 130-135. 
Gobe, G.; Zhang, X-J.; Cuttle, L.; Pat, 8.; Willgoss, D.; Hancock, J.; 
Barnard, R.; Endre, Z. (1999) Bcl-2 genes and growth factors in the 
pathology of ischaemic acute renal failure. lmmun. Cell Bioi. 77: 279-286. 
Golstein, P. (1997) Controlling cell death. Science 275(5303): 1081-1082. 
Golstein, P.; Marguet, D.; Depraetere, V. (1995) Homology between 
reaper and the cell-death domains of Fas and TNFR1. Ce/181: 185-186. 
190 
Gong, J.; Traganos, F.; Darzynkiewicz. Z. (1994) A selective procedure for 
DNA extraction from apoptotic cells applicable for gel electrophoresis and 
flow cytometry. Anal. Biochem. 218(2): 314-319. 
Gorczyca, W.; Gong, J.; Ardelt, B.; Traganos. F.; Darzynlciewicz, Z. (1993) 
The cell cycle related differences in susceptibility of HL-60 cells to 
apoptosis induced by various antitumor agents. Cancer Res. 53(13): 
3186-3192. 
Gottschalk, A.R.; Boise, L.H.; Thompson, C.B.; Quintans, J. (1994) 
Identification of immunosuppressant-induced apoptosis in a murine b-cell 
line and its prevention by bcl-x but not bcl-2. Proc. Nat/. Acad. Sci. U. S. 
A. 91: 7350-7354. 
Greenberg, E.R.; Vessey, M.; McPherson, K.; Yeates, D. (1985) Cigarette 
smoking and cancer of the uterine cervix. Br. J. Cancer 51: 139-141. 
Grem, J.L. (1996) 5-Fiuoropyrimidines. In cancer chemotherapy and 
biotherapy (Chabner, B.A.; Longo, D.L. eds.), Philadelphia: Lippincott-
Raven Publishers. 
Guijon, F.; Paraskevas, M.; Rand, F.; Heywood, E.; Brunham, R.; McNicol, 
P. (1992) Vaginal microbial flora as a cofactor in the pathogenesis of 
uterine cervical intraepithelial neoplasia. Int. J. Gynaecol. Obstet. 37: 185-
191. 
Haldar, S.; Jena, N.; Croce, C.M. (1994) Antiapoptosis potential of Bcl·2 
oncogene by dephosphorylation. Biochem. Cell Bioi. 72: 455-462. 
Haldar, S.; Negrini, M.; Monne, M.; Sabbioni, S.; Croce, C.M. (1994) 
Down-regulation of Bcl-2 by p53 in breast cancer cells. Cancer Res. 54: 
2095-2097. 
Hanada, M.; Aime-Sempe, C.; Sato, T.; Reed, J.C. (1995) Structure-
function analysis of Bcl-2 protein: identification of conserved domains 
important for homodimerization with Bcl-2 and heterodimerization with 
Bax. J. Bioi. Chem. 270(20): 11962-11969. 
Hannun, Y.A. (1997) Apoptosis and the dilemma of cancer chemotherapy. 
Blood 89(6): 1845-1853. 
191 
Harrington, E.A.; Bennett, M.R.; Fanidi, A.; Evan, G.l. (1994) c-Myc-
induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO 
J. 13(14): 3286-3295. 
Harris, C.C. (1996) Structure and function of the p53 tumor suppressor 
gene: clues for rational cancer therapeutic strategies. J. Nat/. Cancer lnst. 
88: 1442-1455. 
Harvey, N.L.; Kumar, S. (1998) The role of caspases in apoptosis. Adv. 
Biochem. Engineering Biotech. 62: 107-128. 
Hawthorne, R. J.; Murdoch, J.B.; Maclean, A.B.; MacKiee, R.M. (1988) 
Langerhans' cells and subtypes of human papillomavirus in cervical 
intraepithelial neoplasia. BMJ 297: 643-646. 
Hedley, D.W.; McCulloch, E.A. (1996) Generation of reactive oxygen 
intermediates after treatment of blasts of acute myeloblastic leukemia with 
cytosine arabinoside: role of bcl-2. Leukemia 10(7): 1143-1149. 
Heidelberger, C.; Chaudhuari, N.K.; Danneberg, P.; Mooren, D.; 
Griesbach, L.; Duschinsky, R.; Schnitxer, R.J.; Pleven, E.; Scheiner, J. 
(1957) Fluorinated pyrimidines. A new class of tumor inhibitory 
compounds. Nature 179: 663-666. 
Haim, S.; Mitelman, F. (1987) Nineteen of 26 cellular oncogenes precisely 
localized in the human genome map to one of the 83 bands involved in 
primary cancer-specific rearrangements. Hum. Genet. 75: 70·72. 
Henderson, D.S.; Banga, 5.5.; Grigliatti, T.A.; Boyd, J.B. (1994) Mutagen 
sensitivity and suppression of position-effect variegation result from 
mutations in mus209, the Drosophila gene encoding PCNA. EMBO J. 
13(6): 1450-1459. 
Herrington, C.S. (1995) Human papillomaviruses and cervical neoplasia. 
II. Interaction of HPV with other factors. J. Clin. Pathol. 48: 1-6. 
Hirose. Y.; Yoshimi, N.; Suzui, M.; Kawabata, K.; Tanaka, T.; Mori, H. 
(1997) Expression of bcl-2, bax, and bcl-xL proteins in azoxymethane-
induced rat colonic adenocarcinomas. Mol. Carcinog. 19: 25-30. 
Hohfeld, J.; Jentsch, S. (1997) GrpE-Iike regulation of the Hsc70 
chaperone by the anti-apoptotic protein BAG-1. EMBO J. 16: 6209-6216. 
192 
Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. (1991) p53 
mutations in human cancers. Science 253: 49-53. 
Hoppe-Seyler, F.; Butz, K. (1994) Cellular control of human papillomavirus 
oncogene transcription. Mol. Carcinog. 10: 134-141. 
Howley, P.M. (1991) Papillomavirinae and their replication. In 
Fundamental virology (Fields, B.N.; Knipe, D.M. eds.) Raven Press Ltd., 
New York. 
Hsu, H.L.; Xiong, J.; Goeddel, D.V. (1995) The TNF receptor-1 associated 
protein TRADD signals cell death and NFKB activation. Cell 81: 495-504. 
Huang, Y .; Waxman, S. (1998) Enhanced growth inhibition and 
differentiation of fluorodeoxyuridine-treated human colon carcinoma cells 
by phenyl butyrate. Clin. Cancer Res. 4: 2503-2509. 
Huibregtse, J.M.; Schaffner, M.; Howley, P.M. (1991) A cellular protein 
mediates association of p53 with the E6 oncoprotein of human 
papillomavirus types 16 or 18. EMBO J. 10(13): 4129-4135. 
Huschtscha, L.l.; Bartier, W.A.; Andersson Ross, C.E.; Tattersall, M.H.N. 
(1996) Characteristics of cancer cell death after exposure to cytotoxic 
drugs in vitro. Br. J. Cancer 73: 54-60. 
ltoh, N.; Yonehara, S.; lshiti, A.; Yonehara, M.; Mizushima, S.; 
Sameshima, M.; Hase, A.; Seto, Y.; Nagata, S. (1991) The polypeptide 
encoded by the eDNA for human cell surface antigen Fas can mediate 
apoptosis. Ce//66(2): 233-243. 
Izquierdo Pastor, M.; Reif, K.; Cantrell, D. (1995) The regulation and 
function of p21 ras during T-cell activation and growth. lmmunol. Today 16: 
159-164. 
Jaattela, M. {1999) Escaping cell death: survival proteins in cancer. Exp. 
Cell Res. 248(1 ): 30-43. 
Kao, G.F.; Kao, W.H. (1994) Malignant transformation of keratinocytes by 
human papillomaviruses. J. Cutan. Pathol. 21: 193-199. 
Kaufmann, S.H. (1989) Induction of endonucleolytic DNA cleavage in 
human acute myelogenous leukemia cells by etoposide, camptothecin, 
and other cytotoxic anticancer drugs: a cautionary note. Cancer Res. 
49(21 ):5870-5878. 
193 
Kelman, Z. (1997) PCNA: structure, functions and interactions. Oncogene 
14: 629-640. 
Keri, J.F.; Wyllie, A.H.; Currie, A.R. (1972) Apoptosis: a basic biological 
phenomenon with wide-ranging implications in tissue kinetics. Br. J. 
Cancer 26: 239-257. 
Kessis, T.D.; Slebos, R.J.; Nelson, W.G.; Kastan, M.B.; Plunkett, B.S.; 
Han, S.M.; Lorincz, A.T.; Hedrick, L.; Cho, K.R. (1993) Human 
papillomavirus 16 E6 expression disrupts the p53-mediated cellular 
response to DNA damage. Proc. Nat/. Acad. Sci. US A. 90(9): 3988-3992. 
Khare, S.; Pater, M.M.; Pater, A. (1995) Role of exogenous cofactors in 
HPV infection and oncogenesis. Papil/omavirus Report 3: 89-93. 
Kiefer, M.C.; Brauer, M.J.; Powers, V.C.; Wu, J.J.; Umansky, S.R.; Tomei, 
L.D.; Barr, P.J. (1995) Modulation of apoptosis by the widely distributed 
Bcl-2 homologue Bak. Nature 374: 736-739. 
Kinlen, L.J.; Spriggs, A.l. (1978) Women with positive cervical smears but 
without surgical intervention: a follow up study. Lancet. 2: 463-465. 
Kirnbauer, R.; Hubbert, N.L.; Wheeler, C.M.; Becker, T.M.; Lowy, D.; 
Schiller, J.T. (1994) A virus-like particle enzyme-linked immunosorbent 
assay detects serum antibodies in a majority of women infected with 
human papillomavirus type 16. J. Nat/. Cancer lnst. 86: 494-499. 
Kitada, S.; Krajewski, S.; Miyashita, T.; Krajewska, M.; Reed, J.C. (1996) 
Gamma-radiation induces upregulation of Bax protein and apoptosis in 
radiosensitive cells in vivo. Oncogene 12( 1 ): 187-192. 
Kluck, R.M.; Bossy-Wetzel, E.; Green, D.R.; Newmeyer, D.C. (1997) The 
release of cytochrome c from mitochondria: a primary site for Bcl-2 
regulation of apoptosis. Science 275(5303): 1132-1136. 
Knudson. C.M.; Tung, K.; Brown, G.; Korsmeyer, S.J. (1995) Bax deficient 
mice demonstrate lymphoid hyperplasia but male germ cell death. Science 
270: 96-99. 
Kobayashi, T.; Ruan, S.; Clodi, K.; Kliche, K-0.; Shiku, H.; Andreeff, M.; 
Zhang, W. (1998) Overexpression of Bax gene sensitizes K 562 
erythroleukemia cells to apoptosis induced by selective chemotherapeutic 
agents. Oncogene 16: 1587-1591. 
194 
Koopman, G.; Reutelingsperger, C.P.M.; Kuijten, G.A.M.; Keehnen, 
R.M.J.; Pats, S.T.; van Oers, M.H.J. (1994) Annexin V for flow cytometric 
detection of phosphatidytserine expression on B cells undergoing 
apoptosis. Blood 84(5): 1415-1420. 
Koshiji, M.; Adachi, Y.; Taketani, S.; Takeuchi, K.; Hioki, K.; lkehara, S. 
( 1997) Mechanisms underlying apoptosis induced by combination of 5-
fluorouracil and interferon-v. Biochem. Biophys. Res. Comm. 240: 376-
381. 
Kowalik, T.; Degregori, J.; Schwarz, J.K.; Nevins, J. (1995) E2F1 
overexpression in quiescent fibroblasts leads to induction of cellular DNA 
synthesis and apoptosis. J. Viral. 69: 2491-2500. 
Krajewska, M.; Moss, S.F.; Krajewski, S.; Song, K.; Holt, P.R.; Reed, J.C. 
(1996) Elevated expression of Bci-X and reduced Bak in primary 
colorectal adenocarcinomas. Cancer Res. 56(10): 2422-2427. 
Krippner, A.; Matsuno-Yagi, A.; Grottlieb, R.; Babior, B. (1996) Loss of 
function of cytochrome c in Jurkat cells undergoing fas-mediated 
apoptosis. J. Bioi. Chern. 271 (35): 21629-21636. 
Kubbutat, M.H.; Ludwig, R.L.; Levine, A.J.; Vousden, K.H . (1999) Analysis 
of the degradation function of Mdm2. Cell Growth. Differ. 1 0(2): 87-92. 
Kullmann, m.; Schneikert, J.; Moll, J.; Heck, S.; Zeiner, M.; Gehring, U.; 
Cato, A.C. (1998) RAP46 is a negative regulaor of glucocorticoid receptor 
action and hormone-induced apoptosis. J. Bioi. Chem. 273(23): 14620-
14625. 
Kumar, S. (1999) Mechanisms mediating caspase activation in cell death. 
Cell Death Differ. 6(11 ): 1060-1066. 
Kyprianou, N.; English, H.F.; Davidson, N.E.; Isaacs, J.T. (1991) 
Programmed cell death during regression of the MCF-7 human breast 
cancer following estrogen ablation. Cancer Res. 51: 162-166. 
Kyprianou, N.; Isaacs, J .T. (1988) Activation of programmed cell death in 
the rant ventral prostate after castration. Endocrinilogy 122: 552-562. 
Lamont, E.B.; Schilsky, R.L. (1999) the oral fluoropyrimidines in cancer 
chemotherapy. Clin. Cancer Res. 5: 2289-2296. 
195 
Lazebnik, Y.A.; Kaufmann, S.H.; Desnoyers, S.; Poirier, G.G.; Earnshaw, 
W.C. (1994) Cleavage of poly(ADP-ribose) polymerase by a proteinase 
with properties like ICE. Nature 371(6495): 346-347. 
Lee, E.Y. (1991) Tumor suppressor genes: a new era for molecular 
genetic studies of cancer. Breast Cancer Res. Treat. 19: 3-13. 
Lee, J.O.; Russo, A.A.; Pavletich, N.P. (1998) Structure of the 
retinoblastoma tumour-suppressor pocket domain bound to a peptide from 
HPV E7. Nature 391 (6670): 859-865. 
Levine, A.J.; Momand, J. (1990) Tumor suppressor genes: the p53 and 
retinoblastoma sensitivity genes and gene products. Biochim. Biophys. 
Acta. 1032(1 ): 119-136. 
Li, S-L.; Kim, M.S.; Cherrick, H.M.; Doniger. J.; Park, N.H. (1992) 
Sequential combined tumorigenic effect of HPV-16 and chemical 
carcinogens. Carcinogenesis 13: 1981-1987. 
Li, Y.; Bhuiyan, M.; Mohammad, R.M.; Sarkar, F.H. (1998) Induction of 
apoptosis in breast cancer cells by TPA. Oncogene 17: 2915-2920. 
Lichtenstein, A.; Tu, Y.; Fady, C.; Vescio, R.; Berenson, J. (1995) 
interleukin-6 inhibits apoptosis of malignant plasma cells. Cell lmmunol. 
162: 248-255. 
Liebermann, D.A.; Hoffman, B.; Steinman, R.A. (1995) Molecular controls 
of growth arrest and apoptosis: p53-dependent and independent 
pathways. Oncogene 11: 199-210. 
Lin, H.J.; Eivner, V .; Prendergast, G. C.; White, E. (1995) Activated H-ras 
rescues E1A-induced apoptosis and cooperates with E1A to overcome 
p53-dependent growth arrest. Mol. Cell Bioi. 15(8 ): 4536-4544. 
Lotem, J.; Sachs, L. (1995) A mutant p53 antagonizes the deregulated c-
myc-mediated enhancement of apoptosis and decrease in 
leukemogenicity. Proc. Nat/. Acad. Sci. US A. 92(21 ): 9672-9676. 
Lowe, S.W.; Ruley, H.E.; Jacks, T.; Housman, D.E. (1993) p53-dependent 
apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-
967. 
196 
LOders. J.; Demand, J.; HOhfeld, J. (2000) The Ubiquitin-related BAG-1 
provides a link between the molecular chaperones Hsc70/Hsp70 and the 
proteasome. J. Bioi. Chem. 275(7): 4613-4617. 
Macdonald, F.; Ford, C.H.J. (1997) In Molecular Biology of Cancer, BIOS 
Scientific Publishers Ltd., Oxford. 
Majno, G.; Joris, I. (1995) Apoptosis, oncosis, and necrosis. An overview 
of cell death. Am. J. Pathol. 146(1 ): 3-15. 
Manabe, A.; Cousta-Smith, E.; Kumagai, M.; Behm, F.G.; Raimond, S.C.; 
Pui, C.H. (1994) lnterleukin-4 induces programmed cell death (apoptosis) 
in cases of high-risk acute lymphoblastic leukemia. Blood 83: 1731-1737. 
Mansur, C.P.; Androphy, E.J. (1993) Cellular transformation by 
papillomavirus oncoproteins. Biochim. Biophys. Acta. 1155: 193-199. 
Mason, R.P. (1999) Calcium channel blockers, apoptosis and cancer: is 
there a biologic relationship? J. Am. Coli. Cardia/. 34: 1857-1866. 
Matsukura, T.; Kanda, T.; Furuno, A.; Yoshikawa, H.; Kawana, T.; 
Yoshiike, K. (1986) Cloning of monomeric human papillomavirus type 16 
integrated within cell DNA from a cervical carcinoma. J. Virol. 58: 979-
982. 
McCance, D.J.; Kopan, K.; Fuchs, E.; Laimins, L.A. (1988) Human 
papillomavirus type 16 alters human epithelial cell differentiation in vitro. 
Proc. Nat/. Acad. Sci. USA 85: 7169-7173. 
McConkey, D.J.; Chow, S.C.; Orrenius, S.; Jondal, M. (1990) NK cell-
induced cytotoxicity is dependent on a Ca2• increase in the target. FASEB 
J. 4: 2661-2664. 
McConkey, D.J.; Nicotera, P.; Hartzell, P.; Bellomo, G.; Wyllie, A.H.; 
Orrenius, S. (1989) Glucocorticoids activate a suicide process in 
thymocytes through an elevation of cytosolic Ca2• concentration. Arch. 
Biochem. Biophys. 269: 365-370. 
McConkey, D.J.; Orrenius, S. (1997) The role of calcium in the regulation 
of apoptosis. Biochem. Biophys. Res. Comm. 239: 357-366. 
McCormick, F. (1995) Ras signaling and NF1. Curr. Opin. Genet. Dev. 
5(1 ): 51-55. 
197 
McGill, G.; Fisher, D.E. (1997) Apoptosis in tumorigenesis and cancer 
therapy. Frontiers Biosci. 2: 353-379. 
McKenna, S.L.; McGowan, A.J.; Cotter, T.G. (1998) Molecular 
mechanisms of programmed cell death. Adv. Biochem. Engineering 
Biotech. 62: 1-31. 
McPake, C.R.; Tillman, D.M.; Poquette, C.A.; George, E.O.; Houghton, 
J.A.; Harris, L.C. (1998) Bax is an important determinant of 
chemosensitivity in pediatric tumor cell lines independent of Bcl-2 
expression and p53 status. Onco/. Res. 10(5): 235-244. 
Meikrantz, W.; Schlegel, R. (1995) Apoptosis and the cell cycle. J. Cell. 
Biochem. 58: 160-174. 
Merritt, A.J.; Patten, C.S.; Kemp, C.J .; Hickman, J.A.; Balmain, A.; Lane, 
D.P.; Hall, P.A. (1994) The role of p53 in spontaneous and radiation-
induced apoptosis in the gastrointestinal tract of normal and p53-deficient 
mice. Cancer Res. 54: 614-617. 
Miller, A.B.; Nazeer, S.; Fonn, S.; Brandup-Lukanow, A.; Rehman, R.; 
Cronje, H.; Sankaranarayanan, R.; Koroltchouk, V.; Syrjanen, K.; Singer, 
A.; Onsrud, M. (2000) Report on consensus conference on cervical cancer 
screening and management. Int. J. Cancer 86: 440-44 7. 
Minagawa, Y .; Kigawa, J.; ltamochi, H.; Kanamori, Y .; Shimada, M.; 
Takahashi, M.; Terakawa, N. (1999) Cisplatin-resistant Hela cells are 
resistant to apoptosis via p53-dependent and -independent pathways. 
Jpn. J. Cancer Res. 90: 1373-1379. 
Mittal, R.; Tsutsumi, K.; Pater, A.; Pater, M.M. (1993) Human 
papillomavirus type 16 expression in cervical keratinocytes: role of 
progesterone and glucocorticoid hormones. Obstet. Gynecol. 81: 5-12. 
Miyashita, T.; Harigai, M.; Hanada, M. (1994b) Identification of a p53-
dependent negative response element in the bcl-2 gene. Cancer Res. 54: 
3131-3135. 
Miyashita, T.; Krajewski, S.; Krajewska, M.; Wang, H.G.; Lin, H.K.; 
Liebermann, D.A.; Hoffman, B.; Reed, J.C. (1994a) Tumor suppressor p53 
is a regulator of bcl-2 and bax gene expression in vitro and in vivo. 
Oncogene 9: 1799-1805. 
198 
Miyashita, T.; Reed, J.C. (1995) Tumor suppressor p53 is a direct 
transcriptional activator of the human bax gene. Cell 80: 293-299. 
Morgenbesser, S.D.; Williams, 8.0.; Jacks, T.; DePinho, R.A. (1994) p53-
dependent apoptosis produced by Rb-deficiency in the developing mouse 
lens. Nature 371: 72-74. 
Morris, G.F.; Bischoff, J.R.; Mathews, M.B. (1996) Transcriptional 
activation of the human proliferating-cell nuclear antigen promoter by p53. 
Proc. Nat/. Acad. Sci. U SA. 93(2): 895-899. 
Motoyama, N.; Wang, F.; Roth, K.A.; Sawa, H. (1995) Massive cell death of 
immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 
267(5203): 1506-1510. 
Muchmore, S.W.; Sattlet, M.; Liang, H.; Meadows, R.P.; Harlan, J.E.; 
Yoon, H.S.; Nettelsheim, D.; Chang, B.S.; Thompson, C.B.; Wong, S.L.; 
Ng, S.L.; Fesik, S.W. (1996) X-ray and NMR structure of human Bcl-xL, an 
inhibitor of programmed cell death. Nature 381(6580): 335-341. 
Munger, K. (1995) The molecular biology of cervical cancer. J. Cell. 
Biochem. 23(Suppl.): 55-60. 
Munger, K.; Scheffner, M.; Huibregtse, J.M.; Howley, P.M. (1992) 
Interactions of HPV E6 and E7 oncoproteins with tumor uppressor gene 
products. Cancer Surveys Volume 12,Tumor Suppressor Genes, the Cell 
Cycle and Cancer. Imperial Cancer Research Fund, London. 
Nagata, S. (1997) Apoptosis by death factor. Cell 88(3): 355-365. 
Nagata, S.; Golstein, P. (1995) The Fas death factor. Science 267: 1449-
1456. 
Nakao, Y.; Yang. X.; Yokoyama. M.; Pater. M.M.; Pater, A. (1996) 
Malignant transformation of human ectocervical cells immortalized by HPV 
18: in vitro model of carcinogenesis by cigarette smoke. Carcinogenesis 
17(3):577-583. 
Nicholson, D.W.; Ali. A.; Thornberry, N.A.; Vaillancourt, J.P.; Ding, C.K.; 
Gallant. M.; Gareau, Y.; Griffin, P.R.; Labelle, M.; Lazebnik, Y.A.; Munday, 
N.A.; Raju, S.M.; Smulson, M.E.; Yamin, T-T.; Yu, V.L.; Miller, O.K. (1995) 
Identification and inhibition of the ICE/CED-3 protease necessary for 
mammalian apoptosis. Nature 376(6535): 37-43. 
199 
Nita. M.E.; Nagawa. H.; Tominaga. 0.; Tsuno, N.; Fujii, S.; Sasaki, S.; Fu. 
C-G.; Takenoue, T.; Tsuruo, T.; Muto, T. (1998) 5-fluorouracil induces 
apoptosis in human colon cancer cell lines with modulation of Bcl-2 family 
proteins. Br. J. Cancer 78: 986-992. 
Nowell, P.C. (1976) The clonal evolution of tumor cell populations. 
Science 194: 23-28. 
Oberhammer, F.; Wilson, J.M.; Dive, C.; Morris, I.D.; Hickman, J.A.; 
Wakeling, A.E.; Walker, P.R.; Sikorska, M. (1993) Apoptotic death in 
epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or 
in the absence of internucleosomal fragmentation. EMBO J. 12(9): 3679-
3684. 
Oltvai, Z.N.; Milliman, C.L.; Korsmeyer, S.J. (1993) Bcl-2 heterodimerizes 
in vivo with a conserved homolog Bax, that accelerates programmed cell 
death. Cell 7 4: 609-619. 
Ormerod, M.G.; O'Neill, C.F.; Robertson, D.; Harrap, K.R. (1994) Cisplatin 
induces apoptosis in a human ovarian carcinoma cell line without 
concomitant internucleosomal degradation of DNA. Exp. Cell Res. 211 (2): 
231-237. 
Orren ius. S.; McConkey, D.J.; Bellomo, G.; Nicotera, P. (1989) Role of 
calcium in toxic celi killing. Trends Pharmacal. Sci. 7: 281-285. 
Orth, G. (1986) Epidermodysplasia verruciformis: a model for 
understanding the oncogenicity of human papillomaviruses. In 
Papillomaviruses Symposium No. 120, CIBA Foundation Symposium, 
John Wiley & Sons, New York. 
Pan, H.; Griep. A.E. (1994) Altered cell cycle regulation in the lens of 
HPV-16 E6 or E7 transgenic mice: Implications for tumor suppressor gene 
function in development. Gene & Dev. 8: 1285-1299. 
Park, T-W.; Fujiwara. H.; Wright, T.C. (1995) Molecular biology of cervical 
cancer and its precursors. Cancer 76(1 0): 1902-1912. 
Parkin, D.M.; Pisani. P.; Ferlay, J. (1993) Estimates of the worldwide 
incidence of eighteen major cancers in 1986. Int. J. Cancer 54: 594-606. 
Parkin, O.M.; Pisani, P.; Ferlay, J. (1999) Estimates of the worldwide 
incidence of 25 major cancers in 1990. Int. J. Cancer 80: 827-841. 
200 
Pater, M.M.; Pater, A. (1985) Human papillomavirus type 16 and 18 
sequences in carcinoma cell lines of the cervix. Virology 145: 313-318. 
Pecoraro, G.; Morgan, 0.; Oefendi, V. (1989) Differential effects of human 
papillomavirus type 6, 16, and 18 DNAs on immortalization and 
transformation of human cervical epithelial cells. Proc. Nat/. Acad. Sci. 
USA 86: 563-567. 
Peterson, 0. (1956) Spontaneous course of cervical precancerous 
conditions. Am. J. Obstet. Gynecol. 72: 1063-1071. 
Petit, P.X.; LeCoeur, H.; Zorn, E.; Dauguet, C.; Mignotte, B.; Gougeon, 
M.L. (1995) Alterations in mitochondrial structure and function are early 
events of dexamethasone-induced thymocyte apoptosis. J. Cell Bioi. 
130(1): 157-167. 
Piacentini, M.; Fesus, 1.; Meline, G. (1993) Multiple cell cycle access to 
the apoptotic death programme in human neuroblastoma cells. FEBS Lett. 
320(2): 150-154. 
Piazza, G.A.; Rahm, A.K.; Finn, T.S.; Fryer, B.H.; Li, H.; Stoumen, A.L.; 
Pamukcu, R.; Ahnen, D.J. (1997) Apoptosis primarily accounts for the 
growth-inhibitory properties of sulindac metabolites and involves a 
mechanism that is independent of cyclooxygenase inhibition, cell cycle 
arrest, and p53 induction. Cancer Res. 57: 2452-2459. 
Pisani, P.; Parkin, D.M.; Bray, F.; Ferlay, J. (1999) Estimates of the 
worldwide mortality from 25 cancers in 1990. Int. J. Cancer 83(1 ): 18-29. 
Pritchard, M.; Potten, C.S.; Hickman, J.A. (1998) The relationships 
between p53-dependent apoptosis, inhibition of proliferation, and 5-
fluorouracil-induced histopathology in murine intestinal epithelia. Cancer 
Res. 58: 5453-5465. 
Qin, X-Q.; Livingston, D.M.; Kaelin, W.G.; Adams, P.O. (1994) 
Deregulated transcription factor E2F-1 expression leads to S-phase entry 
and p53-med iated apoptosis. Pro c. Nat/. A cad. Sci. U S A. 91 : 1 0918-
10922. 
Rabbitts, T. (1994) Chromosomal translocations in human cancer. Nature 
372: 143-149. 
201 
Rampino, N.; Yamamoto, H.; lonov, Y. (1997) Somatic frameshift 
mutations in the Bax gene in colon cancers of the microsatellite mutator 
phenotype. Science 275: 967-969. 
Reagon, J.W.; Fu, Y.S. (1983) The uterine cervix. In Principles and 
practice of surgery pathology (Silverberg, S.G. ed.) Wiley, New York. 
Reed, J.C. (1994) Bcl-2 and the regulation of programmed cell death. J. 
Cell Bioi. 124: 1-6. 
Reed, J.C. (1995a) Prevention of apoptosis as a mechanism of drug 
resistance. Hematol. Oncol. Clin. North Am. 9: 451-474. 
Reed, J.C. (1995b) Regulation of apoptosis by Bcl-2 family proteins and 
its role in cancer and chemoristance. Curr. Opin. Oncol. 7: 541-546. 
Reed, J.C. (1998} Oysregulation of apoptosis in cancer. Cancer J. Sci. 
Am. 4(Suppl.): 8-14. 
Rodrigues, G.A.; Park, M. (1994) Oncogenic activation of tyrosine 
kinases. Curr. Opin. Genet. Dev. 4(1 ): 15-24. 
Ruoslahti, E.; Reed, J.C. (1994} Anchorage dependence, integrins, and 
apoptosis. Ce/177(4): 477-478. 
Salsman, N.P. (1986) In the papovaviradae: polymaviruses. Plenum 
Press, New York. 
Sasson, I.M.; haley, H.J.; Hoffman, D.; Wynder, E.L.; Hellberg, D.; 
Nilsson, S. (1985) Cigarette smoking and neoplasia of the uterine cervix: 
smoke constituents in cervical mucus. N. Engl. J. Med. 312: 315-316. 
Sato, T.; Hanada, M.; Bodrug, S.; lrie, S.; lwama, N.; Boise, L.H.; 
Thompson, C.B.; Golemis, E.; Fong, L.; Wang, H.G.; Reed, J.C. (1994) 
Interactions among members of the Bcl-2 protein family analyzed with a 
yeast two-hybrid system. Proc. Nat/. A cad. Sci. U SA. 91 (20): 9238-9242. 
Schaffner, M.; Werness, B.A.; Huibregtse, J.M.; Levine, A.J.; Howley, 
P.M. (1990) The E6 oncoprotein encoded by human papillomavirus types 
16 and 18 promotes the degradation of p53. Cell63(6): 1129-1136. 
Schlessinger, J. (1994) SH2/SH3 signaling proteins. Curr. Opin. Genet. 
Dev. 4(1 ): 25-30. 
202 
Schwab. M.; Amler, L.C. (1990) Amplification of cellular oncogenes: a 
predictor of clinical outcome in human cancer. Genes Chrom. Cancer 1: 
181-193. 
Schwarz, E., Freese, U.K.; Gissmann, L.; Mayer, W.; Roggenbuck, B.; 
Stremlau, A.; zur Hausen, H. (1985) Structure and transcription of human 
papillomavirus sequences in cervical carcinoma cells. Nature 314: 111-
114. 
Schwarze, M.M.K.; Hawley, R.G. (1995) Prevention of myeloma cell 
apoptosis by ectopic Bel expression or ir.terleukin-6 mediated up-
regulation of Bcl-xL. Cancer Res. 55: 2262-2269. 
Seidel-Dugan, C.; Meyer, B.E.; Thomas, S.M. (1992) Effects of SH2 and 
SH3 deletions on the functional activities of wild-type and transforming 
variants of c-Src. Mol. Cell Bioi. 12(4): 1835-1845. 
Selvakumara, M.; Lin, H.K.; Miyashita, T.; Wang, H.G.; Krajewski, S.; 
Reed, J.C.; Hoffman, B.; Liebermann, D.A. (1994) Immediate early up-
regulation of bax expression by p53 but not TGF beta 1: a paradigm for 
distinct apoptotic pathways. Oncogene 9(6 ): 1791-1798. 
Shah, K.V.; Howley, P.M. (1990) Papillomaviruses. In Virology (Fields, 
B.N.; Knipe, D.M. eds.) Raven Press Ltd., New York. 
Shaw, J.M.: Shaw, K.V.; Yanovich, S.; lwanik, M.; Futch, W.S.; Rosowsky, 
A.; Schook, L.B. (1987) Delivery of lipophilic drugs using lipoproteins. 
Ann. NY Acad. Sci. 507: 252-271. 
Shaw, P.; Bovey, R.; Tardy, S.; Sahli, R.; Sordat, B.; Costa, J. (1992) 
Induction of apoptosis by wild-type p53 in a human colon tumor-derived 
cell line. Proc. Nat/. A cad. Sci. U SA. 89(1 0): 4495-4499. 
Shih, C.; Padhy, L.C.; Murray, M.; Weinberg, R.A. (1981) Transforming 
genes of carcinomas and neuroblastomas introduced into mouse 
fibroblasts. Nature 290: 261-264. 
Shivakumar, C.V.; Brown, D.R.; Deb, S.; Deb, S.P. (1995) Wild-type 
human p53 transactivates the human proliferating cell nuclear antigen 
promoter. Molecular and Cellular Biology 15: 6785-6793. 
Simons, A.M.; Vanherckenrode, C.M.; Rodriguez, J.A.; Maitland, N.; 
Anderson, M.; Phillips, D.H.; Coleman, D.V. (1995) Demonstration of 
smoking-related DNA-damage in cervical epithelium and correlation with 
203 
human papillomavirus type-16, using exofoliated cervical cells. Brit. J. 
Cancer 71: 246-249. 
Sinn, E.; Muller W.; Pattengale P.; Tepler 1.; Wallace R.; Leder P. (1987) 
Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic 
mice: synergistic action of oncogenes in vivo. Cell 49(4 ): 465-4 75. 
Spencer, C.A.; Groudine, M. (1991) Control of c-myc regulation in normal 
and neoplastic cells. Adv. Cancer Res. 56:1-48. 
Sporn, M.B.; Todaro, G.J. (1980) Autocrine secretion and malignant 
transformation of cells. N. Engl. J. Med. 303(15): 878-880. 
St. Croix, B.; Kerbel, R.S. (1997) Cell adhesion and drug resistance in 
cancer. Cur. Opin. Oneal. 9: 549-556. 
Stanger, B.Z.; Leder, P .; Lee, T.H.; Kim, E.; Seed, B. (1995) RIP: a novel 
protein containing a death domain that interacts with Fas/AP0-1 (CD95) in 
yeast and causes cell death. Cell 81: 513-523. 
Steele, R.J.C.; Thompson, A.M.; Hall, P .A.; Lane, D.P. (1998) The p53 
tumor suppressor gene. Br. J. Surgery 85: 1460-1467. 
Stehelin, D.; Varmus. H.V.; Bishop, J.M.; Vogt, P.K. (1976) DNA related to 
the transforming gene(s) of avian sarcoma viruses is present in normal 
avian DNA. Nature 260: 170-173. 
Stellar, H. (1995) Mechanisms and genes of cellular suicide. Science 267: 
1445-1449. 
Strobel, T.; Swanson, L.; Korsmeyer, S.; Cannistra. S.A. (1996) BAX 
enhances paclitaxel-induced apoptosis through a p53-independent 
pathway. Proc. Nat/. Acad. Sci. US A. 93(24): 14094-14099. 
Subramanian, K. (1993) Human papillomaviruses. In The molecular basis 
of human cancer (Neel, B.; Kumar, R. eds.) Futura Publishing Co. Inc., 
Mount Kisco, New York. 
Sun, Q.; Tsutsumi, K.; Kelleher, M.B.; Pater, A.; Pater, M.M. (1992) 
Aquamous metaplasia of normal and carcinoma in situ of H PV 16-
immortalized human endocervical cells. Cancer Res. 52: 4254-4260. 
Sun, Q.; Tsutsumi, K.; Yokoyama, M.; Pater, M.M.; Pater, A. (1993) In 
vitro cytokeratin expression pattern of stratified squamous epithelium from 
204 
human papillomavirus-type-16-immortalized ectocervical and foreskin 
keratinocytes. Int. J. Cancer 54: 656-662. 
Szabo, G.; Damjanovich, S.; 5umegi, J.; Klein, G. {1987) Overall changes 
in chromatin sensitivity to DNase I during differentiation. Exp. Cell Res. 
169(1 ): 158-168. 
Takayama, 5.; Krajewski, S.; Krajewski, M.; Kitada, S.; Zapata, J.M.; 
Kochel, K.; Knee, 0.; Sudiero, D.; Tudor, G.; Miller, G.J.; Miyashita, T.; 
Yamada, M.; Reed, J.C. (1998) Expression and location of Hsp 70 I Hsc-
binding anti-apoptotic protein BAG-1 and its variants in normal tissues and 
tumor cell lines. Cancer Res. 58: 3116-3131. 
Takayama, 5.; 5ato, T.; Krajewski, S. (1995) Cloning and functional 
analysis of BAG-1 : A novel bcl-2-binding protein with anti-cell death 
activity. Ce//80: 279-284. 
Tanaka, N.; Ishihara, M.; Kitagawa, M.; Harada, H.; Kimura, T.; 
Matsuyama, T.; Lamphier, M.S.; Aizawa, S.; Mak, T.W.; Taniguchi, T. 
(1994) Cellular commitment to oncogene-induced transformation or 
apoptosis is dependent on the transcription factor IRF-1. Cell 77(6): 829-
839. 
Tewari, M.; Dixit, V.M. (1995) Fas- and tumor necrosis factor-induced 
apoptosis is inhibited by the poxvirus ermA gene product. J. Bioi. Chem. 
270(7): 3255-3260. 
Thompson, C.B. (1995) Apoptosis in the pathogenesis and treatment of 
disease. Science 267: 1456-1462. 
Tommasino, M.; Crawford, L. {1995) Human papillomavirus E6 and E7: 
proteins which deregulate the cell cycle. BioEssays 17(6): 509-518. 
Trimale, L.A.; Xu, Z.; Lieberman, J. (1999) Clonal expansion of antigen-
specific CDS+ cytotoxic T lymphocytes is regulated by late exposure to 
serum to prevent apoptosis. J. lmmunol. Methods 225: 39-52. 
Tsujimoto, Y.; Cossman, J.; Jaffe, E.; Croce, C. {1985) Involvement of the 
bcl-2 gene in human follicular lymphoma. Science 228: 1440-1443. 
Tsutsu, K.; Sun, Q.; Yasumoto, S.; Kikuchi, K.; Ohta, Y.; Pater, A.; Pater, 
M.M. (1993) In vivo and in vitro analysis of cellular origin of cervical 
squamous metaplasia. Am. J. Pathol. 143: 1150-1158. 
205 
Tsutsumi, K.; Belaguli, N.S.; Qi, S.; Michalak , T.l.; Gulliver, W.P.; Pater, 
A.; Pater, M.M. (1992) HPV 16 DNA immortalizes two types of normal 
human epithelial cells of uterine cevix. Am. J. Pathol. 140: 255-261. 
Tsutsumi, K.; Sun, Q.; Belaguli, N.S.; Pater, M.M.; Pater, A. (1994) 
Distinct phenotypes of human ectocervical cell lines immortalized by 
human papillomavirus type 16. Mol. Cell Diffetentiation 2: 141-157. 
Tu, Y.; Renner, S.; Xu, F-H.; Fleishman, A.; Taylor, J.; Weisz, J.; Vescio, 
R.; Rettig, M.; Berenson, J.; Krajewski, S.; Reed, J.C.; Lichtenstein, A. 
(1998) Bcl-x expression in multiple myeloma: possible indicator of 
chemoresistance. Cancer Res. 58: 252-262. 
Turek, L.P. (1994) The structure function and regulation of papillomaviral 
genes in infection and cervical cancer. Adv. Viral Res. 44: 305-356. 
Turyk, M.E.; Golub, T.R.; Wood, N.B.; Hawkins, J.L.; Wilbanks, G.D. 
(1989) Growth and characterization of epithelial cells from normal human 
uterine ectocervix and endocervix. In Vitro Cell Dev. Bioi. 25: 544-556. 
Ueda, M.; Kumagai, K.; Ueki, K.: lnoki, C.; Orino, 1.; Ueki, M. (1997) 
Growth inhibition and apoptotic cell death in uterine cervical carcinoma 
cells induced by 5-fluorouracil. Int. J. Cancer 71: 668-674. 
Vessey, M.P.; McPherson, K.; Lawless, M.; Yeates, D. (1983) Neoplasia 
of the cervix uteri and contraception: a possible adverse effect of the pill. 
Lancet. 2: 930-934. 
Vogelstein, B. (1990) A deadly inheritance. Nature 348: 681-682. 
Vooijs, G.P. (1991) Benign proliferative reactions, intraepithelial neoplasia 
and invasive cancer of the uterine cervix. In Comprehensive 
cytopathology (Bibbo, M. ed.) W.B. Saunders. Philadelphia. 
Vousden, K.H. (1989) Human papillomaviruses and cervical carcinoma. 
Cancer Cells 1: 43-49. 
Vousden, K.H. (1990) human papillomavirus oncoproteins. Semin. Cancer 
Bioi. 1: 415-424. 
Wagener, C.; Bargou, R.F.; Daniel, P.T.; Bomment, K.; Mapara, M.Y.; 
Royer, H.D.; Darken, B. (1996) Induction of the death-promoting gene 
bax-alpha sensitizes cultured breast-cancer cells to drug-induced 
apoptosis. Int. J, Cancer67{1): 138-141. 
206 
Wang, H-G.; Miyashita, T.; Takayama, S.; Sato, T.; Torigoe, T.; Krajewski, 
S.; Tanaka, S.; Hovey, L.; Troppmair, J.; Rapp, U.R.; Reed, J.C. (1994) 
Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. 
Oncogene 9(9): 2751-2756. 
Wang, L.G.; Liu, X.M.; Kreis, W.; Budman, O.R. (1999a) The effect of 
antimicrotubute agents on signal transduction pathways of apoptosis: a 
review. Cancer Chemother. Pharmacal. 44: 355-361. 
Wang, L.G.; Liu, X.M.; Kreis, W.; Budman, D.R. Adams, L.M. (1999b) 
Activation of MAP kinase during apoptosis mediated by vinorelbine in 
MCF-7 cell. Proc. Am. Assoc. Cancer Res. 40: 13. 
Ward, P.; Coleman, D.V.; Malcolm, 0.8. (1989) Regulatory mechanisms of 
the papillomaviruses. Trends Genet. 5: 97·98. 
Wasan, K.M.; Morton, R.E. (1996) Differences in lipoprotein concentration 
and composition modify the plasma distribution of free and liposomal 
annamycin. Pharm. Res. 13(3): 462-468. 
Weinberg, R.A. (1996) How cancer arises. Sci. Am. 275: 62-70. 
White, E. (1996) Life, death, and the pursuit of apoptosis. Genes & 
Development 10: 1-15. 
White, E.; Cipriani, R.; Sabbatini, P.; Denton, A. (1991) The adenovirus 
E1 B 19-Kilodalton protein overcomes the cytotoxicity of E1A proteins. J. 
Viral. 65: 2968·2978. 
White, E.; Stillman, B. (1987) Expression of the adenovirus E1 B mutant 
phenotypes is dependent on the host cell and on synthesis of E 1 A 
proteins. J. Viral. 61: 426-435. 
White, K.; Grether, M.E.; Abrams, J.M.; Young, L.; Farrell, K.; Steller, H. 
(1994) Genetic control of programmed cell death in Drosophila. Science 
264: 677-683. 
Williams, G.T. (1991) Programmed cell death: apoptosis and oncogenesis. 
Ce/165: 1097-1098. 
Woodworth, C.D.; Bowden, P .E.; Doniger, J. (1988) Characterization of 
normal human exocervical epithelial cells immortalized in vitro by 
papillomavirus type 16 and 18 DNA. Cancer Res. 48: 4620-4628. 
207 
Wu, D.; Wallen, H.; Nunez, G. (1997) Interaction and regulation of 
subcellular localization of CED-4 by CED-9. Science 275(5303): 1126-
1129. 
Wyllie, A.H. (1992) Apoptosis and the regulation of cell numbers in normal 
and neoplastic tissues: an overview. Cancer Metastasis Rev. 11 (2): 95-
103. 
Wyllie, A.H.; Kerr, J.F.; Currie, A.R. (1980) Cell death: significance of 
apoptosis. Int. Rev. Cytol. 68: 251-306. 
Wyllie, A.H.: Rose, K.A.; Morris, R.G.; Steel, C.M.; Foster, E.; Spandidos, 
D.A. (1987) Rodent fibroblast tumours expressing human myc and ras 
genes: growth, metastasis and endogenous oncogene expression. Br. J. 
Cancer 56(3): 251-259. 
Xiao, Z.X.; Chen, J.; Levine, A.; Modjtahedl, N.; Xing, J.; Sellers, W.R.; 
Livingston, D.M. (1995) Interaction between the retinoblastoma protein 
and the oncoprotein MDM2. Nature 375(6533): 694-698. 
Yamakawa, Y.; Forslund, 0.; Chua, K.L.; Dillner, L.; Boon, M.E.; Hansson, 
B.G. (1994) Detection of the BC 24 transforming gragment of the herpes 
simplex virus type 2 DNA in cervical carcinoma tissue by polymerase 
chain reaction. APMIS 102: 401-406. 
Yang, X.; Chernenko, G.; Hao, Y.; Ding, Z.; Pater, M.M.; Pater, A.; Tang, 
S-C. (1998a) Human BAG-1/RAP46 proteins are generated as four 
isoforms by alternative translation initiation and overexpressed in human 
cance cells. Oncogene 17: 981-989. 
Yang, X.; Hao, Y.; Ding, Z.; Pater, A. (2000) BAG-1 promotes apoptosis 
induced by N-(4-hydroxyphenyl)retinamide in human cervical carcinoma cells. 
Exp. Cell Res. 256(2): 491-499. 
Yang, X.; Hao, Y.; Pater, M.M.; Tang, S-C.; Pater, A. (1998b) Enhanced 
expression of anti-apoptotic proteins in human papillomavirus-
immortalized and cigarette smoke condensate-transformed human 
endocervical cells: correlation with resistance to apoptosis induced by 
DNA damage. Mol. Carcinogenesis 22: 95-101. 
Yang, X.; Jin, G.; Nakao, Y .; Rahimtula, M.; Pater, M.M.; Pater, A. (1996) 
Malignant transformation of HPV-16-immortalized human endocervical 
208 
cells by cigarette smoke condensate and characterization of multistage 
cacinogenesis. Int. J. Cancer 65: 338-344. 
Yang, X.; Nakao, Y.; Pater. M.M.; Tang. S-C.; Pater, A. (1997) Expression 
of cellular genes in HPV 16-immortalized and cigarette smoke 
condensate-transformed human endocervical cells. J. Cell. Biochem. 66: 
309-321. 
Yanovich, S.; Preston, L.; Shaw, J.M. (1984) characteristics of uptake and 
cytotoxicity of a low-density lipoprotein: daunomycin complex in p388 
leukemia cells. Cancer Res. 43: 4600-4605. 
Yap, D.B.S.; Hsieh, J-K.; Chan, F.S.G.; Lu, X. (1999) mdm2: a bridge over 
the two tumor suppressors, p53 and Rb. Oncogene 18: 7681·7689. 
Yin, O.X.; Schimke, R. T. (1995) Bcl-2 expression delays drug- induced 
apoptosis but does not increase clongenic survival after drug treatment in 
Hela cell. Cancer Res. 55: 4922·4928. 
Yin, D.X.; Schimke, R.T. (1996) Inhibition of apoptosis by overexpresing 
Bcl·2 enhances gene amplification by a mechanism independent of 
aphidicolin pretreatment. Proc. Nat/. Acad. Sci. U. S. A. 93: 3394-3398. 
Yokoyama, M.; Nakao, Y.; Yang, X.; Sun, Q.; Tsutsumi, K.; Pater, A.; 
Pater, M.M. (1995) Alterations in physical state and expression of human 
papillomavirus type 18 DNA following crisis and establishment of 
immortalized ectocervical cells. Virus Res. 37:139-151. 
Yokoyama, M.; Tsutsumi, K.; Pater, A.; Pater, M.M. (1994) Human 
papillomavirus 18-immortalized endocervical cells with in vitro cytokeratin 
expression characteristics of adenocarcinoma. Obstet. Gynecol. 83(2): 
197-204. 
Yonehara, S.; lshiti, A.; Yonehara, M. (1989) A cell-killing monoclonal 
antibody (anti-Fas) to a cell surface antigen co-downregulated with the 
receptor of tumor necrosis factor. J. Exp. Med. 169(5): 1747-1756. 
Yonish-Rouach, E.; Resnitsky, 0.; Lotem, J.; Sachs, L.; Kimchi, A.; Oren, 
M. (1991) Wide·type p53 induces apoptosis of myeloid leukaemic cells 
that is inhibited by interleukin-6. Nature 352: 345-34 7. 
Yuan, J.; Shaham, S.; Ledoux, S.; Ellis, H.M.; Horvitz, H.R. (1993) The C. 
elegans cell death gene ced-3 encodes a protein similar to mammalian 
interleukin-1 beta-converting enzyme. Ce//75(4 }: 641-652. 
209 
Zakeri, Z.F.; Quaglino, D.; Latham, T.; Lockshin, R.A. (1993) Delayed 
internucleosomal DNA fragmentation in programmed cell death. FASEB J. 
7(5): 470-478. 
Zamai, l.; Falcieri, E.; Marhefka, G.; Vitale, M. (1996) Supravital exposure 
to propidium iodide identifies apoptotic cells in the absence of 
nucleosomal DNA fragmentation. Cytometry 23(4): 303-311. 
Zeng, X-R.; Jiang, Y.; Zhang, S.J.; Hao, H.; Lee, M.Y.W.T. (1994) DNA 
polymerase delta is involved in the cellular response to UV damage in 
human cells. J. Bioi. Chem. 269(19): 13748-13751. 
Zha, H.; Aime-Sempe, C.; Sato, T.; Reed, J.C. (1996) Proapoptotic protein 
Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel 
domain (BH3) distinct from BH 1 and BH2. J. Bioi. Chem. 271 ( 13 ): 7 440-
7444. 
Zhan, Y.; van de Water, B.; Wang, Y.; Stevens, J.L. (1999) The roles of 
caspase-3 and bcl-2 in chemically-induced apoptosis but not necrosis of 
renal epithelial cells. Oncogene 18: 6505-6512. 
Zheng, L.; Fisher, G.; Miller, R.E.; Peschon, J.; Lynch, D.H.; Lenardo, 
M.J. (1995) Induction of apoptosis in mature T cell by tumor necrosis 
factor. Nature 377: 348-351. 
Zhu, Y-M.; Bradbury, D.A.; Russell, N.H. (1994) Wild-type p53 is required 
for apoptosis induced by growth factor deprivation in factor-dependent 
leukaemic cells. Br. J. Cancer 69(3): 468-472. 
Ziegler, A.; Jonason, A.S.; Leffell, D.J.; Simon, J.A.; Sharma, H.W.; 
Kimmelman, J.; Remington, L.; Jacks, T.; Brash, D.E. (1994) Sunburn and 
p53 in the onset of skin cancer. Nature 372: 773-776. 
zur Hausen, H. (1975) Oncogenic herpesviruses. Biochem. Biophys. Acta 
417: 25-53. 
zur Hausen, H. (1976) Condyloma acuminata and human genital cancer. 
Cancer Res. 36: 530-534. 
zur Hausen, H. (1989) papillomaviruses as carcinomaviruses. Adv. Viral. 
Oncol. 8: 1-26. 
210 
zur Hausen, H.; DeVilliers, E.M. (1994) Human papillomaviruses. Annu. 
Rew. Microbial. 48: 427-44 7. 
Zwerschke, W.; Jansen-DOrr, P. (2000) Cell transformation by the E7 
oncoprotein of human papillomavirus type 16: interactions with nuclear 
and cytoplasmic target proteins. Adv. Cancer Res. 78: 1-29. 
211 




